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An increasing number of jurisdictions are legalizing nonmedical cannabis, including Canada in 
October 2018. One of the primary goals under the Cannabis Act is to adequately inform Canadians 
about nonmedical cannabis and risks related to its use. There is a need for evidence to inform 
regulatory measures that are implemented as part of the legal market.  
 
Purpose 
The current study had four specific objectives: 1) to examine current health beliefs and perceptions 
among young Canadian nonmedical cannabis users and non-users, 2) to examine differences in 
perceived effectiveness of text and pictorial health warning labels, 3) to investigate effective 
approaches for labelling cannabis product constituents and dose, and 4) to examine the effect of 
different branding elements and descriptors on product perception among young Canadians. 
 
Methods  
An online cross-sectional survey was conducted from October 10th to October 24th, 2017. The 
sample (N=870) was restricted to individuals aged 16 to 30 years of age with a Canadian IP 
address, and included cannabis users and non-users. The survey assessed sociodemographic 
characteristics, cannabis use behaviours, health knowledge, as well as attitudes and beliefs around 
cannabis use. Study 1 examined young Canadians’ awareness of negative health effects, as well as 
perceptions of risk and harm. The survey also contained three sets of between-group experiments. 
In Study 2, respondents were randomized to view health warnings according to one of two 
experimental conditions: text-only warnings, and pictorial warnings accompanied by text. Study 2 
examined the effectiveness of health warnings for cannabis products and levels of support among 
youth. In Study 3, between-group experiments were conducted to assess comprehension of 
cannabis-related information, including communication of dose and strength of a particular 
product. Finally, Study 4 investigated perceptions of brand imagery on cannabis packaging. In this 
experimental set, respondents were randomized to view and evaluate cannabis product mock-ups 







Most respondents were aware of a cannabis-related physical health effect (78.0%). Approximately 
one-third reported having been exposed to public health messaging about cannabis; digital media 
was reported most frequently. Compared to never users, ever users were less likely to report that 
they perceive cannabis as addictive (p<0.001), and to perceive harm to mental health (p<0.001). 
Approximately one-quarter of past 3-month cannabis users reported they were at least ‘a little’ 
addicted. Respondents who reported using a particular form of cannabis self-administration (e.g., 




Pictorial health warnings for cannabis products were perceived as more effective and believable 
than text-only warnings (p<0.001). Pictorial warnings were rated as more effective than text-only 
warnings for THC dose (p=0.039), co-morbid drug use (p=0.006), and pregnancy (p<0.001). 
Pictorial warnings were also rated as more believable than text-only warnings (p=0.048). Overall, 
87.7% respondents supported health warnings on cannabis products and 84.0% supported the 
inclusion of calls to action such as quit-lines on cannabis products. 
 
Study 3 
Labelling the number of doses per package was associated with the greatest proportion of correct 
responses (54.1%) when respondents had to determine a recommended serving compared with the 
no-label control condition (RR=7.28, 95%CI 4.81-11.04) and THC mg condition (RR=4.05, 
95%CI 2.96-5.54). When product was labelled using a traffic light system, participants were more 
likely to identify THC level: low THC (RR=43.43 95%, CI 16.43-114.79) or high THC 
(RR=16.71, 95%CI 9.61-29.07) than the control condition. 
 
Study 4 
When cannabis product branding was present, respondents were more likely (p=0.027) to report 
greater appeal than when branding was absent. When a pictorial health warning was present, 
respondents were less likely (p=0.010) to report greater appeal than when absent. The presence of 
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a celebrity sponsor (p<0.001), music references (p<0.001), or party references (p<0.001) increased 
the likelihood that respondents would perceive the product to be targeted at someone younger and 
one that was likely to go out and party (p<0.001). Differences by cannabis use status were seen 
across experimental tasks; those that had ever used were more likely to find the presence of 
branding elements appealing. 
 
Conclusions  
Young Canadians report a wide range of beliefs about the health effects of cannabis use. 
Substantial proportions underestimated and overestimated cannabis’ health effects. The findings 
also suggest that cannabis users may be demonstrating a form of ‘optimism’ bias: worry about 
health effects and perceptions of addiction appeared to be lower when they were personalized to 
users rather than asked in the general form. The current study provided the first empirical test of 
cannabis health warnings. Pictorial health warnings for cannabis products were perceived as more 
effective and believable than text-only warnings. Labelling cannabis package content in terms of 
doses per package and using symbols or other graphics to denote potency were considerably more 
effective than the use of THC percentages or milligrams in making decisions about cannabis 
products’ recommended use amounts and potency. Finally, the findings demonstrate that brand 
imagery on cannabis packaging can promote lifestyle associations and influence the appeal of 
cannabis products among young people. There is an urgent need for additional research on 
regulatory approaches and strategizing public health communications campaigns to ensure that 
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Chapter 1: Introduction 
 
Cannabis 
Cannabis is a generic term used to describe the numerous psychoactive preparations of the 
Cannabis sativa, Cannabis indica, and to a lesser extent, the Cannabis ruderalis plants.1,2 More 
than 400 diverse bioactive molecules are derived from these plant species. Of these constituents, 
over 60 cannabinoids contribute to the overall physiological effects that act on neural pathways 
lined with cannabinoid receptors capable of modulating neurotransmitter activity in the 
endocannabinoid pathway.3,4,5,6 Tetrahydrocannabinol (Δ9-THC) is the cannabinoid that is 
primarily responsible for the euphoric sensation associated with the many forms and modes of 
consumption of the plant.7 Cannabidiol (CBD) is secondary to THC and the major non-
psychoactive compound found in cannabis in terms of its concentration; it is often cited and 
investigated for its therapeutic qualities.8,9 
This thesis will use the term “cannabis” instead of the many other names used to denote 
the substance or its preparations colloquially (i.e., marijuana, chronic, pot, dope, kush, bud, etc.) 
or traditionally used in local indigenous cultures around the world (i.e., basuco, bhang, pasta 
base).10  
Prevalence and patterns of use in Canada 
 Cannabis is the most widely used illicit substance around the world.1,11,12 In Canada, it is 
only second to alcohol in terms of use prevalence. According to the 2017 Canadian Tobacco, 
Alcohol and Drugs Survey, the most recent nationally representative survey of the general 
Canadian population’s drug use behaviours, more than 4 in 10 (46.6%) Canadians reported ever 
using cannabis in their lifetime.13 Among young adults aged 20-24 years, approximately half 
(52.6%) reported lifetime use.13 Cannabis use is most common among youth and young adults; see 
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Figure 1 for further detail. The prevalence of use was reported with greater frequency among men 
than women when reporting ever use (52.4% vs. 40.9%), and past 12-month use (18.7% vs 11.1%).  
 




 Over the last decade, national surveys indicate modest decreases in the prevalence of 
cannabis among youth, along with delays in the average age of first use or initiation.14 The most 
recent nationally representative survey of Canadian youth from grades 7 to 12, the 2016-2017 
Canadian Student Tobacco, Alcohol and Drugs Survey (CSTADS), reported figures that were 
consistent with the general population survey, CTADS wherein 16.7% of Canadian students 
reported past 12-month use.15   For the second time since CSTADS, formerly the Youth Smoking 
Survey, was administered in 2004, there existed no significant difference in reported cannabis use 























EVER PAST 12 MONTHS
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Figure 2 Prevalence of cannabis use in the past 12 months, by sex, Grades 7-12, 2006-07 to 2014-15, Canadian 
Student Tobacco, Alcohol and Drugs Survey (Formerly Youth Smoking Survey)15,16  
 
 
 Cannabis use is higher among certain population subgroups such as youth who report poor 
school performance, sensation-seeking personality traits, early use of tobacco, alcohol, and other 
drugs, those fraternizing with drug-using peers, experiencing a difficult family environment, and 
those that report cannabis accessibility and availability.17,18 Use is approximately twice as high 
among Indigenous Canadian youth when compared to youth in the general population.14,18 
Indigenous Canadian youth are also more likely to initiate their use at a younger age than their 
non-Indigenous peers.19 According to the First Nations Regional Health Survey, a survey designed 
to be representative of First Nations individuals living on-reserve and in Northern communities, 
among the general Indigenous Canadian adult population, approximately one third (32.3%) of First 
Nations adults reported use of cannabis in the past year when the survey was last conducted in 
2008/2010. Men reported use in greater numbers (40.5%) than the women (24.1%) in First Nations 
communities surveyed.20  There exists a general void in the literature around Indigenous Canadians 






















Forms and modes of use 
 The most common cannabis preparations include dried herbal forms, hashish, and hash oil; 
these are then available for further processing, such as in edibles, alcohol extractions, etc.1 In 
Canada, the current cannabis regulatory system, the Access to Cannabis for Medical Purposes 
Regulations (ACMPR), allows for dried and fresh cannabis plant as well as cannabis oils.21 
However, cannabis is a versatile substance and the diversity of consumer products includes edibles 
(e.g., cannabis-infused foods, cooking oils, drinks, etc.), oils, ointments, tinctures, creams, 
concentrates (e.g., butane hash, oil, resins, waxes, shatter, etc.).22 A list of common forms and 
modes of use are listed below in Table 1. According to the 2017 CTADS, 9 in 10 (91%) of past-
year cannabis users report smoking it.13 Other methods of administration also reported by past-
year users include mixing it with tobacco (22%), smoking tobacco immediately after inhaling, or 
chasing (34%), ingesting it in edibles (38%), or vaporizing ( 29%).13 
 
Table 1 Common forms/modes of cannabis consumption. 
Smoked dried herb/flower/leaf  
Vaporized dried flower/leaf  
Vaporized liquid form in an e-cigarette  
Mixed with or rolled in tobacco (e.g., blunt)  
Hashish  
Hash oil  
Concentrate (e.g., butane honey oil, shatter, budder, wax etc.)  
Edibles (e.g. cookies)  
Liquid (e.g., cola/tea)  
Tinctures (e.g., concentrated amounts ingested orally or taken under the tongue)  
Topical ointments (e.g., lotions, salves, balms applied directly to the skin)  
Fresh flower/leaf (e.g., for juicing)  
 
The various kinds of cannabis preparations carry different degrees of psychoactive 
potency. Different jurisdictions have operationalized potency to refer to a product’s THC 
content.23 THC is found on and around the flowering parts of the female cannabis plant in greatest 
concentrations – this section may be harvested and dried with its potency dependent on the plant’s 
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genetic composition and growing conditions.24 Potency may be manipulated, perhaps in the most 
extreme example as the “sinsemilla” varieties where female plants are grown together isolated 
from male phenotypes thus maximizing their THC generation.24 The THC content of cannabis has 
increased significantly over the past three decades in North American markets, from approximately 
2% to 9% in its dried herbal form and has reached up to 80% to 90% in high potency products 
such as oils or waxes.25,26,27,28  
Health effects of nonmedical cannabis use 
The past 20 years have brought about a better understanding about the effects of cannabis 
and cannabinoids on human health.59 Cannabis’ effects vary and are dependent on dose, form, 
mode of administration, past experience with the substance, simultaneous substance use, 
contextual factors where use is taking place, and personal expectations, mood, and attitudes 
regarding the effects that cannabis may produce.1  
Cannabis use has not been associated with direct mortality (e.g., fatal overdose), but, it has 
been observed to lead to fatalities from motor vehicle accidents, increased potential for brain and 
respiratory cancers, and has been associated with increased mortality when compared to never-
users.29,59 Little is currently known about the cannabis-attributable disease burden stemming from 
the several known effects to health but numerous studies in Canada have observed it to be 
comparably small despite the large population-level exposure.30,31,32,33 Most of the health 
consequences related to cannabis use occur in individuals who are high frequency and high 
intensity users – these compose a very small proportion of Canadians.34,35,36,37 Other important 
behaviours that lead to an increased disease burden include: operating machinery under the 
influence of cannabis, using products with high THC concentrations, smoking cannabis – 
especially when mixed with tobacco, and using cannabis in early and mid-adolescence – critical 
developmental periods.38 
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Acute Health Effects 
 The acute health effects of cannabis use are those that may occur shortly after a singular 
occasion of use or from relatively few occasions of use and occurring close together in time.1 
During an acute phase of cannabis intoxication, a subjective sensation often described as euphoric 
is experienced; this is the characteristic “high” sought by nonmedical and perhaps some medical 
cannabis users.1,59  THC is a very lipophilic molecule; it interacts with the brain’s dopamine 
pathway that is lined with cannabinoid receptors (CB1 and CB2) and affects regions modulated by 
dopamine. Thus, functions such as cognition and attention, emotionality, motivation, time 
perception, as well as a number of psychomotor functions are affected.1,59,39,40  
Chronic Health Effects 
Chronic health effects of cannabis refer to those that arise from the greater frequency of its 
use, over periods of time that may span months, years, or decades. Regular and heavy exposure to 
cannabinoids may give rise to chronic neurological effects. Chronic and persistent exposure to 
cannabinoids downregulate, or reduce levels of CB1 cannabinoid receptors, some of which 
function within brain regions responsible for memory and cognition.41,42 The particular effects of 
chronic cannabis use are of particular interest to current cannabis legalization decision-makers as 
domains of women’s health such as perinatal health of mother and child, neurological and 
psychosocial development, and general concerns remain hazy in the current literature. 
 
Health effects of interest 
 
Cannabis Use and Driving 
 
The extent to which cannabis use leads to motor vehicle fatalities is a current research 
priority. Although there exist several studies supporting deficits to tasks related to driving that 
include reaction time, concentration,  visual acuity, short-term memory, compromised ability to 
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handle unexpected events, among others, the scientific community is reluctant to attribute driving 
under the influence of cannabis to motor vehicle fatalities.43,44,45,46,47 What has been generally 
accepted is that driving under the influence of cannabis doubles drivers’ risk of collision.74 More 
young Canadians report driving after consuming cannabis than after consuming alcohol.48 
Between 2000 and 2010, 16.4% of drivers killed in motor vehicle collisions tested positive for 
cannabis – of those, drivers aged 16-24 were found to be more than twice as likely as their older 
counterparts aged 35 or older to test positively for cannabis and accounted for 4 in 10 of those 
fatally injured.49 While data is somewhat scarce on young people’s explicit attitudes, the existing 
evidence base suggests that Canadian youth are not sufficiently educated on the potentially 
dangerous effects that cannabis carries, particularly around cannabis-impaired driving.  
Canada does not currently have a set limit for drug-impaired driving other than alcohol.50 
Drug-impaired driving is a criminal offence according to the Criminal Code (S. 253a), however, 
Canadian jurisdictions rely on safety enforcement officers to independently evaluate likely 
impairment of a driver using the Drug Evaluation and Classification system developed more than 
three decades ago in the United States and pair results with a toxicological analysis to proceed 
with charges of drug-impaired driving.51,52 A significant proportion of youth and young adults 
(Figure 1) use cannabis in  Canada. This, coupled with young people’s disproportionate risk for 
being involved in a collision-related mortality than older age groups and limited enforcement 
technologies creates an important policy domain for further research.53  
Health Canada’s 2017 Canadian Cannabis Survey (CCS) indicated that approximately 4 in 
10 (39%) past-year cannabis users reported driving within two hours of using cannabis; of these, 
15% reported that they had combined cannabis and alcohol within two hours of operating a vehicle 
and a minority (2%) reported having an interaction with law enforcement related to driving while 
cannabis-impaired.54 Furthermore, approximately 4 in 10 (39%) Canadian reported having been a 
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passenger in a vehicle operated by someone who had recently used cannabis – further analysis 
revealed that 8 in 10 (79%) cannabis users had been passengers of a vehicle driven by somebody 
under the influence of cannabis.54  A gradient was observed in terms of perceived effects of 
cannabis on driving in the 2017 CCS. Overall, 3 in 4 (75%) Canadians reported that they thought 
cannabis affected driving, however, half of cannabis users (past-year users) reported the same, and 
1 in 5 (19%) reported that it did not affect driving at all.54 
Co-morbid use with other substances 
 
 Different substances including cannabis are often discussed in isolation; however, cannabis 
and/or its derivatives are often used simultaneously with other substances during the same 
occasion.55 A recent review found that up to approximately one-third (29%) of adolescents who 
use cannabis also use other drugs.56 Many of the current findings and our understanding of 
cannabis-related outcomes may be confounded by effects of other substances or the combined 
effects of polysubstance use. There appears to be a strong and consistent association between the 
use of different substances, typically with earlier initiation of smoking followed by cannabis. 
While some suggest that this is evidence of a causal gateway between the substances, the current 
working consensus is that this phenomenon is due to a shared susceptibility or common factor. 
The order of initiation of different substances of interest is primarily related to accessibility and 
availability among youth.57, 58 Nevertheless, the co-morbid use of cannabis with other substances 
can have important implications for patterns of use and consequences.  
Tobacco 
 
 There exists limited evidence that cannabis use is associated with the initiation of tobacco 
use.59 However, there is a strong and consistent association between the uses of both substances. 
The most recent Canadian analyses of nationally representative data indicate that virtually all 
respondents who reported being current tobacco users also reported using cannabis; in contrast, 
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only a fraction of cannabis users reported using tobacco as well.60,61 The sociodemographic 
characteristics of Canadian co-users and extent of co-use use have been observed; past 12-month 
cannabis users who were also ‘current’ smokers were more likely to be young males (aOR=1.8, 
99%CI=1.55-2.21) aged 15 to 19 years of age who were not attending school and indicated that 
they lived in an urban community.62 More recent studies indicate similar results, individuals that 
use tobacco and cannabis concurrently tend to be male, non-daily smokers who report greater 
alcohol and other drug use, not attending school; its relation to ethnicity seems to be variable by 
region.63,64,75 
  Co-administration of tobacco and cannabis may occur in what are known in colloquial 
terms as “blunts”, “spliffs” or as “cigarette chasers” among other ways. Blunts refer to partially or 
completely hollowed out cigars that are re-filled with cannabis. Spliffs refer to cannabis cigarettes, 
or “joints”, containing loose tobacco and cannabis. A cigarette chaser refers to the practice of 
smoking a tobacco cigarette shortly after using cannabis.65  The smoke from the simultaneous use 
of cannabis and tobacco contains a number of common toxic compounds including hydrocyanic 
acid, ammonia, carbon monoxide, naphthalene, as well as known carcinogens such as 
benzanthracene, and benzopyrene.66 The two substances in combination may have additive effects 
that may generate worse health outcomes than either substance on its own in terms of increased 
toxicant exposure from the two substances due to the mechanical aspects of ingestion (i.e., holding 
combusted smoke deeper in the lungs for a longer period of time).67,68,69  Endobronchial biopsies 
of regular co-users have shown that the combination of substance cause significant pathological 
changes to the bronchial mucosa.70 The simultaneous use of tobacco and cannabis may be due to 
the distinct behaviour’s practical economic advantage – tobacco has been observed to increase the 
cannabinoid THC inhaled per gram by up to 45% thereby producing a greater psychoactive effect 




The consumption of alcohol and cannabis often takes place for similar reasons in similar 
social contexts. Limited evidence is available regarding associations between cannabis use and 
patterns of alcohol use behaviours.59 Alcohol tends to be implicated with cannabis use and 
characterized as a substitute, taking its place, or as a complement, its co-administration to complete 
or enhance its effect or experience.72 Alcohol is also the most widely used intoxicant among the 
general Canadian population (77%; past year use) as well as among Canadian youth (40%; past 
year use).15,11 Studies with animal models have found that cannabinoids enhance neural sensitivity 
to ethanol suggesting that simultaneous co-administration of cannabis and alcohol magnifies their 
respective individual effects.73 Both alcohol and cannabis have been found to affect reaction time, 
concentration, visual acuity, short-term memory, compromised ability to handle unexpected events 
among other effects.74,75,76,77,78,79 It should be noted that the magnitude of the impact of cannabis 
use is dwarfed by the evidence of the available half a century of epidemiological research regarding 




Individuals that use cannabis have been identified as having a greater likelihood of using 
other substances (e.g., sedatives, stimulants, and opiates) and to be problematic users of those 
substances.59,81 Piece-meal findings are available for the comorbid use of common drugs. For 
example, 3,4-methylenedioxymethamphetamine (MDMA) or ecstasy and cannabis, for which 
regular users of both substances were more likely to report mental health problems with paranoia 





In Canada, the most common form of administration of cannabis is through combustion.83 
Cannabis smoke shares many of the same properties and contains many of the same compounds 
as tobacco smoke including polycyclic aromatic hydrocarbons (PAHs) such as benzo[α]pyrene 
and phenols; in some cases, these carcinogens and tumor promoters are present at higher 
concentrations than in tobacco smoke (e.g., 20-fold greater concentrations of ammonia, 3-5 times 
more hydrogen cyanide).84,85,86,87,88 Cannabis smoke has been found to be carcinogenic in 
laboratory assays, however, there is mixed data in terms of establishing its precise carcinogenic 
potential.1,59 This is because while cannabis and tobacco smoke share similar chemical properties, 
their pharmacodynamics differ greatly and appear to be somewhat contradictory.89  
Compounds in cannabis have been demonstrated to kill a number of cancer types including 
lung90, breast and prostate91, lymphoma92, glioma93, melanoma94 and pheochromocytoma (a rare 
tumor in the adrenal gland)95, however, low doses of THC have also been observed to stimulate 
the development of lung cancer cells in vitro.96 Some of these very different biological end points 
have been attributed to the enzymatic activity of cytochrome P4501A1 oxidase protein (CYP1A1 
gene product). When PAHs are introduced into the respiratory system through tobacco smoke, 
they stimulate CYP1A1 gene transcription activity which leads to increased enzymatic activity of 
the gene product responsible for the carcinogenic effects of PAHs. In contrast, while cannabis also 
introduces PAHs and upregulates CYP1A1 gene transcription, there is also a direct inhibition of 
the enzymatic activity of the gene product that is stimulated that exerts a protective effect.97,98,99 
Cannabis smoke may contain components that may minimize certain carcinogenic pathways, 
though, not necessarily eliminate them.  The differential practices in smoking tobacco and cannabis 
should also be considered in terms of its potential harm. Cannabis cigarettes are generally smoked 
without filters, are inhaled and held much deeper in the lungs for a greater amount of time to 
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maximize exposure, effectively inhaling 5 times more CO than what would be inhaled in a tobacco 
cigarette.100 Across the world cannabis is mixed with tobacco in what is the most common form 
of administration, perhaps accounting for the contradictory findings in this area.100 The increasing 
popularity of vaporizing devices available to consumers may help to decrease some risks 
associated with cannabis smoke. 
Aside from the concerns regarding carcinogenic potential, exposure to second-hand 
cannabis smoke may lead to positive results on testing of a variety of body fluids (oral fluid, blood, 
urine) and passive exposure may also produce psychoactive effects. Short term and extreme 
cannabis smoke exposure (e.g., room with no air ventilation, 11.3% THC-containing cannabis) has 
been shown to allow for sufficient absorption of THC to produce characteristic effects and be 
detectable in urine assays.101 To date, there are no studies that report on the long-term effects of 
passive exposure to cannabis or to third-hand smoke.102 The limited findings in the area should be 
used carefully. Passive exposure of cannabis smoke among individuals with a history of mental 
health issues that may be exacerbated by the use of cannabis may be at risk of unintended, negative 
health consequences.  As jurisdictions develop regulations around use in public spaces, they should 
keep in mind harm-reduction strategies to avoid these potential consequences. 
Cannabis Use and Pregnancy 
 
The 2008 Canadian Perinatal Health Report found that 5% of pregnant women reported 
use of an illicit substance during pregnancy, though it did not report how much of the use was from 
cannabis.103 This relatively small figure may be a underrepresentation, other studies that include 
prospective longitudinal methodologies have found prevalence rates of illicit drug use ranging 
from 10 to 16% in middle-class samples to 23 to 30% among inner-city populations.104,105 The 
relationship between smoking cannabis and pregnancy and related outcomes is unclear.1,59,106 
However, available systematic reviews and meta-analyses indicate that it is possible that cannabis 
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use during pregnancy may increase the risks of stillbirth, preterm birth, fetal development issues, 
as well as having an adverse effect on child neurodevelopment.107,108  The relationship remains 
hazy due to the fact that existing studies rely on self-reporting cannabis exposure, varied/unknown 
cannabis potency used, as well as a inclusion of a minority of women who exclusively used 
cannabis. Animal models have found that the likelihood of a miscarriage increases when cannabis 
is used early in pregnancy, however, these findings have not been observed in humans.109,110,111 
Three different case-control studies found associations between smoking cannabis during 
pregnancy and childhood cancers.112,113,114 To counter, the incidence of childhood cancers did not 
significantly increase during periods when cannabis use became more prevalent in the United 
States.1  
The neurological development of a fetus is greatly affected by the environmental 
conditions of the intrauterine environment and involves a cascade of events that may be 
interrupted, delayed, or, at the very least, generally affected by the introduction of foreign 
substances. Of particular interest is the endocannabinoid system, accessible to components of 
cannabis that are able to cross the placental barrier including lipophilic THC and other 
cannabinoids. The endocannabinoid system plays a significant role in a broad array of critical 
processes in the developing fetus including cell proliferation and differentiation.106 The extent to 
which cannabinoid exposure in utero may affect development throughout the life course is not 
currently well understood. A summary of findings from three prospective longitudinal cohort 
studies (Ottawa Prenatal Prospective Study (OPPS)115,116, Maternal Health Practices and Child 
Development Study (MHPCD)117, and the Generation R Study118) that describe the impact of 




Table 2 Known potential neurocognitive and behavioural effects of maternal cannabis use during pregnancy. 
 Neurocognitive and Behavioural Effects 
18 months Increased aggressive behaviourc 
Attention deficits (females)c 
 
3 to 6 years Deficits in: 
• Verbal and perceptual skillsab 
• Verbal reasoningab 
• Visual reasoningab 
• Verbal and quantitative reasoningb 






9 to 10 years Deficits in:  
• Abstract and visual reasoningab  
• Executive functioningab  
• Readingab  
• Spellingab  
Hyperactivityab  
Attention deficitsb  
Impulsivityb  
Depressive and anxious symptomsb 
 
14 to 16 years Deficits in: 
• Visual-cognitive functioninga 
• Academic achievementb 
• Information processing speedb 
• Visual motor coordinationb 
Delinquencyb 
 
17 to 22 years Deficits in: 
• Executive functioninga 
• Response inhibitiona 
• Visuospatial working memorya 
Smokingab 
Substance useab 
Early initiation of substance useab 
 
aOPPS bMHPDC  cGeneration R 
Adapted from Porath-Waller et al.106 
 
Cannabis Use in Adolescence 
 
Cannabis use initiation often occurs during adolescence while heaviest use tends to occur 
in the late teens and early twenties.119 In Canada, this is consistently evidenced by nationally 
representative youth and general population substance use surveys (e.g, Figure 1).14 Adolescence 
is a critical developmental period for all biopsychosocial domains and is also a time when different 
patterns of behaviours are established.120 Dose, potency, and cumulative exposure contribute to 
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and determine the consequential effects of cannabis use.121 Cannabis use in adolescence may 
produce persistent impairments in memory, cognition, academic failure, school dropout, 
heightened risk for cannabis dependence, or further abuse of other drugs among other 
consequences.122,123 Several regions of the brain are affected through regular cannabis use and it 
is currently unclear whether the aberrant changes in the neural pathways of regular users are 
reversible.1,59  The most recent review from the National Academies of Sciences on cannabis 
indicates that the most frequent and heavy users are at highest risks of developing schizophrenia, 
psychoses and generally compromise their mental health as a result of consumption.59  
The public discourse around cannabis and its strict regulation has largely been centered on 
the protection of youth health (See: Taskforce Document22, Bill C-45190). The commentariat, 
which includes the media and other sources of information, has historically presented the issue of 
cannabis regulation as a binary – either presenting the idea that cannabis is largely if not completely 
harmless and should be loosely regulated given its benign effects or prohibition-era messaging that 
concentrates on serious harms that have befallen some users as a reason to maintain the status 
quo.124,125 Historically, related policy has been restrictive given the neurobiological research of 
cannabinoids on the developing brain, however, it has also led to ineffective, discriminatory and 
harmful policies that arguably have had greater negative impacts on youth health and life 
trajectories than the substance itself.126 
Cannabis Use and Mental Health 
 
The adverse psychological and emotional issues related with cannabis use have been 
observed among relatively higher intensity users (e.g., daily or near-daily users).1 Canadians aged 
15 to 24 have been found to have the highest rates of mood and anxiety disorders according to the 
2012 Canadian Community Health Survey – Mental Health with 7% identified as experiencing 
depression in the past year compared to 2 to 5% of persons aged 25 years or older.127 The evidence 
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relating cannabis use and depression is moderate, though, it has been found that high intensity 
users exhibit a small increased risk for the development of depressive disorder.59  
Severe depression is associated with suicidal behaviour, suicide being the 2nd leading cause 
of death among young Canadians – 1 in 4 deaths among Canadians aged 15 to 24.128 Cannabis use 
has been associated with panic, depersonalization, at times accompanied with paranoid ideation, 
particularly among first time users – acute depressive reactions have also been documented.129 To 
date, only one study exists that suggests that acute cannabis intoxication precipitates suicidal 
ideation based on the experience of a 32-year old man who presented with suicidal ideation on two 
different occasions after acute cannabis intoxication.130 The most recent meta-analyses of the 
cannabis-suicidality link indicates that chronic cannabis use can predict suicidality, though this 
conclusion is tempered due to the small number of included studies along with many 
heterogeneous features including a lack of homogeneous measurement of cannabis exposure.131 
According to the National Academies of Science, greater intensity of cannabis use is associated 
with suicidal ideation, attempt, and completion.59 
Cannabis use is associated with psychotic symptoms including an increased risk of 
developing psychoses including schizophrenia – greater frequency and intensity of use has been 
observed to increase this risk.59,124 A prospective study of 50,465 Swedish conscripts found that 
youth that had reported cannabis use prior to the age of 18 were more than twice as likely (2.4) to 
be diagnosed with schizophrenia than non-users; further studies confirm these findings along with 
a dose-response relationship.59,132,133,134 Reverse causation may also be a possibility in explaining 
these findings, it may be that sub-clinical or undetected schizophrenic patients self-medicate with 
the use of cannabis for disease-specific symptom relief. Another possibility that has been presented 
is the common cause hypothesis where the association between cannabis use and psychotic 
symptoms is explained by genetic or environmental factors and not cannabis. Findings in this are 
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mixed, however, the National Academies of Science concluded that the magnitude of association 
between cannabis use and the development of a psychotic disorder is moderate to large, appears 
to be dose-dependent and it is possible that it is moderated by genetic factors.1,59 Among 
individuals with psychotic disorders, moderate evidence supports an association between a history 
of cannabis use and better cognitive performance.59  
Overdose 
 
A drug overdose refers to the consumption of a substance beyond a particular quantity 
where its effects elicit a negative outcome, toxic state, or death. Cannabis has an extremely high 
LD50, the dosage required for 50% of test subjects receiving a drug to die of drug-induced toxicity. 
It is estimated that a cannabis user would have to consume 20,000 to 40,000 times as much 
cannabis as is contained in one cannabis cigarette to consume a lethal concentration to affect 
physiological process essential for life; practically speaking, cannabis cannot induce a lethal 
response as a result of drug-related toxicity.135,136 A substance’s LD50 is one of a range of potential 
responses and does not provide a complete depiction of its degree of hazard to human health. There 
do not yet exist reports of fatal cannabis overdoses in the epidemiological literature.137 A recent 
case study by Nappe & Hoyte made national headlines in the United States as it associated a 
pediatric death with cannabis exposure.138,139  The authors determined that there may be an 
association between cannabis exposure and the myocarditis that led to the young patient’s cardiac 
arrest and ultimate death. While this remains insufficient in terms of determining causality between 
cannabis exposure and overdose fatality, there exists moderate evidence of a statistical association 
between cannabis use and an increased risk of overdose injuries – among pediatric populations in 
American states where cannabis has been legalized, respiratory depression or failure, temporary 
coma, and cardiovascular symptoms have been detected.59 All-cause mortality has not yet been 
associated with cannabis use or exposure.  
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At very high levels of THC absorption, an individual can experience panic or anxiety 
attacks, depersonalization, paranoia, and hallucinations among other less documented effects.59,140  
The effects of acute intoxication due to cannabis are particularly important as they have regulatory 
implications in a legalized market which include accidental ingestion (with particular concern for 
ingestion by children), risks associated with methods of using cannabis among experienced and 
inexperienced users, impaired driving, combining substances in the same occasion, along with the 
effects to users’ mental health among other concerns.141 
Addictive Potential 
 
Regular long-term cannabis use has been observed to produce tolerance, withdrawal 
symptoms, compulsive use, impaired ability to control use, and continued use despite 
problems.142,143,144 A 1964 World Health Organization Expert committee introduced the term 
‘dependence” to replace the terms ‘addiction’ and ‘habituation’.145 Dependence refers to a 
constellation of psychological, behavioural, and cognitive phenomena in which the use of a 
particular substance, such as cannabis, takes priority over previously valued behaviours or 
activities. The Diagnostic and Statistical Manual of Mental Disorders (DSM-V) combined DSM-
IV categories of substance dependence and substance abuse into a single disorder measured on a 
gradient from mild to severe – substance use disorder.146 Despite the changes in terminology, the 
term ‘addiction’ is still generally used and refers to the DSM-IV (dependence) or the DSM-V 
(cannabis use disorder, severe) categories.121 Cannabis use disorder becomes moderate/severe 
when the impulse to use interferes with a person’s life in a significant way.147 Daily or near-daily 
use substantially increases the risk of dependence – dependence occurs in approximately 10% of 
ever users, 15% of adolescent users, and one third of daily users.1  
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Therapeutic Effects  
 
Cannabis and its constituent cannabinoids have been used for medical purposes and 
otherwise for millennia; evidence of their use may be dated back to 2737BCE in ancient 
China.148,149 In Canada, evidence of their use is present since its recorded first harvest in 1609.150 
Over time, there have been fluctuations in acceptance of cannabis and cannabinoids as acceptable 
medical therapies. After its criminalization early in the last century, its use largely declined. Today, 
it is accepted that cannabis and cannabinoids appear to be effective therapies for a wide range of 
conditions. The strongest evidence indicates that cannabis or specific cannabinoids are effective 
as analgesics in chronic pain patients (especially among those with neuropathic pain), as 
antiemetics for chemotherapy induced nausea, and for improving patient-reported multiple 
sclerosis spasticity symptoms though limited evidence exists for improving clinician-measure 
multiple sclerosis spasticity.59 Other therapeutic uses such as sleep quality improvement, appetite, 
applications for the treatment of Tourette syndrome, anxiety, and post-traumatic stress disorder 
have more limited evidence in terms of therapeutic efficacy.59 Cannabis in its herbal form is not 
authorized as a drug in Canada (See Section: Legal and Regulatory Status below), however, three 
cannabinoid-based medicines are available for marketing in different countries: Nabiximols 
(Sativex®): oromucosal spray, C. sativa THC and CBD – common use: treatment of MS spasticity, 
neuropathic pain , Nabilone (Cesamet® or Canemes®): oral capsules, synthetic cannabinoid 
similar to  THC, common use: chemotherapy nausea and vomiting, Dronabinol (Marinol® or 
Syndros®): oral capsule or solution containing synthetic THC, common use: anorexia in AIDS 
patients, chemotherapy nausea and vomiting.151 In Canada, Nabiximols and Nabilone are approved 
for use in MS spasticity complications and severe nausea respectively.152,153   
According to the most recently available estimates (September 2017), Health Canada 
reports that 235,621 Canadians are accessing cannabis for medical purposes from approved 
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licensed producers.154 Ontario (96,390) and Alberta (91,150) report the majority of client 
registrations across Canada.154 Findings from the 2013 and 2014 Centre for Addiction and Mental 
Health Monitor Survey of adults in Ontario indicate that more than 1 in 4 (28.8%) individuals who 
used cannabis in the past 12-months, self-reported using it for therapeutic purposes – 15.2% 
reported having medical approval.155 These findings are similar to findings from the 2004 
Canadian Addiction Survey that found that 29% of cannabis users reported use of cannabis use for 
medical purposes.156 
Social and economic costs associated with cannabis use 
The current body of work assessing the social costs associated with cannabis use is limited. 
The most recent comprehensive analyses examined costs in terms of the burden placed on services 
such as health care, public safety, occupational indicators (i.e., loss of productivity), disability or 
premature death of substances including tobacco, alcohol, and illicit substances which included 
cannabis. Overall, in Canada, the economic cost was estimated to be $38.4B CAD; intangible costs 
such as the costs of pain and suffering were not included in this comprehensive analysis.157 The 
most recent figures of cannabis-attributable burden of disease in Canada come from a 2012 study 
which outlined 287 deaths, 10,500 YLLs, 55,800 YLDs and 66,300 DALYs with cannabis-
attributable lung cancer being the largest contributor to mortality and YLLs, and cannabis use 
disorder accounting for most YLDs.158 The current system of prohibition under which cannabis is 
situated disproportionately implicates marginalized communities through criminal records that 
affect employability, housing, and professional prospects. 
Perceptions of health risks related to cannabis use  
 
In 2015, after the Government of Canada announced its intention to legalize the 
nonmedical use of cannabis, the public discourse was anticipated to shift social norms affecting 
perceptions of health risks associated with cannabis.159 Social norms influence substance use 
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behaviours, particularly among young people; they represent expectations about how others 
perceive and evaluate our behaviour. In November 2017, approximately two-thirds (65%) of 
Canadians reported support of cannabis legalization, an increase from one-fourth (26%) in 1975, 
indicating increasingly permissive attitudes toward the substance.160 Once considered a deviant 
behaviour within criminal subcultures, cannabis use is increasingly perceived as a common feature 
of Canadians’ leisure time.161 According to work from Parker and colleagues’ Normalization 
Thesis, this increasingly normalized fixture of Canadian society may provide a sort of stability in 
terms of individuals’ cannabis use behaviours as they bridge their substance use from adolescence 
into adulthood.162  
Cannabis use in this social climate has the potential to become an object of consumption 
and identity formation in parallel ways alongside other sociocultural artefacts such as music, 
fashion, media, and technology.163,164 The divergence between actual risks and perceived risks has 
been well documented among Canadians. Public perceptions of risk due to substance use such as 
cannabis is incongruous with actual risk and imposes cost to Canadian society as discussed in the 
previous section – this can be understood through the Social Amplification of Risk Framework, 
which describes how increased familiarity with a source of risk exerts an attenuating influence on 
perceptions of risk.165 
 Canadian youth perceive that cannabis use is more prevalent and widespread than it 
actually is among their peers as well as the general population.166 Young Canadians report that 
cannabis is generally benign and is a substance used by “everybody” referring to it as “natural” 
and “not really a drug at all”.121,166 Cannabis users tend to have unique perspectives on risks 
associated with use based partly on personal experiences with the product and their observations 
of others’ use of cannabis that contributes to their perspectives. While temporality and 
directionality precludes concrete conclusions regarding risk perception and cannabis use, cross-
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sectional surveys such as the US Monitoring the Future study reveals an inverse association 
between risk perception and youth use – young people who perceive a substance such as cannabis 
to be high risk, are less likely to use it and vice versa.167,168  Exploring more specific risk 
perceptions from a nationally representative survey of Canadians (N=2,088) conducted in 2016 
reveals that approximately 7 in 10 (71%) respondents perceived that driving under the influence 
of cannabis was as bad as driving under the influence of alcohol.159 Approximately 6 in 10 (58%) 
perceived cannabis to be addictive, and 1 in 2 (55%) indicate that use of cannabis does not lead to 
the use of other illicit substances.159 Approximately 1 in 5 Canadians were unsure if cannabis 
caused physical (21%) or mental (23%) harm.159 Young Canadians and the population at large 
have very little knowledge about the health risks associated with cannabis contributing to their 
perceptions of risk.  
Risk perceptions refer to the subjective judgements that individuals make about the severity 
and characteristics of a risk.169 Risk perception’, as a construct, is embedded in a variety of 
behavioural theories used to predict substance use. For example, the Health Belief Model identifies 
perceived risk as a significant factor in an individual’s decision to engage in a particular health-
related behaviour which includes sociodemographic factors such as sex, age, gender, race-
ethnicity, and knowledge in influencing beliefs which in turn influence behaviours.170,171,172,173 As 
a construct, risk perception plays a significant role in influencing an individual’s intention to use 
cannabis.174 An understanding of how individual level factors such as perceptions of risk and 
severity, and how these factors interact with broader environmental factors to culminate and 
manifest themselves in different substance use behaviours is essential.175 Increasing perceptions 
of health risks may be insufficient in reducing a potentially destructive behaviours of interest. 
Greater health knowledge has been associated with behaviours of interest in tobacco control 
research including reductions in smoking initiation, increased engagement in cessation behaviours 
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and long-term abstinence from smoking that may be relevant to cannabis control 
measures.176,177,178,179  
The legal and regulatory status of cannabis in Canada 
 
Although nonmedical cannabis use in Canada was illegal from 1923 until 2018, Canadians 
were granted legal access to cannabis for medical purposes in 2001.180 In 2000, a legal decision 
based on Section 56 exemptions under the Controlled Drugs and Substances Act gave eligible 
individuals with serious medical needs access to the dried herb form of cannabis.181 The 
Marihuana Medical Access Regulations (MMAR), implemented in 2001, gave Canadians who 
were approved and received licences from Health Canada the right to possess a legal supply of 
dried cannabis for medical purposes through one of three options: Health Canada’s supply, a 
personal cultivation licence, or a designated-person licence to produce cannabis for the approved 
individual.182 Several years into the program, few Canadians had obtained MMAR approval, and 
many reported obtaining their supply of medical cannabis through illegal sources.183 
In 2012, the MMAR framework was replaced with the Marihuana for Medical Purposes 
Regulations (MMPR), which addressed concerns related to: the practice of industrial cultivation 
and distribution, access restrictions, lack of plant and seed diversity (licenced producers were only 
legally permitted to produce a single strain), as well as concerns regarding the health and security 
of home cannabis producers (e.g., risk of violent home invasion, health concerns from mould, air 
quality issues, electricity installation).184  
The MMPR outlined the creation of a licensing scheme and development of standard 
conditions for commercial production and distribution.184 Under the MMPR, health care providers 
also had greater flexibility over diagnoses for which they were permitted to prescribe 
cannabis.185,186 In 2015, the MMPR was further modified after the Supreme Court of Canada found 
that it would be unconstitutional to restrict access to cannabis solely to its dried herbal form (R v. 
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Smith); a broader scope of cannabis forms (i.e., bud, oil, fresh leaves, etc.) became legally available 
to approved cannabis users.187 
In 2016, the MMPR was replaced by the Access to Cannabis for Medical Purposes 
Regulations (ACMPR) in response to a Federal Court decision (Allard v. Canada), which found 
that individuals did not have “reasonable access” to medical cannabis under the MMPR (which 
required sole access from licenced producers) and thus it violated section 7 of the Canadian Charter 
of Rights and Freedoms.188 The ACMPR retained aspects of MMAR and MMPR that established 
the framework for conditions for commercial production and distribution by licenced producers, 
as well as additional forms that were legally acceptable under the MMPR. The ACMPR limits the 
quantities of cannabis an individual can possess but allows for the personal production or 
production by a third party for the use of the approved user.181 
In 2016, the Canadian government began the process of legalizing nonmedical cannabis 
use. The government appointed a Task Force on Cannabis Legalization and Regulation, which 
issued a series of recommendations in their final report, released in November 2016.22 The Task 
Force recommendations, intended to minimize the harms of cannabis use, included enforcing a 
minimum age of purchase (18 years), applying limits to cannabis promotion, requiring plain 
packaging and specific labelling requirements, creating limits on maximum THC content per unit, 
clarifying distribution systems, and enhancing efforts to detect and discourage impaired driving 
from cannabis use. A unique feature regarding the Taskforce document is its provision that 
recognizes the benefits that cannabis may have. Part of its guiding principles includes the 
protection of public health and safety as its primary goal, “which includes minimizing harms and 
maximizing benefits”.22 This stipulation and its mention throughout the remainder of the document 
stands in stark contrast to public health messaging in the United States, where the substance is not 
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recognized to have any medical value and is categorized as having a high potential for being 
abused.189  
Using the recommendations developed by the Taskforce’s efforts, the Government of 
Canada introduced Bill C-45 on April 13, 2017, An Act respecting cannabis and to amend the 
Controlled Drugs and Substances Act, the Criminal Code and other Acts, better known by its short 
hand, the Cannabis Act. The proposed Act outlined the creation of a comprehensive national 
framework to legalize and provide restricted access to regulated cannabis. Further, it seeks to 
control cannabis production, distribution, sale, import, export, and possession.190 These controls 
include the regulation of minutiae that include considerations related to production licencing, 
product standards, advertising and marketing restrictions, and shared taxation authority. Provinces 
and territories will be primarily responsible for deciding their respective retail sales regulations.  
The federal government legalized nonmedical cannabis in October 2018 making Canada the 
second country to legalize the nonmedical use of cannabis, after Uruguay.191,192 
History of tobacco marketing and directions for cannabis 
 
 There are parallels between cannabis and tobacco use as has been discussed in terms of 
their similar modes of administration, their frequent co-administration, and their potential 
presentations in the market. In order to understand the importance of marketing strategies and 
health warning labels (HWLs) specific to cannabis products, it is useful to describe, in brief, how 
these came to be such powerful media tools by which Industry and Public Health have sought to 
find solutions to their respective problems, the former with an interest in creating and maintaining 
captive consumers, and the latter attempting to prevent disease and protect human health. Besides 
being a powerful health communications tool, media is able to shape and reflect social values 
around substance use.193  
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In Canada, the period around World War I (1914-1918) resulted in a 28-fold increase in 
tobacco cigarettes consumed – from 87 million in 1896 to approximately 2.4 billion in the early 
1920s.194 Tobacco companies targeted military personnel and supplied troops with tobacco 
products.195,196 A New York Times article of the time stated that smoking cigarettes, “lighten the 
inevitable hardship of war” and were described as, “the last and only solace” of the wounded.196  
Use became widespread and the rapid expansion of cigarette smoking and new consumers entering 
the market was later attributed to the very effective advertising and promotional strategies that 
were employed.197 
Use of tobacco continued to surge until around the time the United Kingdom’s Royal 
College of Physicians and Canada’s Minister of National Health and Welfare Judy LaMarsh 
declared that there was, “scientific evidence that cigarette smoking is a contributory cause of lung 
cancer” in 1963 on separate instances. Six months after LaMarsh’s statements, the US Surgeon 
General, Dr. Luther L. Terry, declared that cigarette smoking was causally related to lung cancer 
in the pivotal work, Smoking and Health: Report of the advisory Committee to the Surgeon General 
of the Public Health Service.198 Figure 3 below depicts patterns of changes in consumption 
behaviours among Canadians before and after this information was communicated.  
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Figure 3 Canadian per capita (age 15+) cigarette consumption (including roll-your-own), 1921–95. Consumption 
during the 1990s includes contraband estimates, as a result there is some uncertainty. Imports, typically very low, 
not included199 
 
The following decades marked the emergent tobacco control effort and in parallel, tobacco 
companies’ efforts to counter claims of their products’ harm to health, disputing what they felt 
were false allegations. The market was flooded with new claims and product presentations that 
implied that the new ‘low-tar’, ‘light’ and filtered products were safer though no evidence existed 
then or now that supported those claims.200 In 1969, a report by the House of Commons Committee 
on Health, Welfare and Social Affairs, also known as the Isabelle Report) contained 
recommendations for a complete ban on advertising, for health warnings to be placed on packages 
and vending machines, listing tar and nicotine levels, restriction of places of distribution such as 
vending machines, among other recommendations.199 Shortly thereafter, in 1971, Bill C-248, the 
Cigarette Products Act, was introduced – it would have eliminated advertising, required warnings 
on packages and in places products were sold and would have created an authority to set maximum 
nicotine and other constituent limits – however, it was never debated and instead, voluntary 
guidelines were developed by the tobacco industry and health warning labels were not 
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implemented until approximately 20 years later.199 A legal battle that started in 1999 regarding the 
historical misrepresentation and deception of the general public about the harms caused by using 
tobacco products culminated in 2017 with the US Federal Court mandating marketing campaigns 
containing a number of statements regarding the health effects of smoking that were broadcast on 
primetime television, and in 50+ influential newspapers (e.g., New York Times, Wall Street 
Journal, USA Today) – a penalty of approximately $30 million in total.201 It is estimated that the 
tobacco industry spends approximately $8 billion, or $24 million per day on advertising, 
promotions and sponsorships in America and Europe alone.202 The Department of Justice decided 
that increasing the public’s health knowledge specific to tobacco products would influence risk 
perceptions and subsequent health behaviours among those exposed to the messaging as discussed 
previously in this dissertation. Notably, unlike their product advertisements and marketing, the 
court-mandated advertisements were void of colour, vivid imagery, or emotion when the messages 
were presented on television, an attempt to dampen potential persuasive effects. 
Advertising is “the use of media to create positive product imagery or positive product 
associations or to connect the product with desirable personality traits, activities or outcomes. 
Promotion, also called marketing, can be defined as the mix of all activities which are designed to 
increase sales”.203 Advertising may also be indirect which refers to practices that accomplish the 
same goals of increasing the appeal of a product’s brand, these activities often occur adjacent to 
traditional advertising media such as the provision of promotional items, contests, free samples, 
holidays, sponsorships, as well as “brand stretching” where the product’s brand is translated onto 
unrelated products such as clothing, cafes etc.204  Advertising and related activities manipulate 
perceptions and appeal of a particular product to increase an individual’s intention to consume. 
Product characteristics affect comparative perceptions of their potential benefits and/or harms.205 
Few young people initiate substance use behaviours due to a substance’s inherent characteristics 
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(i.e., a tobacco cigarette’s nicotine content, a cannabis cigarette’s THC:CBD ratio), rather, they 
have been described as being attracted to the five S’s: sophistication, slimness, social acceptability, 
sexual attractiveness, and status that advertisement of a product is able to manipulate.199  Numerous 
studies have observed positive causal relationships between advertising and promotional activities 
and onset and continuation of smoking among youth and young adults.197,206,207,208 
Since at least 1970, despite continual denials, multinational tobacco companies including 
Philip Morris, British American Tobacco (including Brown & Williamson), and RJ Reynolds have 
considered manufacturing cannabis-containing cigarettes.209,210,211 The 80+ million pages of 
documents that were released during litigation against these industry giants also reveal a sense of 
urgency they felt to develop adequate potential products and paraphernalia to enter the market as 
the sociopolitical climate became increasingly favourable.215 Currently, there are long standing 
interests in the cannabis market from the Tobacco Industry; one that has repeatedly been shown to 
modify its products to increase addictiveness, provide misleading information, and use advertising 
and marketing to increase demand and change and expand how consumers use cannabis.201  
Philip Morris registered the brand name Marley in France in 1993, along with a number of 
other colloquial terms for cannabis.212,213 Denver saw medical cannabis dispensaries outnumber 
Starbucks cafes in 2011 (300 vs 266).214 In 2012, the cannabis industry in the US started 
advertising medical cannabis with a “menthol taste”.215 In March 2014, the first television 
advertisement for medical cannabis appeared on major networks including CNN, Fox, and 
ESPN.216 Also in 2014, Altria (formerly Philip Morris) purchased Green Smoke, an e-cigarette 
company with branding and product offerings suggesting crossover use (Figure 4).215 E-cigarettes 
are another nexus between cannabis and tobacco as these devices may be fitted to be used with 
derivatives of cannabis such as hash oil and are difficult to distinguish from nicotine-delivering e-
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cigarettes. The tobacco industry should be expected to be ready and prepared to enter and be an 
aggressive player in the cannabis market providing incentives to increase cannabis use. 
 
Figure 4 Flavoured product offerings from Altria (formerly Philip Morris). Source: https://www.greensmoke.com 
 
 
Cannabis retailers have established a presence on the internet. Recently, there have been 
attempts to describe young people’s online environments such as social media’s presentation of 
cannabis and related activities, as these cyber spaces may represent credible sources of information 
for youth and young adults.217,218 For example, a recent study by Lamy and colleagues 
demonstrates how social media platforms like Twitter are able to disseminate information about 
cannabis that describes it as “pure”, “clean”, and a “natural medicine”.219 Ouellette and colleagues 
describe how YouTube users are spreading information about cooking with cannabis, receiving 
collectively 15.6 million views though little is currently known regarding the basic effects these 
preparations may have or about users’ habits of ingesting  edibles.220 Work by Ramo and 
colleagues identified more than 700 phone applications related to cannabis and characterized them 
as likely vehicles for cannabis related information and misinformation.221 The online environment 
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is an important burgeoning area of work regarding cannabis-related messaging and a space where 
its normalization is currently taking place. 222 
To date, there exist few studies that have investigated the impact of cannabis-specific 
marketing and its influence on consumer behaviours. The experience from Oregon, which has a 
legalized cannabis market, has been documented and confirms that exposure to cannabis-related 
advertising will be prevalent and influential to surrounding communities as well as subgroups of 
particular interest that include youth and young adults. 223 Similar studies have been conducted that 
confirm and quantify sources of cannabis advertisements and promotional materials.224,225 
According to the Reinforcing Spirals Model of Media Exposure (RSM), which describes processes 
that lead to the formation and subsequent maintenance of attitudes such as ideologies or more 
transient and temporary behaviours, exposure to cannabis-related media increases the likelihood 
of cannabis-related behaviour which may be reinforcing processes that lead to increasing the 
likelihood of continuing to engage in that or similar behaviours.226 A recent study from California 
illustrates RSM; young people’s exposure to medical cannabis advertisements was associated with 
a greater likelihood of cannabis use and stronger intentions to use 1 year later.217 Furthermore, 
clinical work in the area confirms that public advertising of cannabis elicits activations in the 
brain’s reward circuit (striatal activation) similar to those seen after primary rewards such as food 
or water.227 In summary, while there is currently very little work in this area that is specific to 
cannabis advertising. However, what is available seems to be analogous to the experiences with 
tobacco issues in this area in terms of a positive association between exposure to advertising and 
marketing and increased consumption. 
Canada’s proposed policy measures on cannabis products 
 
 The Cannabis Act came into force on October 17, 2018.228 The Cannabis Act’s provisions 
require general prohibitions on the promotion, packaging, labelling and display of cannabis 
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products and related accessories.141 Provinces and territories were given the responsibility to 
determine distribution and retail models and flexibility to determine different related regulations 
related to setting distinct minimum age, decreasing possession limits, restricting locations where 
cannabis may be used, and setting requirements for personal cultivation.229 Across Canada, 
personal public possession limits are consistent at 30g of dried herb or its equivalent, consistent 
with the recommendations of the Cannabis Act and with the exception of Alberta and Quebec that 
decided 18 as the minimum age of purchase, the minimum age of purchase across Canada is set at 
19 in the rest of Canada.229  A summary of regulations is presented in the table below and current 
as of October 22, 2018. 
Table 3 Summary of provincial and territorial nonmedical cannabis restrictions and retail distribution229 
Province Legal Age Retail Public Possession Limit 
Alberta 18 PLS, Online 30 grams 
British Columbia 19 GOS, Online 30 grams 
Manitoba 19 PLS, Online 30 grams 
New Brunswick 19 GOS, Online 30 grams 
Newfoundland and Labrador 19 PLS, Online 30 grams 
Northwest Territories 19 GOS, Online 30 grams 
Nova Scotia 19 GOS, Online 30 grams 
Nunavut 19 GOOS, Phone 30 grams 
Ontario 19 GOOS 30 grams 
Prince Edward Island 19 GOS, Online 30 grams 
Quebec 18 GOS, Online 30 grams 
Saskatchewan 19 PLS, Online 30 grams 
Yukon 19 GOS, Online 30 grams 
PLS=Private licensed stores, GOS= Government operated stores, GOOS=Government-operated online store 
Packaging & Branding 
 
Package, product design, and branding play key roles in determining the level of appeal 
that a particular product has to its consumer. There exists a great deal of evidence from the tobacco 
and alcohol domains that the appearance of a product is designed to encourage initiation of use, 
increase use, and promote brand loyalties.230,231,232,233,234  
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Restrictions on traditional forms of tobacco advertising Canada has left tobacco packaging 
as the primary channel for promotion, development, and maintenance of brand identity which 
create or sustain positive associations, expectations, and reductions of risk perceptions of 
products.235 According to Philip Morris’ International Social Acceptability Research, “[t]he 
following key elements are of prime importance in the enhancement of the smoker’s self-
perceptions: the physical characteristics and appearance of a product, including length, diameter, 
tipping (materials forming the mouth piece), etc. – the package, including brand name, logo, 
design, crest, box, soft pack, etc. – the advertising, including role models, personality/lifestyle-
identification, product support, etc.”236 Indeed, independent studies and tobacco industry research 
documents regarding packaging characteristics and consumer perceptions have described the 
impact on subsequent consumer behaviour and the specific elicited perceptions of each packaging 
detail – refer to the table below.235  
Brand imagery, which encompasses logos, colour, brand variants, etc. encourages 
consumers to draw inferences about the contents of a package and the likely experience they will 
have as a result of consuming the product. Brand imagery aims to satiate needs and social identities 
among existing and prospective consumers.237,238,239,240   
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Table 4 Package characteristics and consumers' elicited product perceptions. 
Package Characteristic Consumers’ Elicited Product Perceptions 
Rounded, octagonal, or ‘beveled’ 
edges241 
stylish, elegant, class 
Novel openings and shapes241 contemporary, modern 
Slim and thin241,242,243 increased attractiveness (particularly women), milder content, less harmful 
Colour combinations244,245 higher quality, lower tar, lower nicotine 
“Smooth” labels246,247,248 lower health risk than “regular” of the same brand 
Lighter colour249,246,250,251,252 less harm, less perceived strength, improved quality, better brand name 
recognition 
Hot colour253 more taste, harsher, stronger 
health oriented descriptors (e.g., 
100% organic)254 




less appealing, less attractive, less projection of personality attributes (i.e., 
cool, popular etc.), lower quality of smoking experience, reduced perceptions 
of implied safety, less sophisticated 
Brand descriptors (e.g., Red, Rich 
Red, Rich Classic Red)248 
increasing number of words associated with greater appeal 
Contains slim diameter 
cigarettes259,260,261 
weaker taste, less harmful 
An important lesson learned from tobacco control was that, short of prohibiting the 
substance, coupling a sizeable and impactful health warning label with vivid imagery and 
standardized packaging including the restriction of brand variants, are proven ways of mitigating 
use and discouraging engagement and initiation of product use and market 
participation.230,262,263,264 
In March 2018, Health Canada released their final proposals for package-specific 
requirements.265 The recommendations include limitations of colours, graphics, and other special 
characteristics to reduce appeal of the product, particularly among youth.141 Packaging for 
cannabis products is required to be opaque, enable inner and outer packaging to accommodate new 
product forms, and be in line with ACMPR regulations (e.g., child-resistant, tamper evident, 
prevents contamination, maintains cannabis dry). The maximum amount of cannabis allowed in a 
single package will be 30 grams of dried herb – or the equivalent for other forms of cannabis and 
consistent with the amount that adults would be able to possess in public spaces under the Cannabis 
Act. A summary of the proposed regulations is outlined in the table on the following page. 
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Table 5 Comparison of proposed packaging and labelling rules for cannabis with current rules under the ACMPR 





Proposed Rules for 
Nonmedical Cannabis 
Proposed/Current 
Rules for Tobacco 
Proposed Rules 
for Vaping 
Universal Symbol REQUIRED (N for narcotic) REQUIRED Not required REQUIRED 
Health warning 
message Not required 
REQUIRED 
required text in yellow 
box; font must be 
largest on the label 
REQUIRED 
graphic and text; 
must cover 75% of 
package 
REQUIRED 
text; standard style 
and size font 
Product Related 
Information REQUIRED REQUIRED RESTRICTED REQUIRED 
Plain packaging     





Font Not restricted 
RESTRICTED 
standard style; size 
limit; single, uniform 
colour 
RESTRICTED 
standard size; size 
limit; Pantone 2C 
grey 
Not restricted 
Brand name Allowed, no restrictions 
RESTRICTED 
size limit; limit of 1 on 
principal display; single, 
uniform colour 
RESTRICTED 












size limit; limit of one 
on principal display 
PROHIBITED Allowed, no restrictions 
Other images or 
graphics 
Allowed, no 





outs, and peel-away 
Allowed, no 
restrictions PROHIBITED PROHIBITED 
Allowed, no 
restrictions 
Package-specific rules    
Standard shape, 
size, material Not Required Not Required REQUIRED Not Required 
Child resistant REQUIRED REQUIRED Not Required REQUIRED 
Opaque or 
translucent REQUIRED REQUIRED Not Required Not Required 
Tamper-evident REQUIRED REQUIRED Not Required Not Required 
The general list of product-related labelling requirements include: name and contact 
information of the product packager, product description, lot number, weight or volume – 
depending on the product class, packaging fat and expiry date, recommended storage conditions, 
THC/CBD content – expressed as a percentage the product could yield and by unit or dose, as well 
as the inclusion of the statements, “KEEP OUT OF REACH OF CHILDREN/ TENIR HORS DE 
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LA PORTÉE DES ENFANTS”, and “Important: Please read the Health Canada document provided 
with this package before using the product/ Important: Veuillez lire le document de Santé Canada 
qui accompagne ce colis avant d’utiliser ce produit”. Standardized cannabis symbol markings are 
required with a minimum size of 1.27 cm (w) x 1.27 cm (h) and be displayed in 25% of the 
principal display panel.  
Figure 5 Standardized cannabis symbol265 
 
 Branding was also accounted for in Health Canada’s regulations which contain strict 
requirements related to the use of branding, logos, and colours. For example, in addition to a brand 
name, only one other brand element may be displayed, other images or colours would be restricted, 
metallic and fluorescent colours would be prohibited, and any colour used would have to contrast 
with required elements in the display of a products package (e.g., cannabis symbol, health 
warnings, etc.).  Examples of the execution of these rules are displayed in Figure 6. 
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Figure 6 Product packaging that is adherent to Health Canada's regulations265 
 
Health warning labels 
 
Accurate health warnings on tobacco products have changed social norms around its use 
and have been very effective in reducing use and consequent disease burden.284 A pack-a-day 
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smoker is potentially exposed to a cigarette pack 7,300 times per year (20 views/day x 365 
days/year). This outweighs exposure to any other public health or other mass messaging campaign 
at minimal cost.266 Well-designed health warnings on cannabis products may have the potential to 
become an important strategy to increase health knowledge and risk awareness through the same 
mechanisms observed with tobacco products and may influence use levels potentially reducing 
harms caused by cannabis use.  
The communication of health risks related to cannabis use will be a priority in cannabis 
control strategies in a legalized market. In tobacco control, health warning labels have proven to 
be the most cost-effective medium to communicate information related to a product’s health 
risks.267,268 Warning labels that display graphic images have been associated with increased 
perceptions of health risks, improved health knowledge, as well as higher measures in motivations 
to quit and increases in cessation behaviours.268  
Cannabis users may benefit from health warnings given that the most recently available 
evidence suggests that cannabis users are not aware of the variety of consequences associated with 
cannabis use and report acquiring health information from a number of uninformed 
sources.159,166,269,270 The U. S. Surgeon General’s report on cannabis expressly stated that the public 
is likely unaware of accurate information about the substance in general but more specifically the 
dosage and potency of cannabis products, both in the licit and illicit markets.271  
While laws are changing, so too is the drug itself with average potency more than 
doubling over the past decade (1998 to 2008) ... products and methods [of using 
cannabis] are unregulated even in states that have legalized marijuana use, users may 
not have accurate information about dosage or potency, which can lead and has led to 
serious consequences such as hospitalizations for psychosis and other overdose-related 
symptoms. Marijuana use can also impair driving skills and, while estimates vary, is 
linked to a roughly two-fold increase in accident risk. The risk is compounded when 




The earliest recorded mention in academic journals proposing the use of health warning 
labels for cannabis products came in 1979 in the United States with many of the same relevant 
conclusions of today. In the event that cannabis should become legalized, it was proposed that it 
should be “…possible for consenting adults to obtain the substance for recreational use. The 
consent element being that they must be aware of the impairment of driving ability, the danger of 
chronic consumption on mental functioning and the possibility of teratogenicity if consumed by a 
pregnant woman…”272 More recent work in the area outlines topic areas where warnings may be 
useful which are not very different from what was outlined in 1979 including messaging around 
drugged driving, mental health and psychological functioning issues, addictive potential, 
responsible use, and perinatal use.273,274,275,276  
In the US, where certain states have legalized the use of cannabis for medical or nonmedical 
purposes, existing labelling policies vary widely. The State of Montana, for example, does not 
currently specify any language or labelling beyond constituent content require to be presented on 
cannabis products according to the most recent Montana Medical Marijuana Act.277 In Alaska, the 
following statement is the only language required on cannabis products, “There are health risks 
associated with consumption of marijuana”.278 Colorado has adopted specific symbols 
differentiating between medical cannabis and nonmedical cannabis, as well as a health warning 
label composed of a paragraph and displayed with the state symbol and the Department of Revenue 
seal. 
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Figure 7 Example warning labels from the United States – Colorado, Washington, and Oregon. THC stands for the 
psychoactive ingredient tetrahydrocannabinol. The ‘M’ in the Colorado warnings indicates that product is medical 










The scant literature on the subject of health warning labels for cannabis products suggests 
that Canada has the potential to have a pioneering role in labelling and implementation of this 
important health communication and education approach. To date, there does not exist any 
empirical evidence regarding the impact that health warnings on cannabis products and population 
health measures or consumer behaviours. Research from other consumer domains indicates that 
the effectiveness of health warnings depends upon their design. Key elements of effective health 
warnings include size, position, borders, and the general appearance of the warning (e.g., colour, 
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graphics and graphic content, and message content).282 Health Canada’s specifications are shown 
in Figure 8. Interestingly, unlike rules for tobacco products, there is no mention of minimum size 
or percentage of main product display that cannabis health warnings must cover. 
 
Figure 8 Health warning messages' layout265 
 
 
The content of the health warnings proposed by Health Canada included the following 
areas: prevention of accidental ingestion, risks associated with different methods of use, risks 
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associated with cannabis use during pregnancy, dangers of impaired driving, risks of combining 
cannabis with other substances, and impacts of cannabis use on mental health – a table of their 
specific messages are presented below, in Table 6.141,283 Health Canada requires mandatory health 
warnings composed of a primary and secondary message to be rotated on package levels. 
 
Table 6 Health Canada's required health warning messages280 
Primary Sentence Secondary Sentence 
WARNING: Cannabis smoke 
is harmful. 
Harmful chemicals found in tobacco smoke are also found in cannabis 
smoke. 
WARNING: Do not use if 
pregnant or breastfeeding. 
Using cannabis during pregnancy may harm your baby and result in 
low birth weight. 
OR 
Substances found in cannabis are also found in the breast milk of 
mothers who use cannabis. 
WARNING: Do not drive or 
operate machinery after using 
cannabis. 
More than 4,000 Canadians were injured and 75 died from driving after 
using cannabis (in 2012). 
OR 
After cannabis use, coordination, reaction time and ability to judge 
distances are impaired. 
WARNING: Cannabis can be 
addictive. 
Up to half of people who use cannabis on a daily basis have work, 
social or health problems from using cannabis.  
OR 
1 in 11 people who use cannabis will become addicted.  
OR 
Up to 1 in 2 people who use cannabis daily will become addicted. 
WARNING: Regular use of 
cannabis can increase the risk 
of psychosis and 
schizophrenia. 
Higher THC content can increase the risk of psychosis and 
schizophrenia. 
OR 
Higher THC content can lower the age of onset of schizophrenia. 
OR 
Young people are especially at risk. 
WARNING: Adolescents are 
at greater risk of harms from 
cannabis. 
Early and regular use increases the risk of psychosis and schizophrenia. 
OR 
Using cannabis as a teenager can increase your risk of becoming 
addicted. 
OR 




Position and Size 
 
 Article 11 of the World Health Organization’s Framework Convention on Tobacco Control 
(FCTC) recommended that graphic warning labels take up 50% or more, but no less than 30% of 
a cigarette pack’s principal display areas – the 2008 guidelines recommended stronger language, 
and that labels cover more than 50% of the packs’ principal display areas.284 Article 11 also 
specifies that Parties should ensure maximum visibility of health warning labels by displaying 
them prominently at the top of the principal display areas.285 Displaying graphic health warnings 
at top of product packs has been shown to increase salience and recall compared to text-only 
warnings appearing on the sides of packages such as those in the US.282,286 A recent simulation 
study in the US determined that the implementation of a prominent pictorial health warning label 
covering prominent cigarette display areas to replace existing text-only warnings on the side of 
cigarette packages has the potential to decrease prevalence of smoking by 5% (2.5%-9%) on the 
short term and up to approximately 20% (4%-19%) over the long term.287 
Size matters when it comes to the impact that health warning labels have on consumer 
perceptions and ensuing behaviours. Empirical research has demonstrated that larger warnings 
increase cognitive reactions and processing of information, are perceived to be more important, 
are more attention grabbing, and are more likely to be remembered.288,289,290 Different countries 
around the world have started to experiment with increasing health warning labels from covering 
50% to 80% of the products’ display areas – this increase in size has been associated with increased 
salience, and greater overall rated effectiveness.290 These findings are consistent with ideas of 
decreasing brand livery to decrease measures of appeal simultaneously increasing warning size to 
heighten risk awareness.  
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Use of Pictures 
Relative to text-only health warnings, pictorial health warnings are more likely to promote 
cognitive elaboration of risks, increased ability to attract and hold attention, and improve recall as 
they are more likely to remain salient over time and promote encoding to memory.291,292,293 
Pictorial warnings have been shown to provoke more thought about the health risks associated 
with tobacco as well as motivations and intentions to cease using tobacco.266 Thus, the combination 
of increased attention, scrutiny, and warning credibility are associated with increased risk 
perceptions.294 A randomized clinical trial of over 2000 American smokers found that significantly 
more individuals in the trial reported quit attempts when they were provided with pictorial health 
warnings than those receiving the normal US packs with text-only warnings.295  
Warnings that display and highlight stark or graphic images of the physical health effects 
of smoking may be particularly effective. Among youth, warnings that highlight negative aesthetic 
effects or those that portray an effect to their ability to participate in some kind of activity are rated 
as having a greater impact.296,297,298,299 Pictorial warning labels also have the potential to better 
inform low-literacy users and promote all of the intended benefits including reduced use, increase 
cessation behaviours, and reduction of overall appeal.300 Defensive avoidance behaviours have 
also been observed to be elicited from pictorial health warnings including health warning 
avoidance as well as reactance, the act of deliberately engaging in a prohibited behaviour in spite 
of the utility a piece of advice may confer to the individual; regardless of these behaviours, 





 Colour is an important aspect of health warning labels. Instructions regarding the health 
warning colours are outlined in Article 11 of the FCTC. Rather than present black and white 
warnings, it is recommended that participating states mandate full colour for pictorials included in 
health warnings, and contrasting colours for text elements.285 Evidence demonstrates that vivid 
colour affects overall noticeability and maximizes legibility of text which may lead to increased 
cognitive processing of content.285,306 Health warning labels presented in colour are perceived to 
be more hazardous and are even more effective when they are presented with signal words such as 
‘DANGER’, ‘CAUTION’, and ‘WARNING’ – ‘DANGER’ outperforms the other two signal 
words in producing higher ratings of perceived hazard.307 
Message content 
 
 It is important that health warning messages be credible, supported sufficiently by an 
established knowledge base, and be relevant to its target audience in order to be effective 
communication tools.298 Additionally, these messages should be presented in a graphic manner 
that produces emotional reactions that discourage use. Negative affect arousal elicited by tobacco 
warning labels has been studied largely in terms of the valence of the elicited emotional arousal, 
that is, whether they evoke positive or negative emotions.308  However, negative emotions such as 
fear, disgust, and anger have been observed to lead to differing resulting behaviours and attitudes. 
Messages that elicit fear or disgust are associated with protective and avoidant behaviours such as 
smoking cessation and increasingly negative attitudes toward tobacco.309,310,311 In contrast, health 
warning communications that provoke anger produce approach tendencies, retributive attitudes, 
and potentially also reactance as the warning represents a kind of threat to personal freedom.301,312 
Among low socioeconomic populations, prompting negatively valanced conversations may 
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activate social networks to further discuss a negative health endpoint portrayed in a warning label 
and prompt further discussion and inquiry thereby supporting control efforts.313 
 The messages that are displayed in warning labels should use clear and concise language 
and include a range of different issues that resonate with different users making them personally 
relevant such as the different themes discussed in the ‘Health effects of nonmedical cannabis use’ 
in this dissertation. Given the lack of work in this area specific to cannabis products, various 
message formats including testimonials, positive and supportive information that have been 
effective in tobacco control efforts should be considered.314 Wear-out or overexposure refers to 
the loss of effectiveness of a particular health message due to desensitization of health impact due 
to diminished salience and noticeability; health warnings should be periodically rotated as per 
Article 11 of the FCTC Implementation Guidelines for this reason to reduce habituation.285 
Information on resources such as telephone quit lines is another way to support control 
efforts as they have shown effectiveness in increasing long term smoking abstinence rates.315 
Generally, the goals of these services aim to increase motivation and self-efficacy among smokers. 
In Canada, the introduction of a toll-free number for a quit-smoking line led to an increase in call 
volumes to existing helpline centers, the number of new callers, as well as a broadening of the 
types of callers that accessed this service.316  Call centre services that are specialized to cannabis 
issues may be perceived as more credible and promote engagement than existing strategies that 





Canada’s decision to legalize nonmedical cannabis in 2018 provides a unique opportunity 
to inform a novel policy domain with important implications to public health. To date, the current 
state of knowledge regarding the health and social impacts of nonmedical cannabis use in the 
Canadian context has been the subject of much debate and speculation.1,59,271 There continues to 
exist many uncertainties regarding the broad implications that cannabis legalization will have 
within Canadian society.318 Much of the empirical evidence that exists comes from U.S. states, 
which operate in much different setting given federal prohibitions on nonmedical cannabis. In 
Canada, the public remains generally unaware of accurate information about cannabis including 
important issues surrounding basic concepts such as potency and dosage in both the licit and illicit 
markets.271 Equipping individuals with evidence-based information about the health and social 
consequences associated with the nonmedical use of cannabis should be a central priority in 
cannabis control efforts. 
Health warning labels have proven to be the most cost-effective medium to communicate 
information related to a product’s health risks and have been associated with use reduction due to 
their prominence and ubiquity. Similar efforts should be translated to cannabis control. The 
Cannabis Act contains language acknowledging the need for comprehensive packaging and 
labelling regulations as well as specific domains of interest with respect to the broad content of 
health warning labels; however there is no substantial empirical research specific to cannabis to 
guide this process.190 The current study was the first to systematically test different text and 
pictorial health warning labels for cannabis products, how Canadian consumers may interact with 
different constituent labelling execution styles, as well as examine different branding elements and 




This thesis investigated the following questions: 
 
 
1. What are current health beliefs and perceptions of risk among young Canadians? To what 
extent do health beliefs and perceptions differ by cannabis use status? 
 
2. What are the differences in perceived effectiveness of text and pictorial health warning labels? 
Are certain health warning themes more likely to be recalled than others? 
 
3. What is the most effective approach for labelling cannabis product constituents and product 
dose? 
 
4. What is the effect of different types of branding elements and descriptors on product 





 There have been substantial efforts to understand the mechanisms underpinning the 
effectiveness of health warnings on tobacco products. Health warning labels represent a powerful 
health communications tools because the potential frequency of exposure can be very high, as 
much as 7,300 times per year for a pack-a-day smoker (20 views/day x 365 days/year) and viewing 
this health communications medium becomes part of the use behaviour – no other health 
promotion strategy has similar reach. To understand different pathways by which health warning 
labels achieve their effectiveness, the International Agency for Research on Cancer’s conceptual 
framework for evaluation of health warning policies will be used; it shares many similarities with 
other models of the hypothesized causal chain of how tobacco control policies exert influence on 
a broad array of resultant use behaviours (Figure 9).319,322  
Within this framework, the effects of health warnings occur through policy-specific and 
general mediators to describe how they influence a range of behaviours. Specifically, health 
knowledge, perceptions of risk, brand appeal, affective reactions and cessation knowledge are 
thought to mediate behavioural outcomes. Increasing risk perceptions and health knowledge have 
been associated with reductions in initiation, increased engagement in health protective 
behaviours, and long-term abstinence from smoking.177,178 Exposure to pro-use cues through 
marketing and branding practices promotes initiation, continuation, and increased use of products 
– restricting, or blunting this effect by making products less attractive to consumers is thought to 
have downstream effects of reducing product use.320,321 Finally, there is a sizeable evidence base 
that suggests that health warnings that elicit affective reactions such as fear or disgust are likely to 
dissuade individuals from using products and that increasing cessation knowledge is another 
pathway through which use reduction may be promoted.291,322  
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Figure 9 Conceptual framework for evaluation of health warning policies (IARC, 2008)322 
 The primary objective of health warning labels on cannabis products is to communicate 
the health effects associated with use. Thus, the ways by which individuals notice, understand, 
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process, and interpret information are central concepts in understanding the connections between 
health warnings and their impact on use behaviours. One broad way to understand how 
individuals make decisions is by conceptualizing them as information processing units. Through 
this lens, people respond according to the inputs or data they are fed which they then process to 
make particular reasoned decisions.323 Under this view, units are limited-capacity information 
processors with physiological limits in their ability to recall, arrange, and rearrange information 
in response to particular stimuli. With regard to substance use, which often makes its debut in 
adolescence, the information-processing unit, the teenager, is limited by her neurophysiology to 
evaluate a risk in the same way as her adult counterpart – instead, she is more likely to be guided 
to seek maximization and optimization of immediate pleasure, deemed rational at this 
psychosocial life stage.324  
The Heuristic-Systematic Model (HSM) is another way to understand how individuals 
formulate a judgement of perceived risk. The HSM posits that when individuals formulate risk 
perceptions, they use solely systematic, effortful scrutiny or solely heuristic processing – whereby 
a shorthand use of cues to arrive more easily at a judgement takes place, or a combination of both 
modes of processing information to make an evaluation of risk.325,326 The work of HSM is an 
extension of the elaboration-likelihood model (ELM), itself also a dual process theory which states 
that aspects of people’s primary motivational concerns are to attain accurate attitudes that are 
congruous with perceived relevant facts.326  In terms of cannabis use behaviours, the HSM-ELM 
suggests that increasing risk perceptions may lead to increasingly systematic thoughts regarding 
potential hazardous outcomes related to cannabis use. Graphic and pictorial health warning labels 
and supporting information may provide a vehicle to initiate thoughts about the potential 
consequences of engaging in cannabis use behaviours and have an impact on these. In contrast, 
individuals that engage in heuristic thought processing, the kind of ‘knee-jerk’ reaction wherein 
 52 
individuals may not be concerned with health-protecting messages due to alarm fatigue (e.g., over-
exposure to a warning327), or are avoidant of the message do not engage in deep thought about it 
and are thus less motivated by the advice. These theories present important principles in guiding 
the effectiveness of warning labels by promoting salience, noticeability, novelty, and credibility to 
influence greater systematic thinking about the health effects associated with cannabis.  
The prediction of engagement in health behaviours has been the focus of substantial 
attention in health psychology with a number of prominent social cognition models, such as the 
Theory of Planned Behaviour (TPB) or the Theory of Reasoned Action (TRA), historically applied 
to a broad range of health behaviours.324,328,329  The TRA describes a resultant human behaviour as 
being determined by intentions, attitudes, and subjective norms. An individual may choose to 
initiate or continue to engage in one or more substance use behaviours if they believe that others 
they hold in high esteem, such as a good friend, provide positive cues that enable the 
behaviour.328,329  Put simply, it describes a subjective evaluation of risks and/or benefits influencing 
behavioural intention.330 This framework for understanding behaviour has implications in terms of 
the ways by which individuals may make choices about the cannabis products they will use and 
how they use them based on the information presented in labelling, packaging, and marketing 
formulations.331 
The theories discussed so far work on the assumption that substance use behaviours are 
rational, conscious, and deliberative. It is difficult to account for irrational and unconscious 
decision-making that occurs in adolescence in terms of impulsivity due to immature pre-frontal 
cortex leading to reactive decision-making.332 From an evolutionary perspective, conjuring up 
thoughts of death and increasing death awareness seems to be related to coalition psychology – 
arguably, the threat of death induces the activation of a social mechanism that involve coalescing 
in alliances as it was through numbers that primitive humans were able to defend against death 
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threats.333 Cannabis use culture involves a social context that includes rituals, symbols, and stories. 
An individual’s participation and level of identification with the subculture induces a deep sense 
of belonging, ultimately identifying with the subculture’s immortal values, norms and existence 
which may provide a sense of control, self-esteem and relief from persistent death awareness.334 
An alternate possibility from work around alcohol consumption is that an alteration of 
consciousness provides temporary cognitive relief of intolerable existential insecurity, death 
anxiety, similar to self-medication for relatively less troubling anxieties (i.e., social anxiety).335  
Either way, explicit mortality appeals are not necessary antecedents to arouse or conjure up 
cognitions related to death – serious health consequences may do so as well.332  Increasing 
awareness of protective behaviours or presenting actionable strategies to mitigate risks (e.g., 
helplines) have the potential to promote health and reduce associated morbidity related to cannabis 
use.  
Brand appeal is understood to mediate effectiveness of health warning labels and may be 
understood using the framework presented in Figure 10. Historically, tobacco companies have 
used packaging to display brand imagery and descriptors that convey false reassurance regarding 
the potential risks associated with their products (e.g., displaying ‘Light’ or ‘Mild’ descriptors to 
communicate reduced harm).336 Perceptions of risk associated with products are understood to be 
mediated by consumers’ information processing strategies, health knowledge, beliefs about 
descriptors, and moderated by their perception of the brand as well as information that is provided 
by health authorities.322 Given the existing evidence related to tobacco control, the implementation 
of graphic health warnings, standardized packaging and the removal or strict limitations of brand 
descriptors and imagery may be effective strategies in minimizing harms that may be associated 
with cannabis products. 
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An online cross-sectional survey was conducted from October 10th to October 24th, 2017. 
The sample was restricted to individuals aged 16 to 30 years of age with a Canadian IP address, 
and included cannabis users and non-users. The study included a comprehensive background 
survey to determine sociodemographic characteristics, cannabis use behaviours, health knowledge, 
as well as attitudes and beliefs around cannabis use. The survey also contained three series of 
between-group experiments. First, respondents were randomized to view health warnings 
according to one of two experimental conditions: text-only warnings, and pictorial warnings 
accompanied by text. The second set of between-group experiments required respondents to 
complete a set of functional tasks related to cannabis product constituent labelling which they were 
randomized into. The final experimental section investigated perceptions of brand imagery on 
cannabis packaging. In this experimental set, respondents were randomized to view and evaluate 




Participants and Recruitment 
 
Survey respondents were recruited via e-mail through Leger’s consumer panel for web 
surveys which consists of approximately 400,000 active members, half of them sampled using 
probability-based methods using the Canadian Census, along with other non-probability based 
methods, including commercial surveys.337 Respondents aged 16 to 30 were recruited across 
Canada directly with the exception of youth in Quebec where youth aged 16 and 17 were recruited 
through their parents; parental consent was obtained prior to Quebec youth accessing the survey. 
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Respondents received remuneration from Leger in accordance with their usual incentive structure 
($2.00 CAD for this study), which includes both points-based and monetary rewards, as well as 
chances to win monthly prizes. All of the data provided by respondents were anonymous and 
information was kept strictly confidential. The study was reviewed by and received ethics 
clearance from the Office of Research Ethics at the University of Waterloo (ORE# 22392). Overall, 
1,045 respondents completed the study. 
Screening and background survey 
 
 The survey was conducted in English and took approximately 30 minutes to complete, on 
average. The questionnaire contained a number of measures that were drawn from existing 
population surveys (e.g., the Canadian Community Health Survey, the Canadian Student Tobacco, 
Alcohol and Drugs Survey, the International Tobacco Control Surveys, among others) and others 
were developed for this study. Details regarding the source of particular measures can be found in 
the survey document (Appendix 1).  
Potential survey participants were assessed for eligibility using their age; they must have 
reported being 16 to 30 years of age at the time of completion. Participants were then explicitly 
informed that they would, “be asked about marijuana or cannabis use behaviours, demographics, 
and beliefs about marijuana use. When we use the term marijuana or cannabis, this includes the 
dried herb, hashish, hash oil, wax or any preparations of the plant commonly known as weed, pot 
or ganja”—this statement was designed to clarify that we were interested in knowing about all 
cannabis forms and its derivatives in this survey. Additionally, respondents were informed that 
they would be able to refuse to answer any question they wanted. 
In all cases, respondents were provided with information about the study and asked to 
provide consent before participating. If participants provided their informed consent to engage 
with our study, they were reassured their anonymity again and proceeded to complete a 
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background survey that included key sociodemographic measures as well as cannabis use and 
consumption measures including ever use, recent, and current use.  
Measures 
 
 A copy of the survey can be found in Appendix 1 which includes all of the measures that 
were used including their sources in the case of previously validated items. 
Sociodemographic variable measures including sex and gender were drawn from the 
Gender Identity in U.S. Surveillance Group (GenIUSS), indigeneity and ethnicity measures came 
from the Health Canada Cannabis Measures Draft Survey (HCCMDS) and the 2016 International 
Tobacco Control Survey (ITC) respectively, and occupational variables came from the Canadian 
Community Health Survey (CCHS). 
Patterns of cannabis use measures were drawn from the Canadian Student Tobacco, 
Alcohol and Drugs Survey (CSTADS) as indicated in the survey document to indicate ever use, 
recent use, and current use. In determining how many days per week respondents who responded 
affirmatively to ever using cannabis and different modes of cannabis use, items from the HCCMDS 
were used. 
Cannabis forms and modes of use measures were adapted from the HCCMDS to allow 
respondents to specify past 12-month use, modes, and forms of use which included options: 
smoked dried herb/flower/leaf, vaporized dried herb/flower/leaf, vaporized liquid in an e-cigarette, 
mixed or rolled with tobacco (e.g., blunt), hashish, hash oil, concentrate (e.g., butane honey oil, 
shatter, budder, wax, etc.), edibles (e.g., cookies), liquid (e.g., cola/tea), tinctures (e.g., 
concentrated amount ingested orally or taken under the tongue), topical ointments (e.g., lotions, 
salves, balms applied directly to the skin), Fresh flower/leaf (e.g., for juicing), as well as including 
an open text field, ‘Other ____ (please specify without providing any identifiable information)’ in 
case we did not consider another form or mode of using cannabis. 
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Known risks or awareness of negative health effects was assessed with the question, “In 
your opinion, what are the most important negative health effects from marijuana use. Please list 
up to five.” Respondents were presented with open fields to determine a baseline knowledge of 
their known risks associated with cannabis use. These responses will be categorized and grouped 
by the type of domain of concern, (1) Physical health concern, (2) Psychological or emotional 
health concern, or (3) Social concern. 
Perceptions of risk and harm were determined through the following four measures 
Perceived likelihood of addiction: (1) “How likely is someone to become addicted to smoking 
marijuana?” with answer options, “Very unlikely”, “Somewhat unlikely”, “Neither likely nor 
unlikely”, “Somewhat likely”, “Very Likely”, “Don’t Know”. Worry for future health: (2) “Are 
you worried that using marijuana will damage your health in the future?” with answer options, 
“Not at all worried”, “Yes, a little worried”, “Moderately worried”, “Very worried”, and “Don’t 
know”. Mental health harm: (3) “In general, do people risk harming their mental health when they 
use marijuana on a regular basis, for non-medical reasons? with answer options, “No risk”, “Slight 
risk”, “Moderate risk”, “Great risk”, “I don’t know”. Perceived addiction: (4) “Do you consider 
yourself addicted to marijuana?” with answer options, “Not at all”, “Yes, a little addicted”, “Yes, 
very addicted”, “Don’t know”.  
Perceptions of relative risk to other substances or forms of administration were 
adapted from the 2015 European School Survey Project on Alcohol and Other Drugs.338 With 
respect to tobacco and alcohol use, participants were asked, “How much do you think people risk 
harming themselves (physically or in other ways), if they… “ participate in a number substance 
use behaviours with varying degrees of frequency and intensity (e.g., smoke cigarettes 
occasionally, smoke cigarettes every day, drink alcohol (3-4 drinks) occasionally, drink alcohol 
(3-4 drinks) daily) with answer options, “No risk”, “Slight risk”, “Moderate risk”, “Great risk”, “I 
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don’t know”. Similarly, with respect to cannabis, respondents were asked the same question about 
smoking cannabis occasionally/daily, vaporizing cannabis occasionally/daily, eating or drinking 
cannabis occasionally/daily, using synthetic cannabis occasionally/daily, and using high potency 
cannabis extracts occasionally/daily. They were provided with the same answer options, “No risk”, 
“Slight risk”, “Moderate risk”, “Great risk”, “I don’t know”. 
Exposure to education on risks and channels of exposure were assessed with the 
questions, “Have you seen any education campaigns or public health messages warning about the 
risks of marijuana use in the past 12 months?” followed up by, “Where have you seen education 
campaigns or public health messages about marijuana in the past 12 months?” with the following 
answer options to determine the channels of exposure if they indicated that they had seen public 
health messaging: “In school?”, “At work?”, “On websites or social media, like Facebook, Twitter, 
YouTube, Instagram or Snapchat?”, “In email or text messages?”, “In bars or pubs?”, “In 
shops/stores that sell marijuana?”, “Outside shops/stores that sell marijuana?”, “At a pharmacy?”, 
“At events like fairs, markets, festivals, sporting events, or music concerts?”, “At kiosks or 
temporary sales locations (in shopping centres, parked in the street, other places, but not at specific 
events)”, “On television or radio?”, “On billboards or posters?”, “In print newspapers or 
magazines?”, “At the movies?”, “Taxis or buses/public transit?”, “In flyers?”, and “Don’t know”. 
Advertising and promotion exposure was assessed with the following question, “In the 
last 30 days, have you noticed marijuana products being advertised or promoted in any of the 
following places?” with the following answer options: “In regular postal mail?”, “On websites or 
social media, like Facebook, Twitter, YouTube, Instagram or Snapchat?”, “In email or text 
messages?”, “In bars or pubs?”, “In shops/stores that sell marijuana?”, “Outside shops/stores that 
sell marijuana?”, “At a pharmacy?”, “At events like fairs, markets, festivals, sporting events, or 
music concerts?”, “At kiosks or temporary sales locations (in shopping centres, parked in the street, 
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other places, but not at specific events)?”, “On television or radio?”, “On billboards or posters?”, 
“In print newspapers or magazines?”, “At the movies?”, “Taxis or buses/public transit?”, “In 
flyers?”, and “Don’t know”. 
Support for health warning elements were assessed with the following yes or no 
questions, “In your opinion, if it were legal to sell marijuana, should health warnings be required 
on products?”, “Should health warnings include pictures?”, “Do you think this information (in the 
red rectangle) should be included on marijuana packages?”. The image referenced in the last 
question is reproduced below. 
 
          Figure 11 Health warning label with call to action 
 
 
Health warning message recall was assessed using an unprompted recall task for four 
health warnings they were presented in the course of the study. Respondents were asked to list any 
details of the health warnings that they viewed. 
Data quality was controlled for using a couple of questions to ensure participants were 
sufficiently engaged with the survey. They were asked, “What is the current month?” and, “One 
last question, did you feel you were able to provide honest answers about your marijuana use 
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during the survey?”. If respondents selected the wrong month or respondent that they felt unable 
to provide honest answers for ‘all questions’, they will not be included in the analytic sample. 
 
Experimental Conditions  
 
Set I: Health Warning Labels 
 
After completing the background survey, respondents were randomized to view four health 
warning labels of a potential pool of eight that were developed. This restriction was implemented 
to avoid respondent fatigue. The health warning themes, which are displayed in Figure 12 on the 
following page, included: 1) driving while intoxicated, 2) use during pregnancy, 3) use and mental 
health, 4) co-morbid use, 5) youth use, 6) addictive potential, 7) dose, and 8) second-hand smoke. 
Randomization occurred in two steps: first, participants were randomized to view 4 of the 8 health 
warning label themes. Then, they were randomized once again to view one of two executions of 
the warning label related to the respective theme: a text-only warning, or a pictorial warning.  
 For each warning, respondents were presented with, respondents were asked to rank the 
overall effectiveness and believability along a 10-point scale from 1=‘Not at all 
effective/believable’ to 10=‘Extremely effective/believable’. 
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Figure 12 Health Warning Labels presented to survey respondents 












    











    
 
     












    















Set II: Comprehension of constituent labelling and functional tasks 
 
Respondents were asked to complete a number of tasks that required them to use different 
labels that were systematically manipulated to isolate characteristics of interest including 
communication of dose and strength of product.  
Task 1: Labelling and dose 
 
Respondents were randomized to view one of 3 product presentations that had been 
manipulated to isolate design elements related to dosing and serving size to determine respondents’ 
ability to interpret this information. In condition 1, participants were presented with a cookie and 
packaging that did not display cannabinoid content or dosing instructions. Condition 2 displayed 
the same cookie and package; however, cannabinoid content was displayed in terms of THC in 
milligrams. Condition 3 displayed the same cookie and packaging and expressed the number of 
doses on its package. 
Figure 13 Constituent labelling conditions – serving considerations 
Condition 1: 
NO THC LABEL 
Condition 2: 
MG THC LABEL 
Condition 3: 
THC DOSE LABEL 
   
 
To assess respondents’ comprehension of the product packaging, they were asked, “Based 
on the information provided, how much of the cookie should someone eat on one occasion if they 
wanted a recommended serving?” with the following answer options: “¼ of a cookie”, “½ of a 
cookie”, “¾ of a cookie”, “1 cookie”, “2 cookies”, “3 cookies”, “More than 3 cookies”, and “Don’t 
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know”. They were then asked, “How many servings are in this package?” with response options, 
“1”, “2”, “3”, “4”, “5”, “More than 5”, “Don’t know”. 
Task 2: Product potency 
 
 In order to determine how different labelling strategies communicate a product’s level of 
THC, a proxy for its potency, respondents were randomized to view one of four conditions. In 
condition 1, only the product’s strain name was used, condition 2, used “%THC” to communicate 
strength of effects, condition 3 used “mg THC”, and condition 4 used a traffic light system to 
communicate product strength. 
Figure 14 Constituent labelling conditions - THC level 



































    
 
Respondents were first randomized into conditions outlined in Task 2a that displayed 
products communicating relatively low THC content. They were asked, “Based on the available 
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information, what is the level of THC in this product?” with responses, “Low”, “Moderate”, 
“High”, “Don’t know”.  Respondents were then once again randomized into one of the four 
outlined conditions in Task 2b, however, the products displayed communicated relatively high 
THC content. They were asked the same question once again and asked to evaluate the level of 
THC in the displayed product. 
Set III: Perceptions of brand imagery on packaging 
 
Participants responded to a series of eight ‘between-group’ experiments. Participants were 
randomized into experimental condition before each of the eight experiments to examine distinct 
package elements: 1) ‘plain’ package and health warnings, 2) a flavour descriptor, 3) an ‘energy’ 
descriptor, 4) a celebrity sponsorship, 5) music references, 6) party references, 7) health claims, 
and 8) fashion references in which they viewed different cannabis packages. Participants rated 
each pack on three outcomes: 1) product appeal, 2) the perceived relative age of the target 
consumer, and 3) a pack-specific question on the design element of interest, such as perceived 
gender, party habits, health perceptions, or fashion, as outlined in the specific experiment 
descriptions below.  
Product appeal was rated using a ten-point scale from 0=“Not at all appealing” to 
10=“Very appealing”.  
Perceived relative age of target consumer was assessed with the question, “In your opinion, 
someone who chooses to use this product is more likely to be…” with answer options, “Younger 
than me”, “My age”, “Older than me”, “Don’t know”. A binary variable was created so that 
“Younger than me” was coded as 1 and the rest were coded as “Not younger than me”. 
Perceived gender of the target consumer for products was assessed with the question, “In 
your opinion, someone who chooses to use this product is more likely to be…” with answer 
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options, “Male”, “Female”, “No difference”, and “Don’t know”.  A binary variable was created so 
that “Likely female” was coded as 1 and the rest were coded as “Not likely female”. 
Perceived lifestyle characteristics of target consumer was assessed with three additional 
questions. To assess perceptions of the party habits they associated with the target consumer of 
each product, respondents were asked, “In your opinion, someone who uses In your opinion, 
someone who chooses to use this product is more likely to…” with answer options, “Go out and 
party”, “Stay home”, “No difference”, and “Don’t know”. A binary variable was created so that 
“Go out and party” was coded as 1 and the rest were coded as “Not go out and party”. 
The perceived level of target consumer’s health consciousness was determined with the 
question, “In your opinion, someone who chooses to use this product is more likely to be…”, with 
answers, “Someone who takes more care of their health”, “Someone who takes less care of their 
health”, “No difference”, and “Don’t know”. A binary variable was created so that “Someone who 
takes more care of their health” was coded as 1 and the rest were coded as “Not someone who 
takes more care of their health”. 
To assess perceptions of fashion sense associated with target consumer, respondents were 
asked, “In your opinion, someone who chooses to use this product is more likely to be…”, with 
answers, “More fashionable”, “Less fashionable”, “No difference”, and “Don’t know”. A binary 
variable was created so that “More fashionable” was coded as 1 and the rest were coded as “Not 
more fashionable”. 
This section was composed of a sequence of eight different experiments for which cannabis 
product packaging designs had been manipulated to examine the effects of brand imagery and 
brand descriptors on perceived appeal and target consumer characteristics.  
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Experiment 1: Examining perceptions of standard packs, branded packs, and packs 
displaying health warning labels. 
 
Respondents were randomized into one of four experimental conditions where they saw 
either: a standardized cannabis pack with a health warning label, a standardized cannabis pack 
without a health warning label, a branded cannabis pack with a health warning label, or a branded 
cannabis pack without a health warning label (Figure 15) They were asked to rate the pack they 
were displayed on appeal, perceived relative age and gender of the target consumer. 
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Experiment 2: Examining perceptions of cannabis packs displaying flavour descriptors. 
 
Respondents were randomized into one of two experimental conditions where they saw 
either a cannabis pack with a flavour descriptor or a cannabis pack without a flavour descriptor 
(Figure 16). They were asked to rate the pack they were displayed on appeal, perceived relative 
age and gender of the target consumer. 
 













Experiment 3: Examining perceptions of cannabis packs displaying energy descriptors. 
 
Respondents were randomized into one of two experimental conditions where they saw 
either a cannabis pack with an energy descriptor or a cannabis pack without an energy descriptor 
(Figure 17). They were asked to rate the pack they were displayed on appeal, perceived relative 
age and party habits of the target consumer. 
 












Experiment 4: Examining perceptions of cannabis packs displaying a celebrity 
sponsorship. 
 
Respondents were randomized into one of two experimental conditions where they saw 
either a cannabis pack with a celebrity sponsor or a cannabis pack without a celebrity sponsor 
(Figure 18). They were asked to rate the pack they were displayed on appeal, perceived relative 
age and party habits of the target consumer. 
 













Experiment 5: Examining perceptions of cannabis packs displaying music references. 
 
Respondents were randomized into one of two experimental conditions where they saw 
either a cannabis pack displaying music references or a cannabis pack without music references 
(Figure 19). They were asked to rate the pack they were displayed on appeal, perceived relative 
age and party habits of the target consumer. 
 













Experiment 6: Examining perceptions of cannabis packs displaying party references. 
 
Respondents were randomized into one of two experimental conditions where they saw 
either a cannabis pack displaying ‘party’ references or a cannabis pack without ‘party’ references 
(Figure 20). They were asked to rate the pack they were displayed on appeal, perceived relative 
age and party habits of the target consumer. 












Experiment 7: Examining perceptions of cannabis packs displaying ‘organic’ and ‘natural’ 
descriptors. 
 
Respondents were randomized into one of two experimental conditions where they saw 
either a cannabis pack with ‘100% Natural/Organic’ descriptors or a cannabis pack without organic 
or natural descriptors (Figure 21). They were asked to rate the pack they were displayed on appeal, 
perceived relative age and health consciousness of the target consumer. 













Experiment 8: Examining perceptions of cannabis packs displaying fashion reference. 
 
Respondents were randomized into one of two experimental conditions where they saw 
either a cannabis pack with a fashion reference or a cannabis pack without fashion references 
(Figure 22). They were asked to rate the pack they were displayed on appeal, perceived relative 
age and fashion sense of the target consumer. 
Figure 22 Packaging with and without fashion references 
Condition 1: 
CANNABIS PRODUCT DISPLAYING 
FASHION REFERENCE 
Condition 2: 
CANNABIS PRODUCT NOT 
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Background: Although recreational cannabis is now legal in Canada, little empirical evidence 
exists regarding young Canadians’ cannabis literacy, cannabis-related risk perceptions, and risk of 
different forms of cannabis or the effect that public health education may have on these 
perceptions. The present study sought to address these knowledge gaps to examine health 
knowledge and risk perceptions associated with cannabis use. 
 
Methods: An online survey was conducted with a national sample (N=870) of Canadians aged 16 
to 30 years in October 2017 using a commercial panel. The study examined young Canadians’ 
awareness of negative health effects related to cannabis, evaluation of known risks, and risk 
perceptions of different forms of administration. 
 
Results: Most respondents were aware of a cannabis-related physical health effect (78.0%). 
Approximately one-third reported having been exposed to public health messaging about cannabis; 
digital media was reported most frequently. Compared to never users, ever users were less likely 
to report general likelihood of addiction (p<0.001), and harm to mental health (p<0.001). 
Approximately one-quarter of past 3-month cannabis users reported they were at least ‘a little’ 
addicted. Respondents who reported using a particular form of cannabis self-administration (e.g., 
edibles, smokables, etc.) were less likely to perceive harm than those who did not use each form 
(p<0.001). 
 
Conclusions: The current study is among the first to measure the knowledge and perceptions of 
risks of Canadian youth about cannabis. The study, conducted in the time immediately preceding 
legalization, may serve as a reference point for future studies examining changes in cannabis 
knowledge and risk perceptions. This will be important in addressing the need for monitoring and 
enhancing public awareness of the impact and potential harms of this newly legalized substance. 
 
KEYWORDS: cannabis literacy, cannabis health knowledge, cannabis risk perceptions, synthetic 






 The Cannabis Act, which came into force in October 2018, outlines a legal framework for 
controlling the production, distribution and possession of cannabis in Canada.1 Two of its primary 
goals are to prevent youth from accessing cannabis and to protect public health and safety by 
allowing safe and legal access of nonmedical cannabis to adults. In Canada, the typical age of 
initiation of cannabis use is 14 years, with prevalence peaking among young adults aged 20 to 24 
years.2,3,4,5 According to the 2017 Canadian Cannabis Survey, past-year use of cannabis among 
Canadians aged 16 to 24 years was double that of Canadians older than 24.6 Cannabis use is higher 
among certain population subgroups such as young people who report poor school performance, 
early use of tobacco, alcohol, and other drugs, those fraternizing with drug-using peers, those 
experiencing a difficult family environment, those who report higher cannabis accessibility and 
availability of cannabis, and those who are high on sensation-seeking.7,8  
Youth who initiate cannabis at an earlier age may be at greater risk of negative health and 
social outcomes than those that delay initiation.9 Young Canadians report a variety of reasons for 
using cannabis, including identity formation, as a tool for social cohesion, boredom, relief of social 
anxiety, perceived acceptability, and lower perceived risk of harm than other substances.10,11,12,13,14  
However, early cannabis use has been associated with greater impairments in memory, cognition, 
academic performance, heightened risk for cannabis dependence, and other negative health 
endpoints than those delay or refrain from use.15,16,17 Other general health effects include the 
exacerbation of mental health disorders, respiratory symptoms, increased risk of motor vehicle 
accidents, and lower birthweight of infants whose mothers smoked cannabis.17 The majority of 
health consequences related to first-hand cannabis use occur among individuals who are high 
frequency and high intensity users.9,18,19  
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Most young Canadians report that regular cannabis use has health risks. For example, the 
2016-17 Canadian Student Tobacco, Alcohol and Drugs Survey found that while 9% of youth 
reported that there was “no risk” of harm associated with smoking cannabis on a regular basis, 
approximately half (54%) thought that smoking cannabis on a regular basis posed “great risk”.2 
Data suggest that most young Canadians are aware of specific potential consequences associated 
with use, however, they do not appear to have an understanding of practical issues such as how 
long impairment might persist.12 Among the general population, three-quarters of young 
Canadians (75%) believe that cannabis affects driving, and approximately 1 in 5 (19%) report that 
it does not affect driving at all.6 Young Canadians report taking solace in the fact that cannabis 
affects everyone differently. Focus groups have found that young people are indifferent to the 
consequences associated with use and selectively decide the harms that use may elicit based on 
personal experience or anecdotes from their peers.12 Indeed, many young people perceive cannabis 
as “natural”, a “soft drug” or “not really a drug at all”.11,12 Approximately 6 in 10 Canadians report 
that cannabis is more helpful than harmful to their mental and physical health.13  
To date, most studies have assessed risk perceptions for cannabis use in general, simply 
probing about whether individuals believe that cannabis carries a level or risk. Few studies have 
examined risk perceptions for different types of cannabis products (e.g. edibles, concentrates) or 
modes of administration. Understanding risk perceptions, as they vary across product and modes 
of administration is critical as they have differential impacts on the body. The pharmacological 
effects of cannabis vary depending on the concentrations of its primary active ingredient, THC 
(tetrahydrocannabinol, Δ9-THC), as well as whether products are smoked, vaped, or ingested orally 
or otherwise.20  The THC content of cannabis has increased significantly over the past three 
decades in North American markets in its dried herbal form, and has reached up to 80% to 90% in 
high potency products such as oils or waxes.21,22,23 In general, frequent use of products containing 
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higher THC concentrations significantly increases the risk of psychotic disorders, paranoia, 
marked effects on memory and dependence.24,25,26,27,28  Synthetic cannabis is the term given to 
mixtures of synthetic compounds marketed as “herbal” mixtures (e.g., Spice, K2m Mamba, 
Afghan Incense) that activate cannabinoid receptors. They are the largest, fastest-growing, and 
most diversified new psychoactive substances which have been observed to precipitate acute 
psychotic symptoms, fatal poisonings, acute myocardial infarction, delusions, renal disfunction, 
among other effects.29,30,31 
According to decades of substance use research, increased perceived riskiness and health 
knowledge influences rates of substance use and are generally associated with reductions in use 
initiation, increased engagement in health protective behaviours, and long-term 
abstinence.32,33,34,35,36,37 Individuals who perceive a substance such as cannabis to be high risk are 
generally less likely to use it, and vice versa.32 When young people are made aware that use 
behaviours are not normative and their misperceptions about how many of their peers actually use 
substances are corrected, substance use behaviours tend to decrease.38,39 However, existing work 
from US contexts that have legalized medical and/or nonmedical cannabis are less clear  the 
relationship between perceived risk, health knowledge, and use behaviours remains poorly 
understood with respect to cannabis.40,41  
Young people access health information from a variety of channels. Of these, online  spaces 
represent credible sources of information for youth and young adults.42,43 A recent study by Lamy 
and colleagues demonstrates how social media platforms like Twitter are able to disseminate 
information about cannabis that describes it as “pure”, “clean”, and a “natural medicine”.44 
Ouellette and colleagues describe how YouTube users are spreading information about cooking 
with cannabis, receiving collectively 15.6 million views though little is currently known regarding 
the basic effects these preparations may have or about users’ habits of ingesting  edibles.45 Work 
 80 
by Ramo and colleagues identified more than 700 smartphone apps related to cannabis and 
characterized them as likely vehicles for cannabis related information and misinformation.46 
Overall, however, there is little population-level data on sources of health information on cannabis 
among young people. This is important given that Health Canada is reportedly spending $100M 
on cannabis education over six years and should consider competing sources of information known 
to be available that may dampen education efforts.47 
The present study examined young Canadians’ awareness of negative health effects, a 
proxy for knowledge, associated with cannabis use, perceptions of risk and harm associated with 
cannabis use, perceptions of relative risk to other substances or forms of administration (e.g., 
smoking, vaping, edibles), how these vary by use intensity (e.g., occasional vs. daily use), and how 







An online cross-sectional survey was conducted from October 10th to October 24th, 2017. 
The inclusion criteria were individuals aged 16 to 30 years of age with a Canadian IP address, and 
included cannabis users and non-users. Recruitment occurred by e-mail through Léger’s consumer 
panel for web surveys consisting of approximately 400,000 active members, half of them sampled 
using probability-based methods using the Canadian Census, along with other non-probability 
based methods, including commercial surveys.48 Respondents aged 16 to 30 were recruited across 
Canada directly with the exception of youth in Quebec where youth aged 16 and 17 were recruited 
through their parents; parental consent was obtained prior to Quebec youth accessing the survey. 
Respondents received remuneration from Léger in accordance with their usual incentive structure. 
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All of the data provided by respondents were anonymous and information was kept confidential. 
In all cases, respondents were provided with information about the study and asked to provide 
consent before participating. They were reassured their anonymity again after providing consent 
and proceeded to the survey. The study was reviewed by and received ethics clearance from the 
Office of Research Ethics at the University of Waterloo (ORE# 22392). 
Measures 
 
Sociodemographic variables: sex (male, female), age, ethnicity (white, non-white), 
cannabis use status (never use, recent use – use in the past 12-months, current use – use in the past 
30-days) were recorded in the survey. Cannabis use status measures were used and adapted from 
the Canadian Student Tobacco, Alcohol and Drugs Survey (CSTADS), “Have you ever tried 
marijuana?” and a new item, “When was the last time you used marijuana” with options “More 
than 12 months ago”, “More than 3 months to 12 months ago”, “Within the last month”. Cannabis 
forms were asked about with the item, “In the past 12 months, did you used marijuana in any of 
the following ways: 1)Smoked dried herb/flower/leaf, 2)Vaporized dried flower/leaf 3)Vaporized 
liquid in an e-cigarette, 4)Mixed with or rolled in tobacco (e.g., blunt), 5)Hashish, 6)Hash oil, 
7)Concentrate, 8)Edibles (e.g., cookies), 9)Liquid (e.g., cola/tea), 10)Tinctures (e.g., concentrated 
amounts ingested orally or taken under the tongue), 11)Topical Ointments, 12) Fresh flower/leaf” 
with answer options “No, I have never done this”, “Yes, but not in the past 12 months”, “Yes, in 
the past 12 months”, “Don’t know”, “Refuse to answer”. 49   
Exposure to education on risks related to cannabis and channels of exposure were 
assessed with the questions, “Have you seen any education campaigns or public health messages 
warning about the risks of marijuana use in the past 12 months?” followed up by, “Where have 
you seen education campaigns or public health messages about marijuana in the past 12 months?” 
with answer options outlined in Table 2. A binary variable was created to determine exposure to 
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education on risks where 0 referred to ‘No exposure’, and 1 to ‘Exposed’ where respondents had 
indicated that they had been exposed to any of the different channels asked about. 
Awareness of negative health effects was assessed with the question, “In your opinion, 
what are the most important negative health effects from marijuana use? Please list up to five.” 
These open-ended responses were coded and classified into three categories: Physiological effects, 
psychological effects, and social effects.  
Perceptions of risk and harm were assessed using four measures. General perceptions of 
harmfulness: (1) Perceived likelihood of addiction: “How likely is someone to become addicted to 
smoking marijuana?” with answer options, “0=Very unlikely”, “0=Somewhat unlikely”, 
“0=Neither likely nor unlikely”, “1=Somewhat likely”, “1=Very Likely”, “0=Don’t Know” and 
(2) Mental health harm: “In general, do people risk harming their mental health when they use 
marijuana on a regular basis, for non-medical reasons?”, with answer options, “0=No risk”, 
“1=Slight risk”, “1=Moderate risk”, “1=Great risk”, “0=I don’t know”. Perceptions of harm to 
self, only asked of past 3-month users: (3) Worry for future health: “Are you worried that using 
marijuana will damage your health in the future?” with answer options, “0=Not at all worried”, 
“1=Yes, a little worried”, “1=Yes, moderately worried”, “1=Yes, very worried”, and “0=Don’t 
know”. (4) Perceived addiction: “Do you consider yourself addicted to marijuana?” with answer 
options, “0=Not at all”, “1=Yes, a little addicted”, “1=Yes, very addicted”, “0=Don’t know”. 
Binary variables were created based on respondents’ answers for each measure (1) 0=Not likely, 
1=Likely, (2) 0= Not Worried, 1=Worried, (3) 0=No risk, 1=Risk, and (4) 0=Not addicted, 
1=Addicted. 
Perceptions of risk depending on form of use were adapted from the 2015 European 
School Survey Project on Alcohol and Other Drugs (ESPAD).50 Participants were asked how much 
they risked harming themselves by the occasional or daily use of the following: smoking cannabis, 
 83 
vaporizing cannabis, eating or drinking cannabis, using high potency cannabis extracts, and using 
synthetic cannabis with answer options, “0=No risk”, “1=Slight risk”, “1=Moderate risk”, 
“1=Great risk”, “0=I don’t know”. Binary variables were created based on respondents’ answers 
(0=No risk, 1=Risk) for each cannabis form and frequency of use asked about. Responses were 
filtered by whether participants used cannabis in those ways. 
Data integrity was assessed using two of questions: “What is the current month?” and, 
“One last question, did you feel you were able to provide honest answers about your marijuana 
use during the survey?”. If respondents selected the wrong month or respondent felt unable to 




All analyses were conducted using SPSS (Version 25.0, Armonk, NY: IBM Corp.). Survey 
weights were generated based preliminary postcensal population estimates from Statistics 
Canada.51,52  Logistic regression models tested whether cannabis use was associated with perceived 
likelihood of addiction, worry for future health, mental health harm, and perceived addiction.  
Logistic regressions also examined whether different forms and modes of administration or use of 
different forms of cannabis and synthetic cannabis were associated with risk (physical or in other 
ways). All of the logistic regressions were adjusted for age, sex, ethnicity, cannabis use status, and 




Table 1 displays the sample characteristics. Overall, 1,045 respondents completed the 
survey. However, due to missing data on core measures of cannabis use and/or failed data integrity 
questions, a final sample of 870 youth and young adults was analyzed. A total of 1,045 respondents 
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completed the survey; however, the final analytic sample was 870 as the rest were excluded from 
analysis due to completing survey from a mobile device instead of a desktop computer (28), 
missing data on key measures including cannabis use status (8) and/or failed data integrity 
questions; 62 records deleted due to incorrectly identifying the current month and 77 respondents 
reported being unable to provide honest answers to all of the survey questions. 
 
EXPOSURE TO EDUCATION OR PUBLIC HEALTH MESSAGING ABOUT CANNABIS USE 
Less than one-third of respondents (31.8%) reported encountering public health messages 
about cannabis in the past year.  Table 2 displays the different locations where reported encounters 
took place. The most common locations reported were online (16.7%), on television or radio 
(15.2%), and in school (12.5%). 
 
AWARENESS OF NEGATIVE HEALTH EFFECTS 
Table 3 summarizes the ‘most important’ negative health effects associated with cannabis 
use reported by respondents. Overall, 78.0% % of all respondents cited at least one physical 
concern, 43.0% cited at least one psychological concern, while 4.5% cited at least one social 
concern.  
Among physical concerns, effects on the brain and respiratory function were the most 
common responses. Never and Ever users were more likely to report physical concerns related to 
cannabis use than Current users (AOR=1.89, 95%CI 1.26-2.85, p=0.002, AOR=1.57, 95%CI 
1.07-2.31, p=0.002 respectively). Furthermore, respondents that reported having encountered 
public health messaging were more likely to report physical concerns than those that had not 
(AOR=2.31, 95%CI 1.60-3.34, p<0.001).  
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Deficits in reaction time in relation to driving among other activities, general mental health 
issues, and memory loss were the most frequently cited psychological concerns. Older respondents 
aged 19-24 years and those aged 25-30 were at a greater likelihood of reporting psychological 
concerns than youth aged 16-18 years (AOR=1.58, 95%CI 1.09-2.30, p=0.015, AOR=1.49, 
95%CI 1.04-2.14, p=0.032 respectively). Encountering public health messaging was also 
associated with a greater likelihood of reporting a psychological concern (AOR=2.26, 95%CI 1.72-
2.97, p<0.001). 
Respondents cited that cannabis may be a gateway drug and were concerned about 
behavioural changes as social concerns. 
 
PERCEPTIONS OF RISK AND HARM 
 
Table 4 presents respondents’ perceptions of health harms associated with cannabis use 
and Table 5 displays related logistic regression analyses examining each risk. 
 
Perceived likelihood of addiction—As indicated in Table 4, perceptions of cannabis 
addiction varied widely across the sample. Logistic regression analyses shown in Table 5 indicated 
that young people aged 19-24 and 25-30 years were less likely to report that someone may become 
addicted to cannabis than youth aged 16-18 years (AOR=0.51, 95%CI 0.35-0.76, p=0.001 and 
AOR=0.49, 95%CI 0.34-0.70, p<0.001 respectively). Compared to female respondents, males 
perceived cannabis as less addictive (AOR=0.69, 95%CI 0.28-0.55, p=0.012). Compared to Never 
cannabis users, Ever and Current cannabis users were also less likely to report that cannabis users 
 86 
would become addicted (AOR=0.39 95%CI 0.28-0.55, p<0.001; AOR=0.35 95%CI 0.24-0.52, 
p<0.001 respectively). No other significant differences were observed. 
 
Mental health harm—One in ten (10.9%) respondents reported that they perceived ‘no 
risk’ of harming mental health as a result of using cannabis. Ever and current cannabis users had 
lower odds of reporting that individuals that use cannabis risk harming their mental health than 
those who reported that they had never used cannabis (AOR=0.48, 95%CI 0.30-0.76, p=0.002; 
AOR=0.35, 95%CI 0.21-0.58, p<0.001 respectively). Furthermore, those who reported having 
been exposed to some form of public health messaging regarding risks associated with cannabis 
were more likely to report that users risk harming their mental health (AOR=2.28 95%CI 1.46-
3.57, p<0.001).  
 
 Worry for future health — Among those who reported using cannabis in the past 3 months, 
about half reported being worried about potential damage to future health (51.3%). There were no 
significant differences between ‘daily’, ‘weekly’, ‘monthly’, or ‘less than monthly’ cannabis users 
in responding affirmatively to worrying about damaging future health as a result of their use. 
However, those that reported seeing public health messaging were more likely to report this type 
of worry (AOR=1.99, 95%CI 1.18-3.37, p=0.010). 
 
 Self-Perceived addiction — More than 1 in 5 (22.8%) of respondents who reported using 
cannabis within the past 3 months reported being ‘a little’ or ‘very’ addicted. Those that reported 
using in the past 30 days were more likely to consider themselves addicted than those that reported 
not having used cannabis in the past 30 days (AOR=3.96, 95%CI 1.49-10.54, p=0.006). Among 
past 3-month users, respondents that reported ‘weekly’, ‘monthly’, or ‘less than monthly’ use were 
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significantly less likely to report perceiving themselves as addicted to cannabis than ‘daily’ users 
(AOR=0.10, 95%CI 0.04-0.24, p<0.001; AOR=0.09, 95%CI 0.03-0.25, p<0.001; AOR=0.04, 
95%CI 0.01-0.11, p<0.001, respectively).  
 
PERCEPTIONS OF RISK OF HARM (PHYSICAL OR IN OTHER WAYS) TO OTHER FORMS 
OF ADMINISTRATION 
 
Figure 1 displays respondents’ perceptions of health risk associated by different forms of 
cannabis use. Overall, daily use of any form of cannabis was perceived to carry greater risk than 
occasional use. Half (50.9%) of all respondents reported that using high potency cannabis carried 
‘great risk’ of harm, physically or in other ways, and approximately 4 in 10 reported the same for 
smoking (44.1%), synthetic cannabis use (43.4%), eating or drinking cannabis (38.2%), and vaping 
cannabis (37.2%). In contrast, less than 1 in 4 thought the same regarding the occasional use of 
any form of cannabis use. 
Table 6 displays the results of logistic regression analyses examining correlates of 
perceived harm associated with daily cannabis use in its different forms. Similar patterns emerged 
across forms; cannabis users consistently display lower odds of perceiving harm from the daily 
use of different forms of cannabis than respondents that report never having used cannabis. 
However, a gradient among cannabis users is evident; those that reported having used, but not in 
the past 30 days, are more likely to report risks of harm from daily cannabis use than those that 
report having used in the past 30 days. Finally, reporting exposure to cannabis risk public health 
messaging was associated with increased likelihood of perceiving harm from daily use of different 
forms of cannabis with the exception of edible or drinkable forms of administration. Similar 
patterns emerge when respondents were asked about occasional use of the different cannabis 
forms. Table S3 in the Supplementary File also displays logistic regression analyses examining 
correlates of perceived harm associated with different intensities of use and different forms of 
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cannabis, however, it is filtered further by whether participants used cannabis in each way. Across 
the different modes of cannabis self-administration, participants that indicated using each 
particular form were less likely to perceive risk of harm than those that did not use the particular 




Canadian youth and young adults reported being aware of a number of important health 
effects associated with cannabis use, as well as a number of channels where they have been 
receptive to public health messaging or educational information. Approximately a third of young 
Canadians reported being exposed to public health messages on cannabis, with digital media, 
television and radio being the most reported channels of exposure in our study. The findings 
reinforce the importance of digital media in reach young people. Virtually all (95%) Canadians 
aged 18 to 24 years use Facebook and nearly all (90%) use YouTube, with a majority being active 
monthly users of these platforms.53 Exposure to education campaigns may have increased 
immediately following the current study, given the range of campaigns implemented in the lead 
up to cannabis legalization, in October 2018. For example, Public Safety Canada launched a 
“Don’t Drive High” campaign the following month and reported that 62% of Canadians aged 16 
to 24 years recalled the message post-campaign.54 The Government of Canada has also engaged a 
number of partner organizations such as Drug Free Kids Canada, Mothers Against Drunk Driving, 
the Canadian Hockey League, and the Centre of Addictions and Mental Health, and made funding 
available for research and outreach in the area to target dissemination efforts of cannabis and health 
information.54 Future studies should examine the population-level reach of these campaigns.  
Overall, young people reported a wide range of beliefs about the health effects of cannabis 
use. Indeed, responses were equally distributed across the scale of likelihood of addiction and risks 
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of mental health. For example, similar proportions reported that cannabis addiction was “very 
unlikely” and “very likely”. This pattern of results reflects the wide diversity of opinions about 
addiction to cannabis: as the Canadian Task Force on Cannabis Legalization and Regulation noted, 
cannabis is one of the few substances for which substantial proportions of the public both 
underestimate and overestimate the health effects.55 Interestingly, approximately one-quarter of 
past 3-month cannabis users reported they were at least ‘a little’ addicted to cannabis, and this 
proportion increased with more frequent use. While perceptions of addiction among users are 
lower than for other substances, such as tobacco smoking, the findings are consistent with studies 
suggesting problematic use in a certain minority of users.18,56  
Future studies should prioritize perceptions of cannabis and mental health. The current 
study indicates a wide range of beliefs about the effects of cannabis on mental health. Indeed, 
many young perceive cannabis to have a net overall benefit on public health.12 Future work should 
discriminate between different aspects of mental health, such as depression and anxiety versus 
psychosis, for which there is a strong evidence base on negative impact.17 
The findings also suggest that cannabis users may be demonstrating a form of ‘optimism’ 
bias: worry about health effects and perceptions of addiction appeared to be lower when they were 
personalized to users rather than asked in the general form. This is similar to optimism bias 
exhibited by smokers, who often underestimate their own risks relative to others.57  
The current study is among the first to examine whether perceptions of risk differ across 
product types and modes of administration. Daily use in all of its forms was consistently perceived 
to be more risky than occasional cannabis use, as expected. In terms of modes of administration, 
smoked, vaped, and edible cannabis products were perceived to have similar risk, whereas high 
potency products and synthetic cannabis products were perceived as somewhat riskier. However, 
similar proportions of young people perceived daily use of synthetic cannabis and daily cannabis 
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smoking to be ‘high risk’. This is a concern given the serious acute health effects of synthetic 
cannabis use, particularly given their ‘legal’ status in many jurisdictions and widespread consumer 
confusion about these products.29,30,31,58,59  Focused attention should be given to highlighting and 
detailing the risks associated with synthetic cannabinoid that dwarf existing known risks associated 
with combusted cannabis. The findings suggest that public education campaigns implemented as 
part of cannabis legalization in Canada should help consumers to identify and understand the 
unique health effects of synthetic cannabis products.  
 
STRENGTHS AND LIMITATIONS 
 
 The sample was recruited from a commercial sample that used probability and non-
probability-based recruitment methods, thus, our findings may not be fully generalizable to 
Canadian young people. Nevertheless, a broad and diverse sample with similar patterns of cannabis 
use and sociodemographic characteristics as the 2017 Canadian Cannabis Survey was recruited.60 
The current sample surveyed aged 16 to 30 years exclusively. While this age group has the highest 
rates of use in Canada, it is unclear to what extent the current findings a representative of older 
adults. It should be noted that directionality regarding beliefs and exposure or noticing public 
health messaging is unclear and an opportunity for future research. Considerable strengths of the 
study include the use of existing international tools that allow for comparability to countries 
participating in the European School Survey Project on Alcohol and Other Drugs (ESPAD), open-
ended fields that allowed respondents to freely communicate the extent of their cannabis health 
knowledge, and this study expands the limited literature on young Canadians’ cannabis health 




The current study is among the first to measure cannabis health knowledge and perceptions 
of risks among Canadian youth in the time immediately preceding legalization; it may serve as a 
reference point for future studies examining changes in cannabis literacy. The findings 
complement and add to the very limited literature specific to young Canadians’ cannabis health 
knowledge and ability to evaluate associated risks.11,12,13 The findings indicate that a minority of 
young people recall seeing or hearing public education on cannabis products over the past year, 
although those that do report greater perceptions of risk. More generally, the study highlights the 
wide discrepancy of views about the potential health effects and addictive potential of cannabis. 
Legalization of non-medical cannabis provides an opportunity—and indeed a mandate—to 
enhance public education on the health effects of cannabis. Helping consumers to understanding 
different modes of administration and the distinct risk profile of synthetic cannabis should be an 







Table 1 – Sample Characteristics  
 






Sex Female 52.1 (453) 49.2 (427) 
 Male 47.9 (417) 50.8 (441) 
    
Age (yrs.) 16–18 25.2 (219) 17.0 (148) 
 19–24 30.7 (267) 40.3 (350) 
 25–30 44.1 (384) 42.7 (370) 
    
Ethnicity White 64.5 (561) 64.6 (560) 
 Non-white 35.5 (309) 35.4 (307) 
    
Cannabis use 
status Never use 41.5 (361) 37.4 (325) 
 Ever use, not in past 30 days 36.0 (313) 38.7 (336) 
 Current use, within past 30 days 22.5 (196) 23.8 (207) 
    
Exposed to education on risks associated with 
cannabis 





Table 2 – Location where education campaigns or public health messages about cannabis 
were encountered by participants in the past year (n=870). 
 
Location % (n) 
On websites or social media like Facebook, Twitter, 
YouTube, Instagram or Snapchat 16.7 (145) 
On television or radio 15.2 (132) 
In school 12.5 (109) 
On billboards and posters 6.8 (59) 
In print newspapers or magazines 5.4 (47) 
At a pharmacy 4.1 (36) 
At work 3.9 (34) 
In e-mail or text messages 2.1 (18) 
In bars or pubs 2.1 (18) 
Taxis or buses/public transit 2.1 (18) 
At events like fairs, markets, festivals, sporting events, or 
music concerts 2.0 (17) 
In flyers 1.6 (14) 
In shops/stores that sell marijuana 1.5 (13) 
At the movies 1.4 (12) 
At kiosks or temporary sales locations (in shopping centres, 
parked in the street, other places, but not at specific events) 1.1 (10) 
Outside shops/stores that sell marijuana 1.0 (9) 
Don't know 0.8 (7) 
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Table 3 – Frequencies of ‘most important’ negative health effects associated with cannabis 
use reported by Canadian youth and young adults (N=870). 
 
Physical Concerns % (N) 
Decreased brain function, cognitive abilities 24.7 (215) 
Respiratory function 23.8 (207) 
Addiction 16.4 (143) 
Carcinogenic 9.7 (84) 
Harmful effects from smoking 7.2 (63) 
Hunger/"munchies" 6.7 (58) 
Drowsiness 6.1 (53) 
General detriment to health 5.4 (47) 
Issues with circulation, heart palpitations 5.3 (46) 
Dry mouth 3.6 (31) 
Youth health, developmental concerns 3.0 (26) 
Bad/"gross" smell 2.6 (23) 
Drug interactions, concerns about tainted product 2.1 (18) 
Obesity 2.0 (17) 
Dizziness 1.8 (16) 
Being high 1.6 (14) 
Nausea 1.6 (14) 
Red eyes 1.5 (13) 
Vision problems 1.4 (12) 
Sexual health  1.4 (12) 
Death 1.1 (10) 
Psychological Concerns   
Reaction time related to driving or other activities 9.3 (81) 
Mental health issues 9.3 (81) 
Judgement/Inhibition issues 8.5 (74) 
Memory loss 8.4 (73) 
Loss of motivation 7.5 (65) 
Anxiety/Panic 5.5 (48) 
Depression 3.7 (32) 
Hallucinations 3.7 (32) 
Loss of concentration 3.7 (32) 
Paranoia 3.4 (30) 
Schizophrenia 1.1 (10) 
Psychosis 1.1 (10) 
Social Concerns   
Gateway drug 1.7 (15) 
Behavioural changes 1.5 (13) 
Money problems 1.0 (9) 
Don’t Know/Refused   
Don’t know 10.0 (87) 
Refused 1.7 (15) 
*Concerns accounting for <1% of overall responses are omitted here.
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Table 4 – Perceptions of health effects associated with cannabis use (N=870)  
 
  Very unlikely Somewhat unlikely 
Neither likely nor 
unlikely 
Somewhat 








14.7 (128) 16.0 (139) 17.0 (148) 27.6 (240) 16.6 (144) 7.9 (69) 
  No risk Slight risk Moderate risk Great risk Don’t know  
 Risk of harming 
mental health 10.9 (95) 32.2 (280) 27.2 (237) 21.8 (190) 7.8 (68)  








damage to future 
health* 
51.3 (137) 34.1 (91) 9.0 (24) 2.6 (7) 3.0 (8)  
  Not at all Yes, a little addicted Yes, very addicted Don’t know   
 Perceived addiction* 76.0 (203) 20.2 (54) 2.6 (7) 1.1 (3)   




Table 5 - Logistic regression analyses examining potential risks associated with cannabis use among 
Canadian youth and young adult cannabis users and non-users. 
169 
Characteristics Ref. Category Agreement % 
Likely someone may become addicted, 
general (N=870) 
p AOR 95%CI 
Age 19-24 16-18 41.2% v. 62.1% 0.001 0.51 0.35-0.76 
 25-30 16-18 35.9% v. 62.1% <0.001 0.49 0.34-0.70 
 19-24 25-30 41.2% v. 35.9% 0.738 1.06 0.76=1.48 
Sex Male Female 40.5% v. 47.5% 0.013 0.69 0.52-0.93 
Ethnicity White Non-white 42.1% v. 47.9% 0.169 0.81 0.60-1.90 
Cannabis use 
status 
Ever use, not in past 30 
days 
Never Use 33.2% v.  60.4% <0.001 0.39 0.28-0.55 
 Current use, within past 
30 days 
Never Use 31.6% v. 60.4% <0.001 0.35 0.24-0.52 
 Ever use, not in past 30 days 
Current Use, within past 
30 days 33.2% v. 31.2% 0.597 1.11 0.75-1.64 
Exposure to 
education Exposed Not Exposed 46.9% v. 42.8% 0.097 1.29 0.96-1.76 
    Risk of harming mental health, general (N=870) 
Age 19-24 16-18 80.1% v. 85.4% 0.533 0.85 0.51-1.42 
 25-30 16-18 79.7% v. 85.4% 0.829 0.95 0.59-1.54 
 19-24 25-30 80.1% v. 79.7% 0.599 0.90 0.60-1.35 
Sex Male Female 81.1% v. 81.5% 0.807 0.96 0.67-1.36 
Ethnicity White Non-white 80.9% v. 81.9% 0.945 1.01 0.70-1.48 
Cannabis use 
status 
Ever use, not in past 30 
days Never Use 78.3% v. 88,1% 0.001 0.48 0.31-0.74 
 
Current use, within past 
30 days Never Use 73.5% v. 88,1% <0.001 0.35 0.22-0.56 
 
Ever use, not in past 30 
days 
Current Use, within past 
30 days 78.3% v. 73.5% 0.155 1.36 0.89-2.08 
Exposure to 
education Exposed Not Exposed 88.1% v. 78.1% <0.001 2.28 1.50-3.48 
    Worry about damage to future health, self (n=267)* 
Age 19-24 16-18 41.3% v. 60.0% 0.080 0.51 0.24-1.08 
 25-30 16-18 49.7% v. 60.0%  0.492 0.78 0.38-1.59 
 19-24 25-30 41.3% v. 49.7% 0.140 0.66 0.38-1.15 
Sex Male Female 50.9% v. 45.8% 0.572 1.16 0.70-1.91 
Ethnicity White Non-white 47.0% v. 51.5% 0.349 0.78 0.45-1.32 
Cannabis use 
status 
Current use, within past 
30 days 
Ever use, not in past 30 
days 
46.9% v. 50.4% 0.721 1.11 0.63-1.95 
Exposure to 
education Exposed Not Exposed 58.9% v. 43.0% 0.010 1.99 1.18-3.37 
    Perceived addiction, self (n=267)* 
Age 19-24 16-18 17.7% v. 33.3% 0.048 0.41 0.17-0.99 
 25-30 16-18 23.3% v. 33.3% 0.220 0.61 0.27-1.35 
 19-24 25-30 17.7% v. 23.3% 0.287 0.68 0.34-1.38 
Sex Male Female 28.8% v. 17.0% 0.068 1.78 0.96-3.30 
Ethnicity White Non-white 22.1% v. 24.4% 0.770 0.91 0.47-1.74 
Cannabis use 
status 
Current use, within past 
30 days 
Ever use, not in past 30 
days 28.1% v. 8.5% 0.003 3.96 1.60-9.78 
Exposure to 
education Exposed Not Exposed 29.3% v. 19.4% 0.125 1.62 0.88-2.99 
 
*Among past 3-month users 
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Figure 2 – Perceptions of level of health risks associated with daily cannabis use by cannabis form/mode of administration 
(N=870). 
6.4 8.0 10.9 5.2 5.2
20.3 21.7 19.8 14.1 13.2
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Table 6 – Logistic regression analyses examining risks of harm (physical or in other ways) perceived by cannabis forms and 




  Characteristics 
Ref. 
Category 
Smoke Cannabis Daily Vape Cannabis Daily Eat/Drink Cannabis Daily 





use in past 
30 days 
Never Use <0.001 0.21 0.11-0.40 <0.001 0.40 0.25-0.64 <0.001 0.24 0.15-0.39 
Ever use, not 
in the past 
30 days 
 0.013 0.45 0.23-0.84 0.343 0.80 0.51-1.27 0.002 0.48 0.30-0.77 
Ever use, not 
in past 30 
days 
Current use, 
use in past 
30 days 




Exposed Not Exposed 0.007 2.09 1.22-3.57 <0.001 2.27 1.48-3.50 0.054 1.47 0.99-2.16 
Characteristics Ref. Category 
Use High Potency Extracts Daily Use Synthetic Cannabis Daily    





use in past 
30 days 
Never Use <0.001 0.32 0.20-0.52 0.008 0.58 0.39-0.87    
Ever use, not 
in the past 
30 days 
 0.056 0.63 0.39-1.01 0.446 0.86 0.59-1.26    
Ever use, not 
in past 30 
days 
Current use, 
use in past 
30 days 








Table S1 - Risk perceptions of OCCASIONAL USE reported by high intensity cannabis users by cannabis form in the past 12 months 
 
RISK  0=No Risk 1= Risk 
  No risk 
%(n)  Slight risk 
Moderate 





Smoking Smoked (n=165) 12.3 (107) 45 12 0 1 6.7 (58) 
Edibles 
Edibles (n=110) 8.0 (70) 25 10 3 2 4.6 (40) 
Liquid (e.g. cola/tea) (n=25) 0.9 (8) 9 4 3 1  2.0 (17) 
Tinctures (n=26) 1.6 (14) 7 3 1 1 1.4 (12) 
Fresh flower (n=14) 0.8 (7) 5 1 1 0 0.8 (7) 
Vaping 
Vaporized (dried herb) (n=91) 6.4 (56) 25 8 0 2 4.0 (35) 
Vaporized (liquid) (n=62) 4.3 (37) 11 12 61 2 9.9 (86) 
High Potency 
Product 
Hashish (n=69) 4.3 (37) 17 9 3 2 3.6 (31) 
Hash Oil (n=43) 2.4 (21) 12 5 3 2 2.5 (22) 
Concentrate (e.g., BHO, shatter, budder, wax etc.) 
(n=61) 2.4 (21) 21 10 4 5 4.6 (40) 
 
 
Table S2 - Risk perceptions of DAILY USE reported by high intensity cannabis users by cannabis form in the past 12 months 
 
RISK  
 0=No Risk 1= Risk 
 No risk  Slight risk Moderate risk Great risk 
Don’t 
know Total 
Smoking Smoked (n=165) 3.3 (29) 69 47 20 1 15.7 (137) 
Edibles 
Edibles (n=110) 4.4 (38) 36 24 9 3 8.3 (72) 
Liquid (e.g. cola/tea) (n=25) 0.6 (5) 7 5 7 0 2.2 (19) 
Tinctures (n=26) 1.3 (11) 10 3 1 0 1.6 (14) 
Fresh flower (n=14) 0.2 (2) 9 2 1 0 1.4 (12) 
Vaping 
Vaporized (dried herb) (n=91) 2.5 (22) 39 19 10 2 8.0 (70) 
Vaporized (liquid) (n=62) 1.5 (13) 19 16 12 1 5.5 (48) 
High Potency 
Product 
Hashish (n=69) 1.6 (14) 24 16 13 2 6.3 (55) 
Hash Oil (n=43) 1.3 (11) 17 5 7 2 3.6 (31) 
Concentrate (e.g., BHO, shatter, budder, wax 
etc.) (n=61) 1.4 (12) 16 12 16 6 5.7 (50) 
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Table S3 - Logistic regression analyses examining risks of harm (physical or in other ways) perceived by 
cannabis forms and frequency of use among Canadian youth and young adult cannabis users and non-users 
(N=867). 
Characteristics Ref. Category 
Affirmative 
Response% 
Smoking Cannabis Occasionally Affirmative 
Response% 
Smoking Cannabis Daily 
p AOR 95%CI p AOR 95%CI 
Age 19-24 16-18 65.2% v. 79.9% <0.001 0.45 0.30-0.70 91.4% v. 93.6% 0.509 0.80 0.40-1.57 
 25-30 16-18 67.2% v. 79.9% 0.003 0.54 0.36-0.81 88.5% v. 93.6% 0.122 0.61 0.33-1.14 
 19-24 25-30 65.2% v. 67.2% 0.300 0.84 0.61-1.17 91.4% v. 88.5% 0.298 1.31 0.79-2.15 
Sex Male Female 69.1% v. 70.4% 0.677 0.94 0.70-1.26 91.4% v. 90.1% 0.262 1.29 0.83-2.02 
Cannabis use  Smokes Does not smoke 35.4% v. 77.4% <0.001 0.156 0.11-0.22 79.1% v. 93.3% <0.001 0.30 
0.19-
0.48 




Exposed 71.5% v. 69.0% 0.010 1.53 1.11-2.12 93.9% v. 89.2% 0.006 2.13 
1.25-
3.65 
    Vaping Cannabis Occasionally  Vaping Cannabis Daily 
    p AOR 95%CI  p AOR 95%CI 
Age 19-24 16-18 64.8% v. 75.8% 0.002 0.54 0.37-0.80 84.3% v. 89.0% 0.139 0.67 0.40-1.14 
 25-30 16-18 63.3% v. 75.8% 0.002 0.56 0.38-0.81 81.5% v. 89.0% 0.082 0.64 0.39-1.06 
 19-24 25-30 64.8% v. 63.3% 0.858 0.97 0.72-1.32 84.3% v. 81.5% 0.828 1.05 0.70-1.6 
Sex Male Female 66.4% v. 67.3% 0.448 0.90 0.68-1.18 84.9% v. 83.7% 0.347 1.19 0.83-1.70 
Cannabis use  Vapes Does not vape 41.3% v. 70.6% <0.001 0.28 0.19-2.19 71.6% v. 86.1% <0.001 0.42 
0.26-
0.67 






Exposed 70.0% v. 65.4% 0.002 1.62 1.20-2.20 89.5% v. 81.8% <0.001 2.28 
1.48-
3.52 
    Eating/Drinking Cannabis Occasionally  
Eating/Drinking Cannabis  
Daily 
    p AOR 95%CI  p AOR 95%CI 
Age 19-24 16-18 64.0% v. 76.3% 0.003 0.54 0.36-0.81 84.3% v. 88.1% 0.515 0.84 0.50-1.42 
 25-30 16-18 63.5% v. 76.3% 0.002 0.55 0.38-0.80 79.4% v. 88.1% 0.044 0.61 0.38-0.99 
 19-24 25-30 64.0% v. 63.5% 0.929 0.99 0.72-1.35 84.3% v. 79.4% 0.115 1.38 0.93-2.06 
Sex Male Female 66.4% v. 67.3% 0.479 0.90 0.68-1.20 82.3% v. 83.9% 0.891 0.98 0.69-1.39 




34.7% v. 72.1% <0.001 0.22 0.15-0.33 61.2% v. 86.6% <0.001 0.26 0.17-0.39 






Exposed 68.2% v. 66.3% 0.066 1.33 0.98-1.80 85.9% v. 81.8% 0.062 0.26 
0.17-
0.39 
    Use High Potency Extracts Occasionally  
Use High Potency Extracts  
Daily 
    p AOR 95%CI  p AOR 95%CI 
Age 19-24 16-18 76.8% v. 79.9% 0.231 0.77 0.50-1.18 85.4% v. 87.7% 0.392 0.80 0.48-1.33 
 25-30 16-18 74.2% v. 79.9% 0.343 0.82 0.55-1.23 83.3% v. 87.7% 0.612 0.88 0.54-1.43 
 19-24 25-30 76.8% v. 74.2% 0.710 0.94 0.67-1.32 85.4% v. 83.3% 0.641 0.91 0.61-1.36 
Sex Male Female 77.2% v. 75.7% 0.689 1.06 0.79-1.44 85.6% v. 84.5% 0.953 0.99 0.69-1.42 








52.6% v. 79.4% <0.001 0.24 0.16-0.37 72.6% v. 86.6% 0.002 0.45 0.28-0.74 
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Background: Health warnings have been shown to increase knowledge and awareness of health 
risks, influence social norms, and reduce consumption of tobacco products. With the legalization 
of non-medical cannabis in Canada and other subnational jurisdictions, there is a need for empirical 
studies to examine the impact of cannabis health warnings on consumer perceptions and behaviour 
relevant to cannabis. 
 
Methods: In October 2017, a between-group experiment was conducted as part of an online survey 
of Canadians aged 16 to 30 years (N=870) recruited from a national consumer panel. Participants 
rated the perceived effectiveness and believability of either text-only or pictorial cannabis health 
warnings and then completed a message recall task. Participants also reported their level of support 
for cannabis warnings, and support for including cessation information and a quitline on the 
warnings. 
 
Results: Pictorial health warnings for cannabis products were perceived as more effective and 
believable than text-only warnings (p<0.001), and the superiority of pictorial warnings was found 
across different warnings: dose (p=0.039), co-morbid drug use (p=0.006), and pregnancy 
(p<0.001). Pictorial warnings were also rated as more believable (p=0.048). Overall, 87.7% 
respondents supported having health warnings on cannabis products, and 84.0% supported the 
inclusion of a quitline number on cannabis health warnings. 
 
Conclusion: The current study provides the first empirical test of cannabis health warnings, 
consistent with the considerable body of evidence on the effectiveness of pictorial warnings on 
tobacco products. There was strong support for the inclusion of picture warnings and the inclusion 
of resources and quitlines on cannabis packaging. 
 
KEY WORDS: Cannabis labeling, cannabis health communication, cannabis product packaging, 




 In October 2018, non-medical cannabis was legalized in Canada.1,2  One of the primary 
objectives of the Cannabis Act is to protect the health of young persons and enhance public 
awareness of associated health risks.2 Cannabis is the most prevalent substance used among 
Canadian youth after alcohol; approximately 17% of students in grades 7 to 12 reported used 
cannabis in the past year according to the nationally representative 2016/17 Canadian Student 
Tobacco, Alcohol and Drugs Survey.3,4 The most recent general population survey on cannabis, 
the 2017 Canadian Cannabis Survey, found that 41% of youth aged 16 to 19 years and 45% of 
those aged 20 to 24 years reported past-year use.5  
Like most other substances, the risks of cannabis depend upon the setting, dose, form, mode 
of administration, and co-morbid substance use.4,6,7,8,9 Overall, two-thirds (62.4%) of Canadian 
current and past 3-month cannabis users have been found to be at a moderate risk of developing 
health or other problems due to their use.10 Early and frequent use of cannabis is among the best 
predictors of subsequent problematic use, lower academic performance, heightened risk for 
cannabis dependence, and problematic use of other drugs. 6,7,11,12,13  Frequent and heavy cannabis 
use is also associated with an increased risk of psychosis and other mental health 
disturbances.6,14,15,16,17 Cannabis use during pregnancy may increase the risks of stillbirth, preterm 
birth, fetal development issues, as well as having an adverse effect on child 
neurodevelopment.6,18,19 Acute impairment from cannabis increases the risk of motor vehicle 
accidents and evidence indicates that chronic exposure to cannabis smoke may increase risk of 
respiratory disease; high potency THC products may also increase adverse health risks.6,20,21 
Finally, concurrent use of cannabis with other drugs may also give rise to negative health and 
social outcomes.22,23  
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Research has identified youth in Canada as having low cannabis literacy. Focus groups 
conducted in 2013 found that many Canadian youth did not recognize the word marijuana in study 
pre-screening forms.24 A more recent focus group study conducted in 2017 found that, while young 
people perceive that they have accurate understanding of the potential adverse health effects of 
cannabis, they just “don’t care” about the health effects and would use cannabis regardless.25 
Young Canadians report that cannabis is generally benign and is a substance used by “everybody” 
referring to it as “natural” and “not really a drug at all”.24,26,27 Young users report taking comfort 
in the opinion that cannabis “affects everyone differently” to selectively determine the degree of 
harm that use might produce.25 As with most other health behaviours, perceptions of risk are 
inversely related to behaviour: youth who perceive cannabis as more harmful are less likely to use 
it.28,29,30  
Health warning labels (HWLs) are a prominent policy measure to communicate the health 
effects of consumer products. Research in the domain of tobacco control demonstrates that HWLs 
have high reach and frequency of exposure with more consumers reporting noticing information 
from product warnings than any other source.31 Comprehensive HWLs have been shown to 
influence social norms, increase health knowledge, and reduce consumption.32,33,34,35  
The effectiveness of HWLs depends upon their design. Key elements of effective health 
warnings include size, position, borders, and the general appearance of the warning (e.g., colour, 
graphics and graphic content, and message content).36 Vivid colour affect overall noticeability and 
maximizes legibility of text which may lead to increased cognitive processing of content.37,38  
Relative to text-only HWLs, pictorial HWLs are more likely to promote cognitive elaboration of 
risks, increased ability to attract and hold attention, and improve recall as they are more likely to 
remain salient over time and promote encoding to memory.35,39,40 Among youth, HWLs that 
highlight negative aesthetic effects or those that portray messages that suggest an inability to 
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participate in a valued activity are rated as having a greater impact.41,42,43,44 Integrating information 
on resources such as telephone quitlines also increases the impact of health warnings on behaviour 
change.45,46 
Canada’s Cannabis Act requires that products feature rotating health warnings, including 
general warnings about potential hazards from use, precautions of use during pregnancy or while 
breastfeeding, driving or operating heavy machinery while intoxicated, addiction, mental health 
implications, and impact from use in adolescence.47,48 Currently, however, there is a lack of 
evidence on the impact of health warnings for cannabis products. Despite increased calls and 
recommendations for health warnings on cannabis, there are no empirical studies examining the 
design or content of messages on consumption perceptions or behaviour.49,50,51,52  
  The current study examined the effectiveness of health warnings for cannabis products. 
The study had three primary objectives: 1) to test differences in perceived effectiveness and 
believability of text and pictorial cannabis product health warning labels; 2) examine whether 
certain label themes were more likely to be recalled than others; and 3) to examine levels of support 
from Canadian youth, including general support for health warnings, support for pictorial 





Between-group experimental tasks were conducted as part of a 30-minute online survey 
examining a range of areas related to cannabis use behaviours, beliefs, and attitudes.53 
Approximately 15 minutes into the survey, respondents were randomized to view either text-only 
or pictorial health warnings. Respondents rated the perceived effectiveness and believability of the 
warnings and completed a message recall task approximately 10 minutes after viewing the 
warnings. Participants also reported their level of support for cannabis warnings, pictorial vs. text 
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warnings, and the inclusion of cessation information and a quitline as part of the warnings. A 
description of the tasks and measures is presented below.   
Respondents 
 Respondents were individuals aged 16 to 30 (N=870) years of age with a Canadian IP 
address, and included cannabis users and non-users. Recruitment for participation in an online 
survey occurred by e-mail through Léger’s consumer panel for web surveys consisting of 
approximately 400,000 active members, with half of respondents sampled using probability-based 
methods using the Canadian Census, along with other non-probability based methods, including 
commercial surveys.54 Respondents aged 16 to 30 were recruited across Canada directly with the 
exception of youth in Quebec where youth aged 16 and 17 were recruited through their parents; 
parental consent was obtained prior to Quebec youth accessing the survey. Respondents received 
remuneration from Léger in accordance with their usual incentive structure. All of the data 
provided by respondents were anonymous and information was kept strictly confidential.  The 
study was reviewed by and received ethics clearance from the Office of Research Ethics at the 
University of Waterloo (ORE# 22392). Data collection was conducted from October 10th to 
October 24th, 2017. 
Development of health warnings 
 
The health warning messages tested in the study were created in a multi-step process. First, 
a literature review was conducted to identify known health effects associated with cannabis use 
and was used to create an initial set of warnings. Second, this initial set of warnings was 
incorporated into an anonymous online survey, hosted by SurveyGizmo (Widgix, LLC, Colorado, 
USA), and was sent to 51 experts on August 26, 2016 (See Appendix 2). These experts included 
members of the Expert Advisory Committee on Information for Physicians on Marihuana for 
Medical Purposes, the Canadian Centre on Substance Abuse Scientific Advisory Council, and 
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other prominent cannabis researchers.55 Of the 51 experts, 25 completed the survey, and the 
warning messages were refined based on their responses. Third, four focus groups were conducted 
in February 11-12, 2017 among 35 Canadian cannabis users (those who had used cannabis in the 
past 12 months) and non-users (those who had either never used or had abstained in the past 12 
months), aged 16 to 24 years. Focus group participants were asked about their perceptions of 
cannabis, and for their opinions of the refined warnings; the focus group results led to a final set 
of warnings, which were then constructed to be consistent with the graphic design of Canadian 
tobacco health warnings. 
Protocol and Measures 
 
Randomization for the between-group health warning experiment occurred in two steps. 
First, participants were randomized to receive 4 of any of the 8 prepared health warning messages: 
1) driving while intoxicated, 2) use during pregnancy, 3) use and mental health, 4) co-morbid use, 
5) youth use, 6) addictive potential, 7) dose, and 8) second-hand smoke (see Figure 1).  
Second, participants were randomized to view either a text-only or text and pictorial 
warnings (henceforth simply ‘pictorial’) for each of the 4 messages they viewed. Participants rated 
each health warning of perceived effectiveness and believability using a 10-point scale from 
1=‘Not at all effective/believable’ to 10=‘Extremely effective/believable’. Ratings were made 
while the message appeared on the screen.  
Following the experimental tasks, three measures of support were assessed. Respondents 
could respond yes/no/don’t to the following questions: 1) “In your opinion, if it were legal to sell 
marijuana, should health warnings be required on products?”; 2) “Should health warnings include 
pictures?”; 3) “Do you think this information (in the red rectangle) should be included on 
marijuana packages?”. The information referenced in the last question is reproduced in Figure 2.  
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At the end of the survey, approximately 10 minutes after viewing the warnings, participants 
were asked to recall as many of the four health warnings they viewed as possible. ‘Unprompted 
recall’ was assessed using open-ended fields. Responses were coded by two coders, both of whom 
were blind to the experimental condition and one who was unaware of the study hypotheses.  A 
correct recall was operationally defined as one that contained references and phrases contained in 
the health warning that had been presented. For example, mentions of “mixing”, “combining”, or 
“using both weed and alcohol” were coded as having recalled the warning about co-morbid drug 
use; mentioning “car accident”, “crashing”, or “too high to drive” were coded as having recalled 
the warning about driving while intoxicated. The percentage of agreement by the two coders of 
correct vs. incorrect recall for 75 of the responses was very high: 97.3%. 
 Sociodemographic characteristics included sex (male or female), age, ethnicity (white, 
non-white), and cannabis use status. Cannabis use status measures (‘never’, ‘recent – in the past 
12-months’, and ‘current use – in the past 30 days’) were drawn from a modified Canadian Student 
Tobacco, Alcohol and Drugs Survey, “Have you ever tried marijuana?” and a new item, “When 
was the last time you used marijuana” with options “More than 12 months ago”, “More than 3 
months to 12 months ago”, “Within the last month”.53,56   
Analysis 
 
All analyses were conducted using SPSS 25.0 (Armonk, NY: IBM Corp.). Generalized 
linear models were fitted to examine perceived effectiveness and perceived believability, while 
accounting for correlated responses across the 8 warnings. The models were adjusted for age, sex, 
ethnicity, cannabis use status, and indicator variables were included for experimental condition 
(0=text-only, 1=pictorial warning), the order by which warnings were shown, and warning label 
theme (1=Driving, 2=Pregnancy, 3=Mental Health, 4=Co-morbid Drug Use, 5=Early use, 
6=Addiction, 7=Overdose, 8=Toxic smoke). Logistic regression models were fitted to examine 
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correlates of support for requiring cannabis product health warning labels, inclusion of pictures on 
labels, and the inclusion of a call to action (0=Not supportive/Don’t Know, 1=Supportive).  
Results 
  
Table 1 displays the sample characteristics. A total of 1,045 respondents completed the 
survey; however, the final analytic sample was 870 as the rest were excluded from analysis due to 
completing survey from a mobile device instead of a desktop computer (28), missing data on key 
measures including cannabis use status (8) and/or failed data integrity questions; 62 records deleted 
due to incorrectly identifying the current month and 77 respondents reported being unable to 
provide honest answers to all of the survey questions. 
 
PERCEPTIONS OF HEALTH WARNING EFFECTIVENESS AND BELIEVABILITY  
 Overall, pictorial warnings were rated as significantly more effective than text-only 
warnings (AOR=1.59, 95%CI 1.33-1.89, p<0.001). Figure 3 displays the mean ratings of perceived 
effectiveness of text-only and pictorial health warnings among participants by message theme. 
Pictorial warnings were rated as more effective than text-only warnings overall, although of the 
eight health message themes, on three the greater effectiveness of pictorial warnings was 
statistically significant: dose, co-morbid drug use, and pregnancy (AOR=1.79, 95%CI 1.03-2.79, 
p=0.039; AOR=1.91, 95%CI 1.20-3.04, p=0.006; and AOR=3.20 95%CI 2.06-4.97, p<0.001 
respectively).  
Table 2 displays the results of linear regression models for perceived effectiveness and 
believability across the eight themes. Pregnancy-related warnings were consistently more likely to 
receive greater mean scores of effectiveness than any of the other health warning themes. For 
example, the pregnancy health warning labels were approximately twice as likely to receive greater 
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mean scores of perceived effectiveness than the drugged driving warnings (AOR=2.09 95%CI 
1.45-3.02, p<0.001).  
Figure 4 displays the mean ratings of believability of the text-only and pictorial health 
warnings by message theme. Pictorial warnings were rated as slightly more believable than text-
only warnings, although the effect size was small (AOR=1.19 95%CI 1.002-1.41, p=0.048), and 
for none of the 8 individual themes did pictorial and text-only warnings differ significantly. Table 
2 displays the results of the linear regression model examining believability across the eight 
themes. The pattern of differences across themes for believability were quite similar to the pattern 
of differences found for ratings of effectiveness. 
SUPPORT FOR HEALTH WARNINGS AND HEALTH WARNING ELEMENTS 
 Table 3 displays respondents’ support of health warning labels on cannabis products, 
pictorial labels, and calls to action displayed on labels such as quitlines. A very high percentage 
of respondents supported putting health warnings on cannabis products (88%). Logistic regression 
analyses revealed that respondents who had used cannabis in the past 30 days (current users) were 
less likely to be supportive of health warnings than those who had never used cannabis (75.5% vs. 
93.6%; AOR=0.23 95%CI 0.13-0.40, p<0.001). In contrast, those who reported that they had ever 
used cannabis, but not in the past 30 days (former users), were associated with greater odds of 
support for health warnings on cannabis products than current users (88.5% vs. 75.5%; AOR=2.51 
95%CI 1.55-4.06, p<0.001).  
 Nearly 7 in 10 respondents (69%) supported having pictorial warnings on cannabis 
products. White respondents had lower odds of supporting pictures on health warning labels than 
non-White respondents (72.9% vs. 81.8%%; AOR=0.57 95%CI=0.39-0.84, p=0.004). Significant 
differences were reported by cannabis use characteristics; 86.1% of never users, 77.4% of former 
users and 53% of current users reported support for pictorial warnings. Former and current 
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cannabis users were less likely to support pictorial warnings than respondents who had never used 
cannabis (AOR=0.61, 95%CI=0.39-0.94, p=0.025 and AOR=0.20, 95%CI=0.13-0.31, p<0.001 
respectively). However, former users had a greater likelihood of supporting pictorial warning 
labels than current users (AOR=3.09 95%CI=2.03-4.70, p<0.001).  
 The inclusion of calls to action such as quitlines were also well-supported (84.0%). Males 
were less likely than females to support the inclusion of these resources (79.1% vs. 88.5%, 
AOR=0.49 95%CI=0.33-0.73, p<0.001). Similar to questions of support for warnings and pictures, 
former users were more likely to support resources such as quitlines than current users (86.9% vs. 
69.4%, AOR=2.89 95%CI=1.83-4.55, p<0.002), and current users had significantly lower odds of 
supporting the same than never users (69.4% vs. 89.5%, AOR=0.28 95%CI=0.17-0.44, p<0.001 
respectively). 
HEALTH WARNING RECALL 
 Table 4 displays the number of times each message theme was accurately recalled as well 
as the number of respondents that were shown each warning (n). For the majority of health warning 
themes, pictorial warnings were recalled with the same or greater frequency as text warnings, with 
the exception of the driving and pregnancy themes that were recalled most frequently.  
Discussion 
 The current study found that pictorial health warnings for cannabis products were 
perceived as more effective and believable than text-only warnings. These findings are consistent 
with the extensive tobacco control literature and recommendations from the WHO Framework 
Convention on Tobacco Control that specify that pictorial health warnings on tobacco product are 
more effective and believable than text-only warnings.35,38,57,58  Notably, however, the greater 
effectiveness of pictorial warnings was not as strong for cannabis as for cigarettes in this study. 
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The current study was also able to identify thematic areas for further public health 
information campaigns, such as cannabis dependence which was consistently rated as relatively 
less effective or believable than the other cannabis health warning themes, and which has been a 
challenging area in cannabis health communications identified by previous researchers.25 Recent 
work from tobacco control research suggests that the use of graphic imagery, enhanced by 
testimonial content may be perceived as more effective and should be considered in the further 
development of cannabis product health warnings.59 These principles may be useful in resonating 
more abstract health effects such as those related to mental health and cannabis use. 
 No significant differences were observed between text and pictorial warning in the recall 
task. The current findings contrast with other studies showing greater recall for pictorial 
warnings.60 Typically, warnings that display and highlight stark or graphic images of physical 
health effects have been observed to enhance effects on memory; inducing an emotional reaction 
has been observed to increase memory for associated information.61,62,63  In the current study, there 
was a general trend towards greater recall of pictorial health warnings across most health effects, 
with the notable exception of the pregnancy warning. This was particularly surprising given that 
previous studies have identified pictorial health warnings of babies as among the most salient 
images tested.60,64 Other than the pregnancy warning, many of the images were abstract in nature, 
which may have contributed to lower levels of recall compared to more concrete images with more 
direct or congruent links to the specific health effect.65 Indeed, most of the images were symbolic 
which are consistent rated as least effective among themes for pictorial health warnings.59 
 There was near universal support for health warning labels on cannabis products and the 
inclusion of calls to action such as quitlines. Most youth and young adults also supported the use 
of pictorial health warning labels. The health warnings that are required by Health Canada under 
the Cannabis Act incorporate some the elements tested in the current study, including contrasting 
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colour and a set of rotating health warnings that depict different health effects.66 Although the 
‘main’ health warnings are text-only, packages are required to display a ‘universal symbol’ to 
indicate that the product contains cannabis. In the regulation and consultation reports, Health 
Canada contrasted the regulations for cannabis warnings against the pictorial warnings required 
on cigarette packages in Canada; the decision to opt for text-only cannabis warnings may be an 
effort to communicate the lesser health effects from cannabis use versus smoking.66 Future 
research should examine the impact of the cannabis health warnings on consumer knowledge and 
perceptions of risk.  
STRENGTHS AND LIMITATIONS 
 
 This study has a number of important strengths and limitations. While a commercial sample 
was used that employed probability and non-probability-based recruitment methods, we were able 
to include a broad and diverse sample with similar patterns of cannabis use and sociodemographic 
characteristics as the 2017 Canadian Cannabis Survey.5  The study surveyed  Canadian young 
people aged 16 to 30, who use cannabis at the highest rates and are a priority population in 
Canada’s legalization efforts.2 However, findings may not necessarily be generalizable among 
older age groups. Furthermore, it could be argued that the health warning labels presented in this 
study were ill-designed, however, an attempt to control for this involved a careful multistage 
process which included expert opinions and focus groups among youth and young adults. The 
between-group experimental design was a considerable strength as was the use of tools previously 




 The current study provides the first empirical test of cannabis health warnings. As with 
warning messages on tobacco products, pictorial warnings were perceived as more effective and 
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believable than text-only warnings. This study also provides evidence of strong support for the 
inclusion of picture warnings on cannabis products and the inclusion of resources and quitlines on 
cannabis packaging to strengthen Canadian cannabis product packaging regulations and inform 
the Government’s continued responsibility to protect population health.
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Figure 1 Health Warning Labels presented to survey respondents 












    











    
 
     












    























Table 1 – Sample characteristics (N=870). 
  % (N) 
Sex Female 52.1 (453) 
 Male 47.9 (417) 
   
Age (yrs.) 16–18 25.2 (219) 
 19–24 30.7 (267) 
 25–30 44.1 (384) 
   
Ethnicity White 64.5 (561) 
 Non-white 35.5 (309) 
   
Cannabis use status Never use 41.5 (361) 
 Former use, not in past 30 days 36.0 (313) 
 Current use, within past 30 days 22.5 (196) 
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Figure 3 – Mean ratings of effectiveness of text-only and pictorial health warning label among Canadian youth and young 
adults (out of 10); (n=851) 
 
Values adjusted for age, sex, ethnicity, and cannabis use status. *p<.05, **p<0.001 
“Overall” columns adjusted for age, sex, ethnicity, cannabis use status, order by which warning was shown, and warning message theme. 
 
Figure 4 – Mean ratings of believability of text-only and pictorial health warning label among Canadian youth and young 
adults (out of 10); (n=853) 
 
Values adjusted for age, sex, ethnicity, and cannabis use status, *p<0.05  
“Overall” columns adjusted for age, sex, ethnicity, cannabis use status, order by which warning was shown, and warning message theme.
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Table 2 – Linear regression analyses examining ratings of effectiveness and believability between cannabis health warning 
labels (n=851). 
Health Warning 
Label Theme Ref. 
Effectiveness Believability 
p OR 95%CI p OR 95%CI 
Pregnancy Driving <0.001 2.09 1.45-3.02 <0.001 1.96 1.35-2.82 
Mental Health  <0.001 0.44 0.29-0.67 0.004 0.54 0.36-0.82 
Co-morbid drug use  0.441 0.84 0.54-1.31 0.189 1.35 0.86-2.10 
Early Use  0.109 0.68 0.42-10.09 0.494 0.85 0.53-1.36 
Addiction  <0.001 0.40 0.24-0.67 <0.001 0.35 0.21-0.58 
Overdose  0.144 0.66 0.38-1.15 0.037 0.56 0.32-0.97 
Smoke toxicity  0.119 0.62 0.34-1.13 0.010 0.46 0.25-0.83 
Mental Health Pregnancy <0.001 0.21 0.15-0.31 <0.001 0.28 0.19-0.40 
Co-morbid drug use  <0.001 0.40 0.27-0.59 0.055 0.69 0.47-1.01 
Early Use  <0.001 0.32 0.22-0.49 <0.001 0.43 0.29-0.65 
Addiction  <0.001 0.19 0.12-0.30 <0.001 0.18 0.11-0.47 
Overdose  <0.001 0.32 0.19-0.52 <0.001 0.29 0.18-0.47 
Smoke toxicity  <0.001 0.30 0.17-0.52 <0.001 0.23 0.13-0.40 
Co-morbid drug use Mental Health <0.001 1.89 1.33-2.70 <0.001 2.48 1.75-3.54 
Early Use  0.027 1.53 1.05-2.22 0.020 1.56 1.07-2.27 
Addiction  0.610 0.90 0.59-1.36 0.036 0.64 0.43-0.97 
Overdose  0.085 1.50 0.95-2.37 0.897 1.03 0.65-1.63 
Smoke toxicity  0.208 1.40 0.83-2.36 0.505 0.84 0.50-1.41 
Early Use Co-morbid drug use 0.223 0.81 0.57-1.14 0.008 0.63 0.45-0.89 
Addiction  <0.001 0.47 0.33-0.69 <0.001 0.26 0.18-0.38 
Overdose  0.271 0.79 0.52-1.20 <0.001 0.42 0.27-0.63 
Smoke toxicity  0.221 0.74 0.45-1.20 <0.001 0.34 0.21-0.55 
Addiction Early Use 0.003 0.59 0.41-0.84 <0.001 0.41 0.29-0.59 
Overdose  0.919 0.98 0.66-1.45 0.036 0.66 0.45-0.97 
Smoke toxicity  0.704 0.92 0.58-1.45 0.008 0.54 0.34-0.85 
Overdose Addiction 0.005 1.67 1.17-2.38 0.009 1.61 1.13-2.29 
Smoke toxicity  0.035 1.56 1.03-2.35 0.205 1.31 0.86-1.97 
Smoke toxicity Overdose 0.714 0.93 0.65-1.35 0.268 0.81 0.56-1.17 




Table 3 – Support for health warnings and health warning elements (N=870). 
Support for % (N) 
Health warning labels on cannabis products 87.7 (763) 
Pictures on health warning labels* 69.8 (607) 
Calls to action/quitlines on cannabis 
products 84.0 (731) 
*Only those that answered in support for health warning labels on cannabis products were asked about support for pictures on said products.  
 
Table 4 – Health Warning Recall   
Health Warning Theme Experimental Condition 
Recalled warning 
%(n) 
Pregnancy (n=430)  49.5 (213) 
Pictorial (n=221) 45.2 (102) 
Text-Only (n=209) 53.1 (111) 
Mental Health (n=414)  43.2 (179) 
Pictorial (n=216) 43.5 (94) 
Text-Only (n=198) 42.9 (85) 
Smoke Toxicity (n=435)   33.1(144) 
Pictorial (n=204) 36.8 (75) 
Text-Only (n=231) 29.9 (69) 
Youth/Early Use (n=440)  29.5 (130) 
Pictorial (n=217) 31.8 (69) 
Text-Only (n=223) 27.4 (61) 
Addiction (n=436)  29.8 (130) 
Pictorial (n=209) 31.1 (65) 
Text-Only (n=227) 28.6 (65) 
Overdose (n=440)  18.4 (80) 
Pictorial (n=221)  19.0 (42) 
Text-Only (n=219) 17.8 (38) 
Co-Morbid Drug Use 
(n=441) 
 17.2 (76) 
Pictorial (n=223)  17.5 (39) 
Text-Only (n=218) 17.0 (37) 
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Background: Cannabis products exist in a wide array of forms and concentrations, with a 
consistent trend towards higher THC concentrations in North American markets. As part of 
cannabis legalization in Canada and several US states, regulations specify how THC levels should 
be labelled on products; however, there is little evidence regarding the extent to which consumers 
understand and use THC labelling to inform consumption amounts.   
 
Methods: Two experiments were conducted in October 2017 among Canadian youth and young 
adults as part of an online cross-sectional survey (N=870). Experiment 1: respondents were 
randomized to one of three labelling conditions (1=No Label, 2=mgTHC, 3=Doses). Respondents 
interpreted a recommended serving and number of servings contained in the package. Experiment 
2: randomized respondents to one of four labelling conditions communicating THC level (1=No 
Label, 2=%THC, 3=mgTHC, 4=Traffic Light System). Respondents determined level of THC in 
the product.  
Results: Labelling the number of doses per package was associated with the greatest proportion 
of correct responses (54.1%) when respondents had to determine a recommended serving 
compared with the no-label control condition (RR=7.28 95%CI 4.81-11.04) and THC mg 
condition (RR=4.05 95%CI 2.96-5.54). When product was labelled using a traffic light system, 
participants were more likely to identify THC level: low THC (RR=43.43 95%CI 16.43-114.79) 
or high THC (RR=16.71 95%CI 9.61-29.07) than the control condition. 
Conclusion: Few consumers can understand and apply quantitative THC labelling; in contrast, 
THC labels that provide ‘interpretive’ information, such as descriptors, symbols, or references to 
servings have greater efficacy. 
 
KEY WORDS: Cannabis constituent labeling, cannabis product packaging, cannabis use, 








Cannabis comes in a wide array of product types (e.g., dried herb, edibles, hashish or kief, 
cannabis oils, concentrates), which lead to a diversity of modes of administration. The various 
product types and preparations (e.g., its combination with tobacco by certain users) deliver 
different levels of the primary psychoactive component Tetrahydrocannabinol, Δ9-THC (THC) – 
a proxy for potency. THC concentrations of street-level dried herb have increased considerably 
over the past 30 years in North American markets.1  Currently, dried herb on both the licit and 
illicit market typically includes 15% to 17% THC, whereas high extract products such as oils or 
solid concentrates like waxes may contain up to 80-90% active THC.2,3,4,5 These increases are of 
public health concern because higher potency products have been associated with increased risk 
of health effects including psychoses, dependence, marked effects on memory and cognition, and 
increased use of emergency hospital services.6,7,8,9,10,11 After alcohol, cannabis is the most widely 
used substance in Canada among youth and young adults.12 According to the 2017 Canadian 
Cannabis Survey, 41% of youth aged 16 to 19 years and 45% of those aged 20 to 24 years reported 
using cannabis in the past year.13   
The most common forms of cannabis consumed among Canadians are dried herb (86%), 
followed by edibles (32%).14 Hashish (20%), cannabis oils (19%) and liquid concentrates (20%), 
which represent relatively higher potency products, were used by 1 in 5 past 3-month cannabis 
consumers in the second quarter of 2018.14 Gender differences in cannabis product use have been 
detected where males used dried herb more than females (90% vs 81%) and females consumed 
more edibles than males (41% vs 26%).14 
The diversity of cannabis products represents challenges to effective regulation such as 
creating clear, effective labelling standards to guide consumer decisions. Given the increasing 
number of jurisdictions that have legalized medical and non-medical cannabis in North America, 
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there is surprisingly little literature on consumer understanding of THC content on other aspects 
of product labelling. 15,16 Labelling frameworks for manufactured (e.g., edibles, concentrates, etc.)  
and non-manufactured (e.g., dried herb, leaf) cannabis products are highly variable from state to 
state, and evaluations of the effectiveness of warnings, such as whether they increase consumer 
knowledge about product potency, are limited to a few studies examining edibles.17,18  
Colorado and Washington require edible cannabis products to display information 
regarding potency and serving size such as, “the standard serving size for this product includes no 
more than 10 milligrams of active THC”; however, focus groups suggest that many consumers are 
unsure about how to interpret THC information. 19 Colorado consumers also reported feeling 
overwhelmed by the amount of information on the product label, the small font size, and being 
confused about some kinds of information, such as information on the variability of testing 
standards.19  Despite Colorado’s requirement for a Universal Symbol indicating that a product 
contains cannabis, it was not clear to nonusers that certain Colorado cannabis products, such as 
edibles, contained cannabis.19 These and other studies suggest that cannabis labelling may not be 
satisfying a principal objective of providing clear and easy-to-understand messages about cannabis 
products that consumers can use to understand key characteristics of these products— both within 
product class (e.g., distinguishing potency within edibles) and between product classes (e.g., 
distinguishing potency between edibles and combustibles).  
Accurate labelling is important in order to avoid or minimize adverse consequences that 
tend to occur when information is incomplete, unreliable, does not promote engagement or lacks 
practical knowledge such as information for first time users including excessive consumption, 
failure to dose properly, and increases in acute adverse events.20 The diversity of cannabis product 
types and their routes of use constitutes a major challenge to labelling of these products, which 
have not been encountered to such a great extent as with other products, such as tobacco products.  
 
 127 
Due to the lack of scientific consensus in many areas of cannabis-related health information, it is 
far more challenging to develop cannabis health warning messages, and thus more important to 
conduct research on cannabis warnings to fill knowledge gaps and develop an evidence base for 
cannabis health warnings. 
Canada became the second country in the world, after Uruguay, to legalize nonmedical 
cannabis in October 2018. The Cannabis Act created a legal framework for the control of 
production, distribution, sale, and possession of cannabis in Canada.21 As part of labelling 
regulations in the Cannabis Act, Health Canada requires cannabis packages to display its 
constituents, product type, potency and other essential information, including THC and CBD 
numbers.22,23  The extent to which consumers can interpret THC numbers is unclear, particularly 
given that some consumers are unfamiliar with terminology used for cannabis products, let alone 
what ‘THC’, ‘CBD’ numbers may communicate. 24,25,26,27 Adults also indicate confusion when 
presented with unfamiliar numerical information.19 Evidence in the areas of nutrition and tobacco 
labelling consistently demonstrate that consumers struggle to understand and apply quantitative 
constituent information. For example, although many consumers report using the calorie and 
nutrient numbers that appear in the ‘nutrition facts tables’ displayed on pre-packaged foods, most 
consumers struggle to correctly apply serving size information.28,29,30 Comprehension of food 
labels has been highly associated with literacy and numeracy skill, however even individuals with 
strong literacy skills appear to have trouble reading food labels.31 There are substantial and 
persistent disparities in consumer understanding and use of quantitative health information: 
consumers with lower education, income, and literacy skills are less likely to use and apply the 
nutrient amounts displayed on product labels. 28 Similarly, findings in cigarette labels indicate 
widespread misperceptions of the tar and nicotine numbers that were routinely displayed on 
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packaging and marketing, to the extent that these numbers have been removed or prohibited in 
many jurisdictions.32,33  
To date there exists no empirical evidence examining cannabis literacy in terms of specific 
constituents such as THC and/or CBD, perceptions of potency, or practical aspects related to 
consumption of cannabis products such as dosing or serving size. Given this considerable gap in 
the literature concerning cannabis consumer behaviour and Canada’s legislative changes around 
practical aspects of cannabis regulation, the current study was designed to assess comprehension 
of cannabis-related information including communication of dose and strength of product on 






Two experiments, each composed of two tasks, were conducted as part of an online cross-
sectional survey conducted among youth and young adults in Canada to assess respondents’ 
comprehension and practical application of information presented on cannabis product labels. The 
survey took place in October 2017. Recruitment occurred by e-mail through Léger’s consumer 
panel for web surveys consisting of approximately 400,000 active members, half of them sampled 
using probability-based methods using the Canadian Census, along with other non-probability 
based methods, including commercial surveys.34 Inclusion criteria included individuals aged 16 to 
30 years of age with a Canadian IP address, cannabis users and non-users. Respondents aged 16 
to 30 were recruited across Canada directly with the exception of youth aged 16 to 18 which were 
recruited through their parents; parental consent was obtained prior to this younger demographic 
accessing the survey. Respondents received remuneration from Léger in accordance with their 
usual incentive structure. All of the data provided by respondents were anonymous and 
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information was kept strictly confidential.  In all cases, respondents were provided with 
information about the study and asked to provide consent before participating. They were 
reassured their anonymity again after providing consent and proceeded to the survey. The study 
was reviewed by and received ethics clearance from the Office of Research Ethics at the University 
of Waterloo (ORE# 22392).  
Measures 
 
Respondents were asked to complete a set of tasks that required them to use different 
labelling executions such as presentations of THC in milligrams, percentages, or more intuitive 
presentations of THC level (e.g., as a ‘dose’, a pictorial ‘traffic light’ system) to determine serving 
sizes, and strength of cannabis products.35 
 
Experiment 1 – Comprehension of cannabis serving size information 
Experiment 1 was designed to examine how three different ways of conveying information 
about serving size affected consumer understanding. As shown in the figures presented in Table 
2, participants were randomized to view cannabis edibles with one of three THC labels: 1) no THC 
label (control), 2) THC in milligrams, and 3) number of ‘doses’. While viewing the labels, 
participants were asked two questions: 1) “Based on the information provided, how much of the 
cookie should someone eat on one occasion if they wanted a recommended serving?” with the 
following answer options: “¼ of a cookie”, “½ of a cookie”, “¾ of a cookie”, “1 cookie”, “2 
cookies”, “3 cookies”, “More than 3 cookies”, and “Don’t know”; and 2) “How many servings are 
in this package?” with response options, “1”, “2”, “3”, “4”, “5”, “More than 5”, and “Don’t know”. 
The responses for each question were recoded into a binary variable where 1 = correct answer, and 
0 = incorrect answer: for the first question, “1/4 of a cookie” was the correct answer; for the second 




Experiment 2 – Comprehension of THC potency information 
Experiment 2 was designed to examine how four different ways of presenting information 
about potency affected potency perceptions. Participants were randomized to view containers of 
dried marijuana leaf where information about potency was expressed in one of four ways, 
displayed in Table 3: 1) no THC Label (control), 2) THC as a percent, 3) THC in milligrams, and 
4) traffic-light graphic (green for ‘low’ potency, and red for ‘high’ potency). Participants first 
viewed the ‘low’ potency container, and then the ‘high’ potency container. While viewing each 
image, participants were asked the following question: “Based on the available information, what 
is the level of THC in this product?” with responses, “Low”, “Moderate”, “High”, “Don’t know”. 
Binary variables were created where 1=Correctly identified THC potency of displayed product, 
and 0=Did not correctly identify THC potency of displayed product. 
 
Data Integrity 
Data quality was controlled for using two questions to ensure participants were sufficiently 
engaged with the survey. Near the end of the survey, they were asked, “What is the current month?” 
and, “One last question, did you feel you were able to provide honest answers about your marijuana 
use during the survey?”. If respondents selected the wrong month or respondent that they felt 
unable to provide honest answers for ‘all questions’, they were not included in the analytic sample. 
Analysis 
 
All analyses were conducted using SPSS Statistical Software (Version 25.0, Armonk, NY: 
IBM Corp.). Bivariate tests were conducted to detect differences between sex, age, race and 
cannabis use status across experimental conditions with no differences detected. Logistic 
regression models were fitted to examine correct responses to interpreting a single serving size, 
 
 131 
identifying number of servings contained in a cannabis package, identifying the ‘low’ THC 
product, and identifying the ‘high’ THC product. Relative risk estimates are presented. For the 
first experiment, an indicator variable representing experimental condition was entered into the 
model (1= “No THC Label”, 2= “mg THC Label”, 3= “THC as ‘dose’ label”) along with sex, age, 
race, and cannabis use status. For the second experiment an indicator variable was also constructed 
representing experimental condition (1= “No THC Label”, 2= “% THC”, 3= “mg THC”, 4= 
“green/red traffic-light”) along with sex, age, race and cannabis use status. A two-way interaction 
term was tested between cannabis use status and experimental condition for each of the tasks, but 
significant interactions were not found. 
Results 
 
 Table 1 displays the current study’s sample characteristics. A total of 1,045 respondents 
completed the survey, however, the final analytic sample was 870 as the rest were excluded from 
analysis due to completing survey from a mobile device instead of a desktop computer (28), 
missing data on key measures including cannabis use status (8) and/or failed data integrity 
questions; 62 records deleted due to incorrectly identifying the current month and 77 respondents 
reported being unable to provide honest answers to all of the survey questions. 
Experiment 1 – Comprehension of serving size information 
Recommended serving size—As Table 2 indicates, less than 1 in 10 (7.4%) respondents in 
the control condition were able to correctly interpret a recommended serving size as ¼ of the 
cookie, or 10mg of THC. When products included constituent information such as “mg THC”, 
only 13.4% of respondents correctly identified the recommended survey amount; although this 
represented a significant increase from the no label control condition (RR=1.80 95%CI 1.09-2.97) 
as detailed in Table 3. More than one-quarter of respondents who viewed the THC mg label 
incorrectly reported the recommended serving was the entire cookie, while almost half selected 
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‘don’t know’. Labelling the number of doses per packages was associated with the greatest 
proportion of correct responses (54.1%) compared with the no-label control condition (RR=7.28 
95%CI 4.81-11.039) and THC mg condition (RR=4.05 95%CI 2.96-5.54). Respondents who 
reported using within the past 30 days (current users) were 1.5 times more likely to correctly 
identify the commended serving size than never users (RR=1.47 95%CI 1.12-1.92). 
Number of servings per package—No differences were observed between the ‘no label 
control condition’ and the THC mg condition in the proportion of participants who correctly 
identified the number of servings in the package (5.1% vs. 6.0%).  In contrast, 77.9% of 
participants were able to correctly identify the number of servings as four when the THC 
information was displayed as ‘doses’, a significant increase from the no label control and the THC 
mg conditions (RR=15.38 95%CI9.36-25.28; RR=13.02 95%CI 8.18-20.73, respectively). Current 
users were more likely to correctly identify the number of servings contained in the package than 
never users (RR=1.32 95%CI 1.03-1.70).  
 
Experiment 2 – Comprehension of THC potency information  
Table 4 displays the results of the second experiment examining ‘low’ and ‘high’ level 
THC products. In the control condition of the set communicating ‘low’ THC levels, where there 
was no THC information, virtually no respondents (2.0%) identified the displayed product as 
having a ‘low’ THC level. In contrast, approximately one-third (35.3%) of respondents correctly 
identified THC level as ‘low’ in the condition that displayed THC as a percentage, a significantly 
higher proportion compared to the control condition (RR=18.10 95%CI 6.76-48.52). Table 5 
shows relative risk estimate analyses for Experiment 2. Respondents who viewed the cannabis 
product displaying a green traffic light which read “Low THC” had a much greater likelihood in 
correctly identifying it as a low THC product than when no THC information was present (85.1% 
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vs. 2.0; RR=43.43 95%CI 16.43- 114.79). Current users had greater odds of correctly identifying 
the ‘low’ THC level products they were displayed than never users using the product labels 
(RR=1.41 95%CI 1.14-1.75). Similar patterns emerged in the conditions where high THC level 




The current study found that intuitive cannabis constituent labelling strategies that include 
symbols or simple, common units of measurement such as “dose” were better understood by 
Canadian youth and young adults compared to THC numbers. These findings are consistent with 
existing literature regarding the ways in which consumers interact with product information 
including pre-packaged food and beverage or tobacco products.28,29,30,32,33 The inclusion of easily 
understandable THC and serving size considerations on product packaging is an important 
approach to educate the public on the consumption of cannabis products, particularly among first 
time and low-literacy populations. These findings are consistent with consumer studies of nutrition 
labelling, in which the use of simple, interpretive information increases consumer understanding.36 
Although there may be a tendency for regulators to present information in precise and accurate 
technical terms (e.g., mg, mL), doing so is likely to be less effective in conveying the necessary 
understanding for consumers to make accurate choices about dosing and potency of cannabis 
products. The current study demonstrated that only a third of consumers accurately identified a 
high potency product for what it was when technical information was presented compared to the 
traffic light system. It should also be noted that even for the most effective labelling condition, in 
which the number of doses was displayed on packages, almost half of participants continued to 
select an incorrect consumption amount or indicated that they did not know how much of the 
cannabis edible to consume. This highlights the importance of other packaging standards, such as 
unit-dose packaging, in which each THC serving or dose is packaged separately, rather than multi-
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serving units, such as the cannabis cookie tested in the current study which are common to both 
the legal and illegal cannabis markets. For example, Canada has recently proposed new regulations 
for edibles, in which each 10mg unit of THC must be packaged separately.37 This represents a 
more prescriptive approach than US states such as Colorado, which require 10mg servings to carry 
individual cannabis symbols, but not to be packaged separately.  
The findings also suggest that interpretative symbols may be effective in providing context 
for THC levels with respect to whether they are ‘high’ or ‘low’. This is particularly important 
given the diversification of the cannabis market and the wide range of THC levels in products, 
ranging from very low THC products, to concentrates that can exceed 90% THC levels. The 
findings are consistent with the use of traffic light symbols to communicate nutrient amounts and 
research on the efficacy of graphic formats in enhancing consumer comprehension38,39,40 However, 
one potential limitation of traffic light symbols is that a ‘green’ or ‘low’ symbol can be 
misinterpreted by consumers as an indicator of permissiveness or decreased risk.41,42,43 In the case 
of cannabis products, consumption amounts are ultimately determined by consumers, and ‘lower’ 
or ‘moderate’ THC products can still be consumed in excessive amounts. For example, in the 
current study, a green traffic light was equated to 5% THC or 5mg THC, which to a regular 
cannabis consumer may be ‘low’ potency; however, a first-time or novice user may not consider 
it ‘low’. Perhaps for this reason, the Quebec government in Canada has avoided any symbol or 
descriptor associated with ‘low’ when labelling cannabis products on its government-run online 
cannabis store; instead, products are labelled ‘moderate’, ‘medium’, or ‘high’ depending on the 
THC level.44   
Existing online retail practices from the Ontario Cannabis Store use percentages, allow 
ambiguous language such as “mid-range THC Content” to describe product potency, product 
experience as having a “woody and earthy aroma”, with expected effects to include “relaxation, 
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happiness and/or euphoria”.45 The limited objective information to make decisions about product 
use may be outweighed by a wide range of pleasant product descriptors that may promote initiation 
and continued consumption of cannabis among the Canadian population. Additional research 
should examine the efficacy of symbols and other graphical formats for communicating THC 
levels and potency through product labelling. 
 
STRENGTHS AND LIMITATIONS 
 
 The commercial sample in the current study used probability and non-probability-based 
recruitment methods. As a result, the findings may not be representative of Canadian youth and 
young adults. However, a broad and diverse sample was surveyed with similar sociodemographic 
characteristics and patterns of cannabis use as the 2017 Canadian Cannabis Survey.5 The sample 
consisted of young people aged 16 to 30 exclusively. This subgroup has the highest rates of 
cannabis use in Canada and a key population of interest in legalization efforts. Another limitation 
may be in the alignment of the mocked-up product potencies; for example, in the second 
experimental task, the quantity of dried herb was not labelled on the container; therefore, 100mg 
THC may not neatly align with a 25% THC product, further the quantities of each product were 
not displayed which would help inform consumers gauge level of THC. Study strengths include 
the use of between-group experimental design as well as the use of existing products within our 
experimental conditions and demonstration of parallel findings between tobacco control and 
nutrition literature.  
Conclusion 
 THC numbers used to express potency have little or no meaning to most youth and young 
adults in Canada. Expressing THC in terms of the number of ‘doses’ or servings may provide 
consumers with better guidance on consumption amounts for cannabis edibles; however, 
additional measures, such as unit-dose packaging, may be required to provide consumers with 
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clear, unequivocal guidance on THC levels. Future research should consider whether other 
labelling, such as symbols or descriptors provide additional benefit.  
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Table 1 – Sample characteristics (N=870) 
  % (N) 
Sex Female 52.1 (453) 
 Male 47.9 (417) 
   
Age (years) 16–18 25.2 (219) 
 19–24 30.7 (267) 
 25–30 44.1 (384) 
   
Race White 64.5 (561) 
 Non-white 35.5 (309) 
   
Cannabis use status Never use 41.5 (361) 
 Ever use, not in past 30 days 36.0 (313) 






Table 2 –Interpreting recommended serving size contained in a cannabis package without THC indicators, “mg THC” label, 
or “Doses” label (N=870). 
 
Experimental conditions 
   
No THC Label Control  “mg THC” Label  “Doses” Label 
 n=296 n=284 n=290 
How much should someone eat on one occasion if they wanted a recommended serving?  
¼ of a cookie* 7.4 (22) 13.4 (38) 54.1 (157) 
½ of a cookie 8.1 (24) 11.3 (32) 5.9 (17) 
¾ of a cookie 1.7 (5) 1.1 (3) 1.0 (3) 
1 cookie 37.8 (112) 27.8 (79) 16.9 (49) 
2 cookies 3.4 (10) 2.1 (6) 1.0 (3) 
3 cookies 0.3 (1) 0.0 (0) 0.3 (1) 
More than 3 cookies 0.3 (1) 0.4 (1) 2.8 (8) 
I don’t know 49.9 (121) 44.0 (125) 17.9 (52) 
    
How many servings are in this package?   
1 serving 33.8 (100) 29.9 (85) 9.7 (28) 
2 servings 7.1 (21) 7.4 (21) 1.0 (3) 
3 servings 3.4 (10) 2.8 (8) 0.7 (2) 
4 servings* 5.1 (15) 6.0 (17) 77.9 (226) 
5 servings 1.0 (3) 2.5 (7) 0.0 (0) 
More than 5 servings 2.0 (6) 1.8 (5) 0.7 (2) 
I don’t know 47.6 (141) 49.6 (141) 10.0 (29) 




Table 3 – Relative risk estimates examining correct responses to questions regarding recommended serving size and number 
of servings in cannabis product packages   
Characteristics Comparison Correct Response % 
Correctly identified 
recommended serving size Correct Response % 
Correctly identified 
servings in package 
RR 95%CI RR 95%CI 
Age 
(years) 19-24 16-18 25.1% v. 20.1% 1.25 0.89-1.75 29.6% v. 29.7% 0.98 0.76-1.31 
 25-30 16-18 27.6% v.  20.1%  1.37 1.01-1.87 29.7% v. 29.7% 1.00 0.78-1.29 
 19-24 25-30 25.1% v. 27.6% 0.91 0.70-1.18 29.6% v. 29.7% 1.00 0.78-1.27 
Sex Female Male 24.9% v. 24.9% 1.00 0.79-1.26 31.4% v. 28.0% 0.89 0.73-1.10 
Race Non-White White 26.2% v. 22.7% 0.87 0.67-1.11 31.2% v. 26.9% 0.86 0.69-1.07 
Cannabis 
use status 
Ever use, not in 
past 30 days Never Use 23.3% v. 22.2% 1.05 0.80-1.39 28.1% v. 27.4% 1.03 0.80-1.31 
 
Current use, 
within past 30 
days 
Never Use 32.7% v. 22.2% 1.47 1.12-1.95 36.2% v. 27.4% 1.32 1.03-1.70 
 Ever use, not in past 30 days 
Current Use, 
within past 30 
days 
23.3% v. 32.7% 0.71 0.54-0.95 28.1% v. 36.2% 0.78 0.60-1.00 
Labelling 
Condition “mg THC” Label 
No THC Label 
Control 13.4 % v. 7.4% 1.80 1.09-2.97 6.0% v. 5.1% 1.18 0.60-2.32 
 “Doses” Label No THC Label Control 54.1% v. 7.4% 7.28 4.81-11.04 77.9% v. 5.1% 15.38 9.36-25.28 





Table 4 –Determining cannabis product potency through four labelling strategies, no THC label control, THC presented as a 
percentage, in milligrams, and a traffic light system; (N=870) 
  What is the level of THC in this marijuana product? %(n) 
 
    
LOW 
POTENCY No THC Label Control “5% THC” Label “5mg THC” Label Traffic Lights “Green” 
n= 204 232 232 202 
Low* 2.0 (4) 35.3 (82) 27.6 (64) 85.1 (172) 
Moderate 9.3 (19) 13.8 (32) 15.5 (36) 4.5 (9) 
High 6.4 (13) 4.3 (10) 3.9 (9) 1.5 (3) 
I don’t know 82.4 (168) 45.7 (106) 53.0 (123) 8.9 (18) 
 
    
HIGH 
POTENCY No THC Label control “25% THC” Label “100mg THC” Label Traffic Lights “Red” 
n= 231 220 221 198 
Low 3.5 (8) 15.9 (35) 7.2 (16) 2.5 (5) 
Moderate 8.7 (20) 30.9 (68) 18.1 (40) 1.5 (3) 
High* 5.2 (12) 22.7 (50) 29.0 (64) 86.4 (171) 





Table 5 – Relative risk estimates examining correct responses to questions regarding cannabis product potency   
Characteristics Comparison Correct Response % 
Correctly identified cannabis 
with low potency Correct Response % 
Correctly identified 
cannabis with high potency 
RR 95%CI RR 95%CI 
Age (years) 19-24 16-18 38.3% v. 34.7% 1.11 0.87-1.40 31.3% v. 33.3% 0.94 0.73-1.22 
 25-30 16-18 37.5% v. 34.7% 1.08 0.87-1.35 36.7% v. 33.3% 1.10 0.88-1.39 
 19-24 25-30 38.3% v. 37.5% 1.02 0.84-1.25 31.3% v. 36.7% 0.85 0.68-1.06 
Sex Female Male 34.9% v. 39.1% 1.12 0.94-1.34 35.6% v. 33.0% 0.93 0.77-1.11 
Race Non-White White 38.4% v. 34.6% 0.90 0.75-1.09 34.7% v. 33.3% 0.96 0.79-1.17 
Cannabis use 
status 
Ever use, not in past 
30 days Never Use 37.5% v. 32.1% 1.17 0.95-1.44 34.0% v. 31.7% 1.07 0.86-1.33 
 Current use, within past 30 days Never Use 45.4% v. 32.1% 1.41 1.14-1.75 39.3% v. 31.7% 1.24 0.99-1.56 
 Ever use, not in past 30 days 
Current Use, 
within past 30 
days 
37.2% v. 45.4% 0.83 0.67-1.01 34.0% v. 39.3% 0.87 0.69-1.09 
Labelling 
Condition % THC Trade name 35.3% v. 2.0% 18.10 6.76-48.52 22.7% v. 5.2% 4.40 2.41-8.03 
 mg THC Trade name 27.6% v. 2.0% 14.07 5.22-37.96 29.0% v. 5.2% 5.57 3.09-10.04 
 Traffic Light System Trade name 85.1% v. 2.0% 43.43 16.43-114.79 86.4% v. 5.2% 16.71 9.61-29.07 
 %THC Traffic Light System 35.3% v. 85.1% 0.42 0.35-0.50 22.7% v. 86.4% 0.26 0.21-0.34 
 mg THC Traffic Light System 27.6% v. 85.1% 0.32 0.26-0.40 29.0% v. 86.4% 0.33 0.27-0.41 








Chapter 5: The efficacy of health warnings and 
package branding on perceptions of cannabis 




Cesar Leos-Toro BSc1, Geoffrey T Fong PhD2,3, David Hammond PhD1  
 
1 School of Public Health & Health Systems, University of Waterloo, 200 University Ave. 
W., Waterloo, ON, Canada, N2L 3G1 
2 Department of Psychology, University of Waterloo, 200 University Ave. W., Waterloo, ON, 
Canada, N2L 3G1 
3 Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, 
Toronto, ON, Canada, M5G 0A3 
 
 




University of Waterloo 
School of Public Health & Health Systems 
200 University Ave W. 
Waterloo, ON N2L 3G1 
Tel. (519) 888-4567 ext. 36462 
dhammond@uwaterloo.ca 
 
Conflicts of Interest: None to declare. 
 
Funding acknowledgment:  
This study was supported by a Canadian Institutes of Health Research (CIHR) Project Bridge 
Grant (PJT-153342). Additional support was provided by a CIHR Research Chair in Applied 
Public Health (DH), and a CIHR Foundation Grant (FDN-148477) and a Senior Investigator 
Award from the Ontario Institute for Cancer Research (GF). 
 
 
Word Count: 3,884 
 











Canada requires mandatory health warnings and restrictions on advertising and promotion as 
part of nonmedical cannabis legalization. Similar regulations have proven effective in shaping 
product perceptions and consumer behaviour in other domains; however, little empirical 
evidence exists about the efficacy of labeling and marketing restrictions in a regulated cannabis 
market. This study examined perceptions of cannabis product packaging designs, health 
warning labels (HWLs), and perceptions of packs displaying brand imagery and leading 
descriptors on measures of appeal, and perceived consumer attributes. 
 
Design, Setting, Participants 
An online experimental survey of Canadian cannabis users and non-users (N=870) aged 16 to 
30 years containing 8 between-group experimental tasks.  
 
Measurements 
The primary outcomes were appeal and perceptions of consumer attributes of cannabis product 
packaging and HWLs including: greater likelihood of being younger, female, fashionable, 
health conscious, and likely to go out and party. 
 
Findings  
When cannabis product branding was present, respondents were more likely (AOR=1.76 
95%CI 1.07-2.91 p=0.027) to report greater appeal than when branding was absent. When a 
HWL was present, respondents were less likely (AOR=0.52 95%CI 0.32-0.86 p=0.010) to 
report greater appeal than when absent. The presence of a celebrity sponsor (AOR=3.06 95%CI 
2.16-4.36 p<0.001), music references (AOR=3.64 95%CI 2.37-5.60 p<0.001), or party 
references (AOR=12.29 95%CI 8.08-18.69 p<0.001) increased the likelihood that respondents 
perceived the product as targeted at someone younger, and a party lifestyle. Differences by 
cannabis use status were observed across experimental tasks; those that had ever used were 
more likely to find the presence of branding elements appealing. 
 
Conclusions 
Plain/standardized cannabis packs with a HWL were perceived as less appealing than those 
with branding or without a HWL. A variety of lifestyle associations can be communicated 
through brand imagery on cannabis packaging. 
 





Advertising and promotion have a strong influence on consumer health behaviours, 
such as tobacco use.1,2,3,4 Advertising can influence perceptions of risks, as well as positive 
associations between smoking and desirable outcomes, such as independence, social approval, 
sexual attraction and thinness. Packaging represents an important component of product 
marketing and serves as the cornerstone of brand imagery, which encompasses logos, colours 
and other brand identities. Brand imagery encourages consumers to draw inferences about the 
contents of a package and the likely experience they will have as a result of consuming the 
product, including social identities.5,6,7,8  
Evidence from the tobacco and alcohol research domains indicates that the appearance 
of a product influences initiation of use, increased consumption, and brand loyalties.9,10,11,12,13 
Indeed, independent studies and tobacco industry research documents regarding packaging 
characteristics and consumer perceptions have described the impact on subsequent consumer 
behaviour and the specific elicited perceptions of each packaging detail. For example, lighter 
colours communicate cues that elicit perceptions of reduced harm and strength, superior 
quality, and better brand recognition.14,15,16,17,18 Health-oriented descriptors (e.g., 100% 
organic) have been shown to increase intentions to purchase, increase general favourable 
perceptions, and reduce perceived harm associated with the product’s use.19 Products presented 
in relatively slim and thin designs increase attractiveness (particularly among women), 
communicates milder content, and are perceived as less harmful.20,21,22 In contrast, 
plain/standardized packaging has been observed to elicit less perceived appeal, be perceived as 
less attractive, promote less projections of personality attributes (i.e., cool, popular), reduce 
perceptions of implied safety, and is perceived as less sophisticated than packs that display 
branding elements. 
To date, few studies have investigated the impact of cannabis-specific marketing and 
its influence on consumer behaviour. Research conducted in the US suggests widespread 
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exposure to cannabis advertising, particularly through digital media.23,24   A study conducted 
in Oregon following legalization of non-medical cannabis in 2015 indicated higher levels of 
exposure to cannabis marketing than general US samples, primarily via storefronts, street signs, 
and billboards. 25 In California, exposure to medical cannabis advertisements among 6th and 8th 
graders was associated with a greater likelihood of cannabis use and stronger intentions to use 
one year later.26 Furthermore, brain imaging studies suggest that cannabis marketing produces 
similar brain reactivity and reward cues as marketing for alcohol and tobacco products.27  
Packaging also serves as an important channel for communicating health risks through 
product labels and health warnings. In tobacco control, health warning labels (HWLs) have 
proven to be the most cost-effective medium to communicate information related to a product’s 
health risks.28 Large pictorial health warnings on tobacco products have been effective in 
changing social norms and reducing consumption, including among youth.29 In Canada, dried 
cannabis products are required to display one of six different warnings communicating risks 
related to pregnancy, addiction, adolescent use, impaired driving, and psychosis/schizophrenia. 
Cannabis users may benefit from health warnings given that the most recently available 
evidence suggests that many cannabis users have low awareness of health effects and obtain 
their limited health information about cannabis from unreliable sources.30,31,32,33 To date, 
however, there is no empirical evidence on the impact of health warnings on cannabis products.  
In October 2018, nonmedical cannabis was legalized in Canada. The federal Cannabis 
Act establishes several international precedents for restrictions on advertising and promotion, 
packaging, and labelling of cannabis products.34 In particular, the Act prohibits any form of 
lifestyle advertising or promotion that appeals to young people, including restrictions on brand 
imagery of cannabis packaging.35 Packaging restrictions on brand imagery are often referred 
to as ‘plain’ or ‘standardized’ packaging; however, unlike restrictions on tobacco packages, the 
cannabis regulations in Canada allow manufacturers to choose one colour (as opposed to 
mandating the same colour across all packages) and a certain amount of brand imagery 
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equivalent in size to the mandated ‘cannabis symbol’.  Cannabis products will also be required 
to feature one of six large text-only health warnings. The cannabis industry is widely expected 
to issue a legal challenge to the package regulations in Canada. Similar challenges issues in 
response to tobacco packaging standards have required the independent effectiveness of health 
warnings and restrictions on pack branding. In this context, it is important to test the efficacy 
of standardized packaging with and without health warnings. The current study examined 
perceptions of standardized and branded packaging designs, perceptions of packs with and 
without HWLs, and perceptions of packs displaying brand imagery and leading descriptors on 
measures of appeal, perceived target age of consumer, and other characteristics and lifestyle 







An online cross-sectional survey was conducted from October 10th to October 24th, 
2017. The inclusion criteria were individuals aged 16 to 30 years of age with a Canadian IP 
address, included cannabis users and non-users, it required users to complete the survey from 
a desktop computer. Recruitment occurred by e-mail through Léger’s consumer panel for web 
surveys consisting of approximately 400,000 active members, half of them sampled using 
probability-based methods using the Canadian Census, along with other non-probability based 
methods, including commercial surveys.36 Respondents aged 16 to 30 were recruited across 
Canada directly with the exception of youth in Quebec where youth aged 16 to 18 were 
recruited through their parents; parental consent was required prior to Quebec youth accessing 
the survey. Respondents received remuneration from Léger in accordance with their usual 
incentive structure. All of the data provided by respondents were anonymous and information 
was kept strictly confidential.  In all cases, respondents were provided with information about 
the study and asked to provide consent before participating. They were reassured their 
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anonymity again after providing consent and proceeded to the survey. The study was reviewed 
by and received ethics clearance from the Office of Research Ethics at the University of 
Waterloo (ORE# 22392).  
PROCEDURE 
 
The current study consisted of a series of eight between-group experimental tasks. 
Participants were randomized before each of the eight experimental tasks to examine eight 
distinct package elements. Task 1 examined perceptions of brand imagery and health warnings 
where participants were randomized to one of the following four conditions: i) a 
plain/standardized pack that displayed a health warning label (HWL), ii) a plain pack without 
a HWL, iii) a branded pack that displayed a health warning label, and iv) a branded pack. For 
the remaining experimental tasks, respondents were repeatedly randomized into one of two 
conditions where the following branding characteristics were present or absent: Task 2) a 
flavour descriptor, Task 3) an ‘energy’ descriptor, Task 4) a celebrity sponsorship, Task 5) 
music references, Task 6) party references, Task 7) health claims, and Task 8) fashion 
references. Participants rated each pack on three dimensions: 1) appeal, 2) the perceived target 
age of the consumer, and 3) a pack-specific question on the design element of interest, such as 
perceived gender, party habits, health perceptions, or fashion, as shown in Tables 2, 4, 6, 8, 
and 10. 
Measures 
Sociodemographic characteristics included sex (male or female), age, ethnicity (white, 
non-white), and cannabis use status. Cannabis use status measures (‘never’ vs. ‘ever use’) were 
drawn from the Canadian Student Tobacco, Alcohol and Drugs Survey (CSTADS) – “During 
your lifetime have you ever used or tried marijuana?” (Yes=‘Ever Use’).37   
Product Appeal was rated using a ten-point scale from 0=“Not at all appealing” to 
10=“Very appealing”. Perceived target age of consumer for each brand was assessed with the 
question, “In your opinion, someone who chooses to use this product is more likely to be…” 
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with answer options, “Younger than me”, “My age”, “Older than me”, “Don’t know”. A binary 
variable was created so that “Younger than me” was coded as 1 and the rest were coded as 
0,“Not younger than me”. Perceived gender of the target consumer for products was assessed 
with the question, “In your opinion, someone who chooses to use this product is more likely to 
be…” with answer options, “Male”, “Female”, “No difference”, and “Don’t know”.  A binary 
variable was created so that “Likely female” was coded as 1 and the rest were coded as 0, “Not 
likely female”. Perceived consumer characteristics were assessed with the following questions. 
To assess perceptions of the party habits they associated with the target consumer of each 
product, respondents were asked, “In your opinion, someone who chooses to use this product 
is more likely to…” with answer options, “Go out and party”, “Stay home”, “No difference”, 
and “Don’t know”. A binary variable was created so that “Go out and party” was coded as 1 
and the rest were coded as 0, “Not go out and party”. The perceived level of target consumer’s 
health consciousness was determined with the question, “In your opinion, someone who 
chooses to use this product is more likely to be…”, with answers, “Someone who takes more 
care of their health”, “Someone who takes less care of their health”, “No difference”, and 
“Don’t know”. A binary variable was created so that “Someone who takes more care of their 
health” was coded as 1 and the rest were coded as “Not someone who takes more care of their 
health”. To assess perceptions of fashion sense associated with target consumer, respondents 
were asked, “In your opinion, someone who chooses to use this product is more likely to be…”, 
with answers, “More fashionable”, “Less fashionable”, “No difference”, and “Don’t know”. A 
binary variable was created so that “More fashionable” was coded as 1 and the rest were coded 
as 0,“Not more fashionable”. 
Two data integrity questions were included in the survey, “What is the current month?” 
as well as, “One last question, did you feel you were able to provide ‘honest’ answers about 
your marijuana use during the survey?” with options, “No”, “Some questions, but not all”, “All 
questions”. Respondents that did not provide accurate answers for ‘current month’ or did not 
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feel that they were able to provide honest answers to ‘all questions’ were excluded from the 




All analyses were conducted using SPSS Statistical Software (Version 25.0, Armonk, 
NY: IBM Corp.). The study sample was characterized using descriptive statistics with respect 
to: age, sex, ethnicity, and cannabis use status. Chi square tests were used to test the 
effectiveness of randomization and potential differences in age, sex, ethnicity, and cannabis 
use status between experimental conditions. Chi square tests and ANOVA models were used 
to examine differences in the experimental outcomes for categorical and continuous measures, 
respectively. Two-way interactions were tested and are presented in the text as appropriate. 
Linear regression models were fitted to examine correlates of continuous measures adjusting 
for age, sex, race, and cannabis use status. Logistic regression models examined correlates of 
target consumer attributes including perceived target age, likely gender, party habits, relative 





Table 1 displays the sample characteristics. A total of 1,045 respondents completed the 
survey; however, the final analytic sample was 870 as the rest were excluded from analysis due 
to completing survey from a mobile device instead of a desktop computer (28), missing data 
on key measures including cannabis use status (8) and/or failed data integrity questions; 62 
records deleted due to incorrectly identifying the current month and 77 respondents reported 
being unable to provide honest answers to all of the survey questions. Due to inaccuracies in 
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Canadian internet provider geolocation, 172 respondents aged 16 to 18 years were asked for 
parental consent across Canada. Experimental Task 1 that examined plain packaging, branding, 
and health warning labels, was completed by 526 respondents; this discrepancy is due to a 
programming error wherein respondents were randomized into three conditions instead of four. 
Léger re-contacted all of the original survey respondents and 526 respondents completed the 
experimental task as intended; 22 cases were not part of the analytic sample due to responses 
“Don’t know” (19) or refusals to answer (3). 
 
BRAND IMAGERY, PLAIN PACKAGING, & HEALTH WARNINGS 
 
 
Table 2 displays respondents’ mean appeal scores and perceived consumer attributes 
for the packs displayed in the first experimental task. Table 3 displays the results for the 2 x 2 
test of brand imagery and health warning labels (HWLs) that examined the influence of product 
branding (present or absent) and HWLs (present or absent) on ratings of appeal of cannabis 
products. Main effects of health warning labels (F(1,493)=6.694, p=0.010) and branding 
(F(1,493)=4.542, p=0.034) were detected on ratings of appeal of cannabis products. Packs that 
did not display a HWL (M=5.03 SD=3.09) received greater appeal scores on average, than 
packs that displayed a HWL (M=4.44, SD=2.95), (MD=0.593, t(502)=2.21, 95%CI 0.07-1.12, 
p=0.028). Differences in means were not detected between branded (M=4.98, SD=3.06) and 
unbranded packs (M=4.48, SD=2.99) (MD=-0.497, t(502)=-1.845, 95%CI -1.21-0.03, 
p=0.066)). No interaction between the presence or absence of HWLs and branding was 
observed (F(1,493)=0.659, p=0.417). 
Table 3 displays the full analyses of appeal, and perceptions of consumer attributes 
including target age and gender for the first experimental task. Respondents were more likely 
to rate the plain/standardized pack without a HWL as significantly more appealing (AOR=2.38, 
95%CI 1.18-4.82, p=0.016) than the plain pack bearing a HWL. Similarly, the branded packs 
with and without HWLs were rated as significantly more appealing than the plain pack 
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displaying a HWL (AOR=2.17, 95%CI 1.08-4.36, p=0.029; AOR=3.40, 95%CI 1.68-6.88, 
p=0.001, respectively). 
A main effect of experimental condition on the perceived age of the target consumer 
was found (X2(3, 523) =16.970, p=0.002). Differences were detected between conditions where 
branding and HWLs were present and absent (X2(1,523)=10.311, p=0.001 and 
X2(1,523)=5.449, p=0.003) and between plain packs with and without HWLs X2(1,259)=8.368, 
p=0.004). The plain pack that did not display a HWL was rated as being intended for a 
relatively younger target consumer less frequently than the other three conditions. When 
branding was present, respondents had twice the odds of perceiving the target consumer to be 
younger than when the product did not have the pink branding (AOR=1.76, 95%CI 1.07-2.91, 
p=0.027). Respondents were more likely (AOR=1.62, 95%CI 1.08-2.43, p=0.020) to report 
that the likely consumer was relatively younger than when HWLs or branding were displayed 
on product packs.  
When the pink, stylized branding was present on a product’s package, respondents were 
significantly more likely to report that the consumer was likely female (AOR=66.99, 95%CI 
29.78-150.66, p<0.001). When HWLs were displayed, respondents were and less likely 
(AOR=0.61, 95%CI 0.42-0.90, p=0.011) to report that the consumer was likely female than 
when there were no HWLs on the package.  
 
LIFESTYLE BRAND IMAGERY 
 
 
Table 4 shows pack ratings for the experimental tasks examining the presence of 
flavour descriptors. A main effect was detected between the presence of a flavour descriptor 
and ratings of appeal (F(1,824)=7.138, p=0.001), ratings were higher when one was present 
(M=6.39 SD=2.71) than when one was not (M=6.00 SD=3.00). As displayed in Table 5, 
respondents were more likely to indicate greater appeal when a flavour was present on the 
product package (AOR=1.60, 95%CI 1.11-2.31 p=0.012) and that the target consumer was 
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likely female than when one was not present (AOR=4.47, 95%CI 3.22-6.21 p<0.001). 
Respondents that had ever used cannabis were more likely to report greater appeal scores when 
a flavour descriptor was displayed on the pack (p<0.001). 
Table 6 shows pack ratings for the four experimental tasks examining energy 
descriptors, celebrity references, music references, and party references. Table 7 shows that, as 
expected, packs that displayed music or party references were more likely to be rated higher 
on appeal (AOR=1.86, 95%CI 1.28-2.69 p=0.001; AOR=2.55, 95%CI 1.77-3.68 p<0.001, 
respectively). This was not the case for packs that displayed celebrity references. The cannabis 
pack that was manipulated to include an energy descriptor produced a contrary finding as it 
received a significantly lower mean appeal rating than when an energy claim was absent 
(AOR=0.56 95%CI 0.39-0.80 p=0.002). Males reported greater ratings of mean appeal than 
females for packs that included music or party references. In fact, the highest mean ratings of 
appeal (5.95) in this set were for the cannabis pack that displayed music references, ‘Reggae 
Chill’ and an image of Bob Marley with traditional Rastafarian colours. Across experimental 
tasks displayed in Table 6, respondents that reported past or current cannabis use were more 
likely to report greater appeal scores than never users (p<0.001). 
When celebrity sponsorships (AOR=3.06, 95%CI 2.16-4.36, p<0.001), music 
references (AOR=3.64, 95%CI 2.37-5.60, p<0.001), or party references (AOR=12.29, 95%CI 
8.08-18.69, p<0.001) were displayed on packs, respondents were more likely to rate them as 
being intended for a relatively younger consumer. The cannabis packs that included energy 
descriptors (AOR=3.17, 95%CI 2.30-4.38, p<0.001), celebrity sponsorships (AOR=3.60, 
95%CI 2.70-4.80, p<0.001), music references(AOR=3.99, 95%CI 2.80-5.70, p<0.001), or 
party references (AOR=30.82, 95%CI 20.42-46.50, p<0.001), were more likely to be rated as 
being targeted at consumers that were perceived to “like to party”. 
Table 8 shows ratings of appeal, perceived target gender of consumer, as well as the 
likelihood that someone who uses the pack that bears the fashion descriptor ‘Vogue’ is 
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perceived as more fashionable. Table 9 shows that past or current cannabis users were more 
likely to report greater appeal scores than those that reported never having used (p<0.001). The 
target consumer of the pack that displayed a fashion descriptor was perceived as someone who 
was more likely to be female (AOR=8.22, 95%CI 5.63-12.01, p<0.001). 
 
 ‘ORGANIC / NATURAL’ BRAND IMAGERY 
 
 
Table 10 displays ratings for a cannabis pack that has a ‘100% natural/organic’ 
descriptor on its pack, and one that does not have such descriptors. As shown in Table 11, past 
and current cannabis users were more likely to report greater appeal score when 
‘natural/organic’ descriptors were present (p<0.001). However, these descriptors did not affect 
ratings of appeal or perceptions of the target consumer’s perceived age. As expected, the 
intended consumer of the pack that displayed a natural/organic descriptor was perceived as 
someone who was more likely to be health conscious (AOR=2.63, 95%CI 1.94-3.56, p<0.001). 
Discussion 
 
The findings demonstrate that brand imagery on cannabis packaging can promote 
lifestyle associations and influence the appeal of cannabis products among young people.  
Consistent with previous research on tobacco products, plain/standardized cannabis packs with 
a health warning were perceived as the least appealing.39,40,41,42 As expected, differences in 
appeal were greater among female participants for those experiments that examined marketing 
strategies more likely to appeal to females: the branding tested in the experimental task featured 
female-oriented brand imagery in the form of pink packages with a floral design. Accordingly, 
females perceived the branded packs as significantly more appealing than the plain packages, 
relative to males. This is consistent with the finding that both males and females 
overwhelmingly perceived the target consumer to be males when the brand imagery was 
displayed; whereas only 3% of participants identified the plain packaging as overtly male. 
These findings are consistent with studies on tobacco products, in which plain packaging 
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reduces the effectiveness of influencing product perceptions of specific subgroups through 
branding. The findings also suggest that health warnings and plain packaging may have 
independent effects and work in a complementary fashion: in other words, plain packaging 
may reduce the appeal of products beyond the effect of health warnings alone as observed 
among tobacco products although further study is required to conclusively determine this for 
cannabis products.43 The presence of health warning labels decreased the likelihood of young 
Canadians finding a cannabis product appealing. Health warnings can reduce the appeal of 
consumer products both by highlighting negative health effects and by displacing promotional 
branding that can enhance appeal. 
The addition of fruit or candy flavours has previously been shown to increase the appeal 
of tobacco and alcohol products among young people, and among females in particular.44,45,46,47   
In the current study, females perceived a peach-flavoured product as significantly more 
appealing than male respondents did. This is notable given the proliferation of cannabis edibles 
with similar fruit and candy flavours in legal markets.  
The findings also demonstrate the variety of lifestyle associations that can be 
communicated through brand imagery on cannabis packaging. Robust associations were 
observed for female-oriented brand imagery, such as packs that displayed names such as 
‘Vogue’. Previous work has demonstrated that products with typically feminine brand imagery 
have greater appeal to female consumers.48,49 Manipulations of lifestyle associations were 
detected with each pack except that which displayed an energy boosting claim; the reverse 
effect was seen: the pack without the ‘energy’ descriptor was rated as more appealing.  
Previous research has shown that exposure to images of celebrities promotes 
associations between the product and the positive traits and lifestyle associated with the 
celebrity, which helps to normalize the product or behaviour.50 The current study did not find 
significant differences in mean appeal ratings for cannabis packs that featured celebrity 
sponsorship, although the products were perceived to be targeting younger consumer who likes 
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to party, particularly among young female participants. In addition, the product displaying an 
image of Bob Marley was perceived as significantly more appealing and intended for younger 
consumers who “like to party”.  
 References such as ‘natural’ and ‘organic’ are among the most common health-
oriented descriptors for consumable tobacco products, and have been shown to increase the 
appeal of food and tobacco products.19,51,52,53  In the current study, products labelled as 
“100% Natural Organic”  were perceived as ‘less harmful’, with no effect on the perceived 
target age of products.  
 
STRENGTHS AND LIMITATIONS 
 
 
 The sample was recruited from a commercial sample that used probability and non-
probability-based recruitment methods; thus, the sample may not be fully representative of 
Canadian youth. Nevertheless, a broad and diverse sample with similar patterns of cannabis 
use and sociodemographic characteristics was recruited.54 The current sample included 16 to 
30 years old individuals; while this age group has the highest rates of cannabis use in Canada, 
it is unclear to what extent the current findings generalize to older adults, particularly given 
that marketing can have a greater impact among young people.4 It should be noted that a 
majority of youth required parental consent to opt into the survey, however, the prevalence of 
use among this age group in the current study (31%) is consistent with existing prevalence 
measures (28%) from the most recent nationally representative 2016/17 Canadian Students 
Tobacco, Alcohol and Drugs Survey.55 It may also be possible that responses to later 
experimental tasks may have been influenced by the previous tasks – for example being shown 
what respondents may have considered appealing in the first task may have influenced their 
ratings of appeal in subsequent tasks. However, participants were randomized to each task 
separately; therefore, any effect of previous experimental tasks could not account for the 
difference observed between experimental conditions for subsequent tasks. A considerable 
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strength of the study was the between-group experimental design for testing packaging and 
brand imagery. The use of actual product images is also a strength, although the effects of 
brand imagery may be underestimated in an online environment compared to the experience of 




 The study provides experimental evidence that branding on cannabis packaging can 
promote lifestyle associations and appeal to youth. The findings are consistent with evidence 
from tobacco and alcohol research on the importance of packaging and brand imagery to 
consumer behaviour and suggests the same principles may apply to cannabis products.56,57,58 
The findings support the efficacy of marketing restrictions included in Canada’s Cannabis Act, 




Table 1 – Sample Characteristics (N=870) 
 
  % (N) 
Sex Female 52.1 (453) 
 Male 47.9 (417) 
   
Age (years) 16–18 25.2 (219) 
 19–24 30.7 (267) 
 25–30 44.1 (384) 
   
Ethnicity White 64.5 (561) 
 Non-white 35.5 (309) 
   
Cannabis use status Never use 41.5 (361) 
 Ever use, not in past 30 days 36.0 (313) 





Table 2 – Perceptions of brand imagery and health warnings among Canadian youth and young adults aged 16-30 years; Experimental 









    





PLAIN PACK,  
NO HWL 
Condition 3: 




BRANDED PACK,  
NO HWL 
nmales= 60 68 58 48 
nfemales= 69 63 76 84 
     
Mean appeal (SD) 4.04 (2.94) 4.93 (2.98) 4.82 (2.92) 5.13 (3.20) 
Mean appeal score among males (SD) 4.85 (3.05) 5.84 (3.07) 5.13 (2.87) 4.30 (2.78) 
Mean appeal score among females (SD) 3.32 (2.66) 4.03 (2.63) 4.59 (2.95) 5.61 (3.35) 
     
Consumer is ‘relatively younger’ %(n) 27.9 (36) 13.0 (17) 33.6 (45) 29.5 (39) 
Among males %(nmales) 31.7 (19) 10.3 (7) 37.9 (22) 27.1 (13) 
Among females %(nfemales) 24.6 (17) 15.9 (10) 30.3 (23) 31.0 (26) 
     
More likely to be female %(n) 2.3 (3) 3.1 (4) 50.7 (68) 72.7 (96) 
Among males %(nmales) 1.7 (1) 2.9 (2) 46.6 (27) 62.5 (30) 




Table 3 – Linear and logistic regressions examining appeal and perceptions of consumer attributes of plain and branded cannabis pack 
variations and health warning labels among Canadian youth and young adults aged 16-30 years (n=504). 
Characteristics Ref. Category 
Appeal 
Perceived consumer attributes 
 “relatively younger”  “more likely to be female” 
Mean 
Scores 
p AOR 95%CI Affirmative 
Response % 
p AOR 95%CI Affirmative 
Response % p AOR 95%CI 
Age 19-24 16-18 4.62 v. 4.49 0.214 0.64 0.32-1.30 14.9% v. 39.3% <0.001 0.26 0.14-0.49 40.3% v.21.4% 0.004 2.81 1.38-5.69 
 25-30 16-18 4.92 v. 4.49 0.295 0.71 0.38-1.35 24.3% v. 39.3% 0.008 0.51 0.32-0.84 34.8% v. 21.4% 0.001 3.14 1.60-6.15 
 19-24 25-30 4.62 v. 4.92 0.734 0.90 0.48-1.67 14.9% v. 24.3% 0.023 0.51 0.29-0.91 40.3% v. 34.8% 0.723 0.89 0.48-1.67 
Sex Male Female 5.08 v. 4.46 0.020 1.82 1.10-3.03 26.1% v. 26.0% 0.838 1.04 0.69-1.58 25.6% v. 38.0% 0.024 0.55 0.33-0.92 
Race White Non-White 4.77 v. 4.65 0.527 0.84 0.50-1.43 28.0% v. 22.2% 0.166 1.37 0.88-2.14 34.7% v. 28.3% 0.052 1.71 0.99-2.93 
Cannabis 
Use 
Past use, not past 30 
days Never Use 5.21 v.3.74 <0.001 4.86 2.68-8.82 23..2% v. 29.5% 0.724 0.91 0.55-1.50 34.3% v. 29.5% 0.961 0.99 0.54-1.81 
 Current use, within past 30 days Never Use 6.00 v. 3.74 <0.001 10.79 5.42-21.46 23.8% v. 29.5% 0.594 0.86 0.48-1.52 36.2% v. 29.5% 0.392 1.36 0.67-2.74 
 Past use, not in past 30 days 
Current use, within 
past 30 days 5.21 v. 6.00 0.020 0.55 0.33-0.91 23.2% v. 23.8% 0.825 1.07 0.59-1.93 34.3% v. 36.2% 0.376 0.73 0.37-1.49 
Experimental 
Condition Plain pack, no HWL Plain pack, HWL 4.93 v. 4.04 0.016 2.38 1.18-4.82 13.0% v. 27.9% 0.004 0.38 0.20-0.73 3.1% v. 2.3% 0.731 1.31 0.28-6.00 
 Branded pack, HWL Plain pack, HWL 4.82 v. 4.04 0.029 2.17 1.08-4.36 33.6% v. 27.9% 0.237 1.39 0.81-2.39 50.7% v. 2.3% <0.001 49.68 14.79-166.84 
 Branded pack, no HWL Plain pack, HWL 5.13 v. 4.04 0.001 3.40 1.68-6.88 29.5% v. 27.9% 0.517 1.20 0.69-2.10 72.7% v. 2.3% <0.001 130.31 38.04-446.44 
 Branded pack, HWL Plain pack, no HWL  4.82 v. 4.93 0.798 0.91 0.45-1.84 33.6% v. 13.0% <0.001 3.64 1.92-6.90 50.7% v. 3.1% <0.001 38.03 13.05-110.82 
 Branded pack, no HWL Plain pack, no HWL  5.13 v. 4.93 0.324 1.43 0.70-2.90 33.6% v. 13.0% 0.001 3.15 1.64-6.05 72.7% v. 3.1% <0.001 99.77 33.45-297.52 
 Branded pack, no HWL Branded pack, HWL 5.13 v. 4.82 0.207 0.64 0.32-1.28 29.5% v. 33.6% 0.601 1.154 0.68-1.97 72.7% v. 50.7% <0.001 0.01 0.00-0.03 
 Packs with HWL Packs without HWL 4.44 v. 5.03 0.010 0.52 0.32-0.86 30.8% v. 21.3% 0.020 1.62 1.08-2.43 27.0% v. 38.0% 0.011 0.61 0.42-0.90 


























 Condition 1:  
FLAVOUR  
DESCRIPTOR 
Condition 2:  
NO FLAVOUR 
DESCRIPTOR 
nmales= 203 214 
nfemales= 218 235 
   
Mean appeal (SD) 6.39 (2.71) 6.00 (3.00) 
Mean appeal - males (SD) 6.07 (2.72) 6.26 (2.94) 
Mean appeal - females (SD) 6.66 (2.67) 5.77 (3.06) 
   
Consumer is ‘relatively younger’ %(n) 26.4 (111) 26.1 (117) 
Among males %(nmales) 26.1 (53) 26.6 (57) 
Among females %(nfemales) 26.6 (58) 25.5 (60) 
   
More likely to be female (%n) 43.5 (183) 15.1 (68) 
Among males %(nmales) 33.0 (67) 13.1 (28) 
Among females %(nfemales) 53.2 (116) 17.0 (40) 
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Table 5 – Linear and logistic regressions examining appeal and perceptions of consumer attributes of packs with flavour descriptors 
among Canadian youth and young adults aged 16-30 years (n=830). 
Characteristics Ref. Category 
Appeal 
Perceived consumer attributes 
“relatively younger” “more likely to be female” 
Mean Scores p AOR 95%CI Affirmative Response % p AOR 95%CI Affirmative Response % p AOR 95%CI 
Age 19-24 16-18 6.44 v. 5.95 0.468 0.83 0.50-1.38 21.0% v. 9.1% 0.001 2.63 1.50-4.61 26.6% v. 30.6% 0.196 0.75 0.48-1.16 
 25-30 16-18 6.15 v. 5.95 0.017 0.56 0.34-0.90 39.8% v. 9.1% <0.001 6.42 3.80-10.83 29.6% v. 30.6% 0.990 1.00 0.66-1.52 
 19-24 25-30 6.44 v. 6.15 0.073 1.49 0.96-2.30 21.0% v. 39.8% <0.001 0.41 0.29-0.59 26.6% v. 29.6% 0.130 0.75 0.51-1.09 
Sex Male Female 6.17 v. 6.21 0.630 0.91 0.63-1.32 26.4%v. 26.1v% 0.952 0.99 0.72-1.37 22.8% v. 34.5% <0.00
1 
0.50 0.36-0.69 
Race White Non-White 6.04 v. 6.47 <0.001 0.49 0.33-0.73 27.7% v. 23.7% 0.241 1.23 0.87-1.73 29.1% v. 28.6% 0.413 0.87 0.62-1.22 
Cannabis Use Past use, not past 30 days Never Use 6.75 v. 5.13 <0.001 6.54 4.20-10.19 31.4% v. 20.6% 0.650 1.09 0.70-1.65 31.1% v. 29.4% 0.832 1.04 0.72-1.52 
 Current use, within past 30 days Never Use 7.20 v. 5.13 <0.001 10.01 6.10-16.41 28.6% v. 20.6%  0.742 1.08 0.74-1.60 24.5% v. 29.4% 0.610 0.89 0.58-1.38 
 Past use, not in past 30 days 
Current use, 
within past 30 
days 
6.75 c. 7.20 0.090 0.65 0.40-1.07 31.4% v. 28.6% 0.938 1.02 0.68-1.53 31.1% v. 24.5% 0.484 1.17 0.76-1.80 
Experimental 













 EXPERIMENTAL TASK 3: 
ENERGY REFERENCE 
EXPERIMENTAL TASK 4: 
CELEBRITY REFERENCE 
EXPERIMENTAL TASK 5: 
MUSIC REFERENCE 































nmales= 220 197 208 209 217 236 192 225 
nfemales= 233 220 230 223 208 209 221 232 
         
Mean appeal (SD) 5.08 (2.75) 5.62 (2.78) 5.99 (3.13) 5.73 (2.81) 5.95 (3.06) 5.36 (2.76) 5.63 (2.85) 4.72 (2.75) 
Mean appeal - males 
(SD) 5.01 (2.84) 5.94 (2.81) 5.92 (3.24) 5.79 (2.82) 6.54 (3.05) 5.10 (2.76) 5.86 (2.96) 4.80 (2.87) 
Mean appeal - females 
(SD) 5.14 (2.67) 5.34 (2.73) 6.06 (3.03) 5.67 (2.81) 5.39 (2.98) 5.59 (2.74) 5.43 (2.74) 4.65 (2.63) 
         
Consumer is ‘relatively 
younger’ %(n) 
9.5 (43) 11.0 (46) 31.3 (137) 14.8 (64) 22.1 (94) 7.6 (34) 45.0 (186) 8.1 (37) 
Among males %(nmales) 10.9 (24) 12.2 (24) 32.7 (68) 12.0 (25) 20.2 (42) 10.5 (22) 39.6 (76) 8.4 (19) 
Among females 
%(nfemales) 
8.2 (19) 10.0 (22) 30.0 (69) 17.5 (39) 24.0 (52) 5.1 (12) 49.8 (110) 7.8 (18) 
         
More likely to ‘go out 
and party’ %(n) 
38.6 (175) 16.8 (70) 56.4 (247) 26.6 (115) 34.4 (146) 11.9 (53) 70.9 (293) 7.4 (34) 
Among males %(nmales) 39.5 (87) 16.8 (33) 52.9 (110) 24.4 (51) 34.1 (71) 11.5 (24) 65.6 (126) 10.7 (24) 
Among females 
%(nfemales) 
37.8 (88) 16.8 (37) 59.6 (137) 28.7 (64) 34.6 (79) 12.3 (29) 75.6 (167) 4.3 (10) 
 
 164 
Table 7 – Linear and logistic regressions examining appeal and perceptions of consumer attributes of packs bearing lifestyle brand 







Characteristics Ref. Category 
Appeal Perceived consumer attributes 
“relatively younger” “more likely to be go out and party” 
Mean Scores p AOR 95%CI Affirmative 
Response % p AOR 95%CI 
Affirmative 






Age 19-24 16-18 5.24 v. 5.44 0.004 0.47 0.28-0.78 8.0% v. 4.1% 0.106 1.97 0.87-4.49 28.7% v. 27.4% 0.289 1.26 0.82-1.93 
 25-30 16-18 5.35 v. 5.44 0.003 0.48 0.29-0.77 15.5% v. 4.1% <0.001 4.12 1.94-8.74 28.6% v. 27.4% 0.229 1.28 0.85-1.93 
 19-24 25-30 5.24 v. 5.35 0.960 0.99 0.64-1.53 8.0% v. 15.5% 0.007 0.48 0.28-0.82 28.7% v. 28.6% 0.919 0.98 0.68-1.41 
Sex Male Female 5.45 v. 5.24 0.440 1.16 0.80-1.67 11.6% v. 9.1% 0.359 1.24 0.79-1.94 28.9% v. 27.8% 0.665 1.07 0.79-1.46 
Race White Non-White 5.18 v. 5.63 0.001 0.51 0.35-0.76 9.5% v. 11.8% 0.324 0.79 0.50-1.26 29.1% v. 26.9% 0.369 1.16 0.84-1.62 
Cannabis Use Past use, not in past 30 days Never Use 5.70 v. 4.65 <0.001 3.86 2.48-6.01 12.3 % v. 8.6% 0.767 1.08 0.63-1.85 27.7% v. 30.1% 0.390 0.85 0.59-1.23 
 Current use, past 30 days Never Use 6.01 v. 4.65 <0.001 5.15 3.15-8.43 10.3% v. 8.6% 0.896 0.96 0.52-1.78 26.0% v. 30.1% 0.139 0.73 0.48-1.11 
 Past use, not in past 30 days Current use, past 30 days 5.70 v. 6.01 0.246 0.75 0.46-1.22 12.3% v. 10.3% 0.682 1.13 0.63-2.02 27.7% v. 26.0%  0.476 1.17 0.77-1.77 






Age 19-24 16-18 5.96 v. 5.78 0.113 0.65 0.38-1.11 20.4% v. 5.9%  <0.001 3.89 2.02-7.49 46.2% v. 42.7% 0.570 1.12 0.76-1.66 
 25-30 16-18 5.84 v. 5.78 0.011 0.52 0.31-0.86 35.1% v. 5.9%  <0.001 9.01 4.82-16.85 38.2% v. 42.7% 0.294 0.82 0.56-1.19 
 19-24 25-30 5.96 v. 5.84 0.332 1.26 0.79-1.99 20.4% v. 
35.1%  
<0.001 0.43 0.29-0.64 46.2% v. 38.2% 0.066 1.37 0.98-1.93 
Sex Male Female 5.85 v. 5.87 0.741 0.94 0.63-1.38 22.4% v. 23.9% 0.361 0.85 0.60-1.20 38.9% v. 44.5% 0.142 0.81 0.60-1.08 
Race White Non-White 5.71 v. 6.13 0.001 0.51 0.34-0.76 23.0% v. 23.5% 0.557 0.90 0.62-1.29 42.4% v. 40.7% 0.964 1.01 0.74-1.37 
Cannabis Use Past use, not in past 30 days Never Use 6.33 v. 4.96 <0.001 5.38 3.37-8.61 28.1% v. 17.2% 0.336 1.22 0.81-1.84 42.8% v. 40.9% 0.318 1.19 0.84-1.69 
 Current use, past 30 days Never Use 6.76 v. 4.96 <0.001 7.74 
4.60-
13.00 
26.5% v. 17.2% 0.263 1.30 0.82-2.05 41.8% v. 40.9% 0.540 1.13 0.77-1.66 
 Past use, not in past 30 days Current use, past 30 days 6.33 v. 6.76 0.169 0.70 0.42-1.17 28.1% v. 26.5% 0.790 0.94 0.61-1.45 42.8% v. 41.8% 0.773 1.06 0.72-1.55 






Age 19-24 16-18 5.68 v. 5.43 0.052 0.60 0.36-1.01 13.6% v. 3.2% <0.001 4.61 1.96-10.81 24.2% v. 28.1% 0.321 0.80 0.51-1.25 
 25-30 16-18 5.75 v. 5.43 0.025 0.57 0.35-0.93 22.4% v. 3.2% <0.001 9.00 3.98-20.39 19.5% v. 28.1% 0.066 0.67 0.43-1.03 
 19-24 25-30 5.68 v. 5.75 0.830 1.05 0.68-1.63 13.6% v. 
22.4% 
0.003 0.51 0.33-0.80 24.2% v. 19.5% 0.380 1.20 0.80-1.79 
Sex Male Female 5.81 v. 5.50 0.257 1.24 0.85-1.80 15.5% v. 14.3% 0.645 1.10 0.74-1.64 23.0% v. 23.2% 0.760 0.95 0.68-1.33 
Race White Non-White 5.48 v. 5.96 <0.001 0.47 0.32-0.70 15.5%v. 13.7% 0.542 1.14 0.74-1.76 21.6% v. 25.8% 0.203 0.80 0.56-1.13 
Cannabis Use Past use, not in past 30 days Never Use 6.12 v.4.52 <0.001 6.67 
4.25-
10.48 
17.7%  v. 
11.8% 0.736 1.09 0.67-1.75 21.0%  v. 28.6% 0.230 0.78 0.53-1.17 
 Current use, past 30 days Never Use 6.87 v. 4.52 <0.001 12.86 
7.83-
21.13 
15.9% v. 11.8% 0.961 0.99 0.58-1.69 16.4% v. 28.6% 0.006 0.52 0.32-0.83 
 Past use, not in past 30 days Current use, past 30 days 6.12 v. 6.87 0.009 0.52 0.32-0.85 17.7% v. 15.9% 0.714 1.10 0.66-1.83 21.0% v. 16.4% 0.093 1.52 0.93-2.47 






Age 19-24 16-18 5.17 v. 4.85 0.536 0.85 0.51-1.42 24.2% v. 5.9% <0.001 5.57 2.85-10.90 37.6% v. 36.2% 0.985 1.01 0.61-1.67 
 25-30 16-18 5.32 v. 4.85 0.662 0.90 0.55-1.46 38.5% v. 5.9% <0.001 14.52 7.50-28.10 39.1% v. 36.2% 0.687 1.11 0.68-1.80 
 19-24 25-30 5.17 v. 5.32 0.812 0.95 0.61-1.47 24.2% v. 
38.5% 
<0.001 0.38 0.25-0.58 37.6% v. 39.1% 0.667 0.91 0.59-1.41 
Sex Male Female 5.29 v. 5.03 0.291 1.22 0.84-1.77 23.0% v. 
28.4% 
0.025 0.65 0.44-0.95 36.3% v. 39.3% 0.580 0.90 0.62-1.31 
Race White Non-White 4.97 v. 5.49 <0.001 0.50 0.34-0.74 26.9% v. 23.9% 0.728 1.07 0.72-1.59 38.4% v. 37.0% 0.710 0.93 0.63-1.37 
Cannabis Use Past use, not in past 30 days Never Use 5.49 v. 4.39 <0.001 3.42 2.18-5.36 29.8% v. 19.0% 0.895 1.03 0.66-1.61 40.6% v. 36.4% 0.268 1.29 0.82-2.01 
 Current use, past 30 days Never Use 5.95 v. 4.39 <0.001 5.37 3.28-8.80 32.1% v. 19.0% 0.090 1.53 0.94-2.52 36.2% v. 36.4% 0.718 1.10 0.67-1.81 
 Past use, not in past 30 days Current use, past 30 days 5.49 v. 5.95 0.071 0.64 0.39-1.04 29.8% v. 32.1% 0.099 0.67 0.42-1.08 40.6% v. 36.2% 0.526 1.17 0.72-1.93 





Table 8 – Perceptions of fashion related references among Canadian youth and young adults aged 16-30 years; Experimental Task 7 
(N=870). 










nmales= 226 191 
nfemales= 228 225 
   
Mean appeal (SD) 5.42 (2.96) 5.48 (2.82) 
Mean appeal - males (SD) 5.21 (2.92) 5.51 (2.94) 
Mean appeal - females (SD) 5.62 (2.99) 5.47 (2.72) 
   
More likely to be female %(n) 45.6 (207) 10.1 (42) 
Among males %(nmales) 43.8 (99) 7.3 (14) 
Among females %(nfemales) 47.4 (108) 12.4 (28) 
   
More likely to be ‘more fashionable’ %(n) 51.3 (233) 48.1 (200) 
Among males %(nmales) 52.2 (118) 46.1 (88) 





Table 9 – Linear and logistic regressions examining appeal and perceptions of consumer attributes of packs bearing fashion references 
among Canadian youth and young adults aged 16-30 years (n=829). 
 
Characteristics Ref. Category 
Appeal 
Perceived consumer attributes 
“more likely female” “likely more fashionable” 
Mean 
Scores p AOR 95%CI 
Affirmative 
Response % p AOR 95%CI 
Affirmative 
Response % p AOR 95%CI 
Age 19-24 16-18 5.62 v. 5.07 0.738 0.91 0.54-1.55 25.9% v. 23.3% 0.237 1.33 0.83-2.12 52.3% v. 48.2% 0.603 1.10 0.76-1.61 
 25-30 16-18 5.55 v. 5.07 0.289 0.76 0.46-1.26 33.9% v. 23.3% 0.006 1.84 1.19-2.86 49.7% v. 48.2% 0.928 0.98 0.69-1.40 
 19-24 25-30 5.62 v. 5.55 0.428 1.20 0.77-1.87 25.9% v. 33.9% 0.096 0.72 0.49-1.06 52.3% v. 49.7% 0.477 1.12 0.82-1.54 
Sex Male Female 5.34 v. 5.55 0.235 0.79 0.54-1.16 27.3% v. 30.2% 0.160 0.79 0.57-1.10 49.9% v. 50.3% 0.865 0.98 0.75-1.28 
Race White Non-White 5.31 v. 5.70 0.002 0.52 0.35-0.78 31.0% v. 24.5% 0.026 1.49 1.05-2.12 49.6% v. 51.0% 0.628 0.93 0.70-1.24 
Cannabis Use Past use, not in past 30 days Never Use 6.04 v. 4.48 <0.001 5.60 3.54-8.88 31.0% v. 25.1% 0.935 0.98 0.66-1.46 51.3% v. 47.2% 0.316 1.18 0.85-1.63 
 Current use, within past 30 days Never Use 6.23 v. 4.48 <0.001 6.50 3.92-10.78 32.1% v. 25.1% 0.109 1.44 0.92-2.24 53.6% v. 47.2% 0.148 1.31 0.91-1.88 
 Past use, not in past 30 days 
Current use, 
within past 30 
days 
6.04 v. 6.23 0.563 0.86 0.52-1.43 31.0% v. 32.1% 0.088 0.69 0.44=1.06 51.3% v. 53.6% 0.587 0.91 0.63-1.30 
Experimental 
Condition Fashion reference 
No fashion 




Table 10 – Perceptions of organic and natural brand references among Canadian youth and young adults aged 16-30 years; 












 8.  ORGANIC / NATURAL DESCRIPTOR 
 
  




NO ORGANIC/ NATURAL 
DESCRIPTOR 
nmales= 226 191 
nfemales= 221 232 
   
Mean appeal (SD) 5.97 (2.79) 6.18 (2.97) 
Mean appeal - males (SD) 6.06 (2.81) 6.22 (2.98) 
Mean appeal - females (SD) 5.88 (2.76) 6.15 (2.96) 
   
Consumer is ‘relatively younger’ %(n) 6.5 (29) 7.6 (32) 
Among males %(nmales) 8.0 (18) 6.3 (12) 
Among females %(nfemales) 5.0 (11) 8.7 (20) 
   
More likely to be health conscious %(n) 42.3 (189) 21.7 (92) 
Among males %(nmales) 38.9 (88) 18.3 (35) 
Among females %(nfemales) 45.7 (101) 24.7 (57) 
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Table 11 – Linear and logistic regressions examining appeal and perceptions of consumer attributes of packs bearing organic/natural 
references among Canadian youth and young adults aged 16-30 years (n=833). 
 
Characteristics Ref. Category 
Appeal 
Perceived consumer attributes 
“relatively younger” “likely more to be health conscious” 
Mean Scores p AOR 95%CI Affirmative 
Response % p AOR 95%CI 
Affirmative 
Response % p AOR 95%CI 
Age 19-24 16-18 6.26 v. 5.70 0.489 0.84 0.51-1.39 5.3% v. 2.3% 0.135 2.24 0.78-6.47 38.9% v. 26.6% 0.054 1.50 0.99-2.27 
 25-30 16-18 6.16 v. 5.70 0.099 0.67 0.41-1.08 11.0% v. 2.3% 0.001 4.92 1.86-13.03 31.5% v. 26.6% 0.785 1.06 0.71-1.59 
 19-24 25-30 6.26 v. 6.16 0.303 1.26 0.81-1.93 5.3% v. 11.0% 0.015 0.46 0.24-0.86 38.9% v. 31.5% 0.045 1.42 1.01-2.00 
Sex Male Female 6.13 v. 6.02 0.733 1.07 0.74-1.54 7.2% v. 6.9% 0.983 1.01 0.59-1.72 29.9% v. 35.1% 0.062 0.75 0.56-1.01 
Race White Non-White 5.87 v. 6.45 <0.001 0.43 0.29-0.63 6.8% v. 7.5% 0.614 0.87 0.50-1.52 32.7% v. 32.1% 0.849 0.97 0.71-1.33 
Cannabis Use Past use, not past 30 days Never Use 6.53 v. 4.94 <0.001 6.37 4.08-9.93 8.6% v. 5.3% 0.531 1.23 0.65-2.34 36.1% v. 26.9% 0.054 1.43 0.99-2.05 
 Current use, within past 30 days Never Use 7.33 v. 4.94 <0.001 13.43 8.25-21.86 7.7% v. 5.3% 0.681 1.17 0.56-2.41 36.2% v. 26.9% 0.089 0.97 0.71-1.33 
 Past use, not in past 30 days 
Current use, within 













 The studies contained in this thesis provide important information and contribute to the 
very limited evidence on Canadian youth and young adults’ perceptions of different aspects 
related to nonmedical cannabis in the year immediately preceding its legalization in Canada.  
Health Knowledge and Perceptions of Risk 
 
 Chapter 2 addressed the first research question by providing an overview of young 
Canadians’ health knowledge and perceptions of risk resulting from cannabis use in terms of 
its health effects and across product types and modes of administration. This is important as 
the literature in the area of young Canadian cannabis literacy is at a very early stage. Digital 
media and traditional media, including television and radio, were important sources of cannabis 
health information for our respondents, consistent with prior work in this area.1,2 Respondents 
reported seeing educational campaigns online, on television or radio, or at school most 
frequently. Additionally, approximately two-thirds of respondents were able to cite at least one 
important health effect associated with cannabis use, and one-fourth reported that they were 
most concerned about decreased brain and respiratory function. The findings indicate that 
young Canadians have a wide range perceptions regarding the potential health effects of 
cannabis which manifest themselves as underestimating or overestimating potential risks that 
may arise from using cannabis for nonmedical purposes.3 Younger Canadians aged 15 to 18 
years and those that reported greater frequency of cannabis use were consistently less likely to 
perceive harm from cannabis use making them important targets for future educational 
campaigns. The findings suggest that exposure to educational campaigns may be beneficial, or 
it may reflect a bias in which those that believe that cannabis is harmful may more readily 
engage with educational campaigns. Increased risk perception of substance use behaviours is 
associated with reductions in use initiation, increased engagement in health protective 
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behaviours and long-term abstinence in the substance use literature.4,5,6,7,8,9 Another important 
outcome of the study was the identification of a false equivalency in perceived risk profiles 
between synthetic cannabis and dried herbal cannabis among youth and young people. This is 
a concern given the serious acute health effects of synthetic cannabis use, particularly given 
their characterization as a ‘legal high’ in many jurisdictions and widespread consumer 
confusion about these products.10,11,12,13,14 
 Since the current work took place, the Government of Canada announced a $9.6M 
investment public education and surveillance activities related to cannabis which will be 
important to examine changes in beliefs of cannabis-related health effects and perhaps due to 
exposure to public health education efforts.15 Recently, Constellation Brands, owners of 
Corona beer, announced an investment of $4B into Canada’s top cannabis producer Canopy 
Growth; Altria, owners of cigarette brands like Marlboro, have made a $1.86B investment into 
the Cronos Group, another Canadian cannabis producer; and Coca-Cola has also been in talks 
with Aurora to invest a still undisclosed amount in the Canadian cannabis industry.16,17 Public 
health communication efforts have the potential to be drowned out by industries that have been 
waiting to enter the market since at least 1970.18,19,20,21  
 
Cannabis health warning labels – perceptions of effectiveness and 
believability 
 
 Chapter 3 addressed the second research question by examining perceptions of 
effectiveness and believability of pictorial and text-only cannabis health warning labels, 
whether certain label themes were more likely to be recalled, evaluated levels of support for 
cannabis health warning labels, support for pictorial warnings, and whether calls to action such 
as quit lines and websites/further information should also be displayed. Pictorial cannabis 
health warning labels were found to be perceived as more effective and believable than text-
only warnings, consistent with literature in tobacco control.22,23,24,25  There were no statistically 
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significant differences in recall detected between pictorial and text-only cannabis health 
warning labels which was unexpected given the graphic nature of the images that were used 
for the warning about pregnancy, for example. According to existing literature in tobacco 
control, warning labels that display and highlight stark and graphic images of physical health 
effects promote cognitive elaboration from its elicited emotional reaction and increase memory 
for the associated information.26,27,28 Nearly all respondents supported cannabis health warning 
labels and a majority supported the use of accompanying pictures and calls to action to be 
displayed on cannabis product packaging. 
 Although exposure to cannabis packaging may be somewhat lower than for tobacco 
products, health warnings provide broad reach among public education initiatives, are self-
sustaining over time, and have minimal costs. Canadian cannabis regulations require text-only 
health warning labels, which may be a conscious effort to communicate higher relative risk for 
cigarettes, for which there are pictorial warnings in Canada. The only exception is the 
requirement for products to display a ‘universal’ symbol, which is intended to alert consumers 
that a package includes cannabis, particularly with respect to children and youth. It remains to 
be seen whether regulatory agencies in other jurisdictions opt for pictorial imagery as part on 
the ‘main’ health warnings on cannabis products.   
 
Cannabis product constituent labelling 
 
 Chapter 4 addressed the third research question by exploring different approaches for 
labelling cannabis product potency and dosing information. The findings indicate that intuitive 
cannabis constituent labelling strategies that make use of simple interpretative or descriptive 
labels, such as “dose” or “low/high”, were better understood by Canadian youth and young 
adults. On the other hand, numbers, percentages, milligrams, and other quantitative information 
that may require math calculations were less successful effective in communicating THC levels 






 Currently, the Cannabis Act requires the communication of THC/CBD content for dried 
cannabis and cannabis oil retail products. As pictured in Health Canada’s example label 
formatting requirements (Figure 21), existing regulations require a number of different units 
of measurement of contents.29  This mode of presenting product constituents is at odds with 
our study’s findings of providing important information related to a product’s potency in an 
intuitive way to maximize understanding of the effects that a cannabis product may produce. 
These principles are particularly relevant for the legal sale of cannabis edibles and concentrates 
in October 2019.30 Health Canada is proposing to label edibles and concentrates using THC 
numbers in a similar way as dried herb, although it has proposed ‘unit dose’ packaging, in 
which each edible can have a maximum of 10mg of THC.31 The current findings suggest that 
these packaging requirements will help inform consumers regarding ‘standard servings’ 
beyond the THC numbers printed on packages and are consistent with research in food 
labelling and tobacco constituent labelling.32,33,34,35,36 




Impact of packaging, branding, and health warning labels on cannabis 
product perceptions 
 
 Chapter 5 addressed the fourth research question which investigated the efficacy of 
health warnings and package branding (e.g., plain/standardized packaging), on perceptions of 
cannabis products among youth and young adults. Plain/standardized cannabis packages 
displaying health warnings were perceived as least appealing compared to branded packs with 
and without health warnings and the branded pack without a health warning, consistent with 
research in tobacco control.37,38,39,40 Our findings demonstrate that brand imagery on cannabis 
packaging can promote lifestyle associations and influence appeal among Canadian youth and 
young adults. 
Health Canada released their final packaging requirements in March 2018.41 The 
requirements included restrictions on colours, graphics, and other special characteristics to 
reduce appeal of the product, particularly among youth.29 Packaging for cannabis products 
should be opaque, enable inner and outer packaging to accommodate new product forms, and 
be child-resistant, tamper evident, prevent contamination, and maintain cannabis dry. The 
maximum amount of cannabis allowed in a single package will be 30 grams of dried herb – or 
the equivalent for other forms of cannabis and consistent with the amount that adults would be 
able to possess in public spaces under the Cannabis Act. An important lesson learned from 
tobacco control was that, short of prohibiting the substance, mandating comprehensive health 
warningswith vivid imagery and standardized packaging are effective measures for 
discouraging product use.42,43,44,45 Moving forward, it will be important to monitor industry 
practices and brand associations among consumers to address gaps in existing regulations. As 
noted previously in this section, multinational tobacco and beverage companies have entered 
the Canadian cannabis market and cross-branding with an existing products, like Coca-Cola, 





  In 2018, Canada became the second country in the world, after Uruguay, to legalize 
the nonmedical use of cannabis.46 This regulatory shift represents a major health policy 
experiment that will set precedents for other countries that liberalize nonmedical cannabis 
policies. The current studies provide the first evidence to inform specific regulatory measures 
that may influence the impact of cannabis legalization on Canadian youth and young adults – 
populations of interest to the Canadian government. While current cannabis control regulations 
have adopted many of the lessons learned from tobacco control, they will require revision over 
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Appendix 1 – Canadian Cannabis Study: Survey Document 





STOP HERE IF YOU ARE USING A SMARTPHONE! The survey will only work on a laptop, desktop 
computer or tablet.  
 
Do NOT click 'next' if you are using a smartphone: you will be locked out of the survey. 
 




How old are you today? _________ [numeric] 
 





Before you start the survey, please read the following information to let us know if you agree to participate. 
The purpose of this study is: 
(1) to examine patterns of marijuana or cannabis (a joint, pot, weed, hash, or hash oil etc.) use, 
(2) gather your thoughts and opinions about different aspects of health warning labels and symbols 
that may be present on marijuana products in the future, 
(3) examine knowledge, perceptions and behaviours related to the use of marijuana among Canadian 
youth and young adults, and 
(4) increase our general understanding of marijuana in Canadian society. 
You will be asked about marijuana or cannabis use behaviours, demographics, and beliefs about marijuana 
use. 
 
When we use the term marijuana or cannabis, this includes the dried herb, hashish, hash oil, wax or any other 
preparations of the plant commonly known as weed, pot, or ganja. 
 




To thank you for your time, you will receive the usual compensation from Léger. 
 
This survey will take about 30 minutes to complete. 
 
You must be between 16 and 30 years of age to participate in this study 
 
Participation is voluntary. You can click, 'refuse to answer' to any question you do not wish to answer and 
will still receive your remuneration. You can withdraw your participation at any time by not submitting your 
response (e.g., by closing your browser); however, you will not receive remuneration. 
 
All of the information you provide will be considered confidential and grouped with responses from other 
participants which means that there will be no way to identify participants individually. 
 
The data will be stored for a minimum of 7 years in a secure University of Waterloo server. Researchers 
will not collect or use internet protocol (IP) addresses or other information which could link your 
participation to your computer or electronic device. When information is transmitted over the internet, 
privacy cannot be guaranteed. There is always a risk your responses may be intercepted by a third party (e.g., 
government agencies, hackers). 
 
This study has been reviewed and received ethics clearance through a University of Waterloo Research 
Ethics Committee (ORE#22392).  
 
If you have questions for the University of Waterloo Research Committee, contact the Chief Ethics Officer, 
Office of Research Ethics at 1-519-888-4567, ext. 36005 or ore-ceo@uwaterloo.ca. 
 
For all other questions about the study, please contact Dr. David Hammond of the University of Waterloo at 






Based on the information you received, do you agree to take part in this research study being conducted by 






SECTION 1: Background Questionnaire 




The first few questions help us learn a little more about you. 
 
To ensure confidentiality, we will group your responses with those of other 



























4= Do not identify as female, male, or transgender 
5= Other _________ 
-77  Don’t know  










Source: Health Canada 
Draft Survey 
Are you an Aboriginal person, that is, First Nations (North American Indian), Metis 
or Inuk (Inuit)?  
Note: First Nations (North American Indian) includes Status and Non Status 
Indians. 
 
1= No, not an Aboriginal person  
2= Yes, First Nations (North American Indian)  
3= Yes, Métis  
4= Yes, Inuk (Inuit) 
 






Source: ITC 2016 
People in Canada come from many racial and cultural groups. Select the group(s) 
that best apply to you. 
 
Select all that apply. 
 
1= White 




6= Latin American 
7= Arab 
8= Southeast Asian (e.g., Vietnamese, Cambodian, Laotian, Thai, etc.) 
9= West Asian (e.g., Iranian, Afghan, etc.) 
10= Korean 
11= Japanese 
12= Other __________ (please specify without providing any identifiable 
information) 
-77  Don’t know  
-88  Refuse to answer 
 

















9=Prince Edward Island 




-77  Don’t know  







Last week, was your main activity working at a paid job or business, looking for 
paid work, going to school, caring for children, household work, retired or 
something else? 
 
1= Working at a paid job or business 
2= Vacation (from paid work) 
3= Looking for paid work 
4= Going to school (including vacation from school) 
5= Caring for children 
6= Household work 
7= Retired 
8= Maternity/paternity leave 
9= Long term illness 
10= Volunteering 
11= Care-giving other than for children 
12= Other 
















-77  Don’t know  









Did your work in the past 12 months pose any risk to you or others, including 
driving or use of heavy equipment? 
 
1= No risk 
2= Minimal risk 
3= Moderate risk 
4= Substantial risk  
-77  Don’t know  
-88  Refuse to answer 
 






Use & Consumption 
 
CANNABIS USE INTRO 
 
PROGRAMMER NOTE: MAKE FONT SIZE 1.5 TIMES THE SIZE OF THE TEXT IN THE SURVEY QUESTIONS. 
 
The following questions ask about cannabis or marijuana. Marijuana can be used with medical 
approval, recreationally, or for other non-medical purposes. 
 
We will use the term marijuana (also known as pot, weed, hash, kush) to refer to all of the 
different forms the plant and its preparations such as dried herb/flower, hash/hash oil, edible, 
concentrate (wax, shatter, etc.), liquid (tea, cola) etc. 
 




CANNABIS USE INTRO 
 
PROGRAMMER NOTE: MAKE FONT SIZE 1.5 TIMES THE SIZE OF THE TEXT IN THE SURVEY QUESTIONS. 
 
We understand this is a sensitive issue and some people aren’t comfortable sharing this information.  
 
Your answers to this survey will be anonymous and will never be stored with any personal 
information.  
 
To protect your privacy, we don’t collect your name, address, or any other contact information. 
 






Source: CSTADS 2016/2017 




-77  Don’t know  








Source: CSTADS 2016/2017.  
 
When was the last time you used marijuana? 
 
1= More than 12 months ago  
2= More than 3 months to 12 months ago 
3= Between 1 to 3 months ago 
4= Within the last month 
-77  Don’t know  
-88  Refuse to answer 
 





Source: CSTADS 2016/2017.  
 
Do you currently use marijuana? 
 
1= Less than once per month  
2= Monthly  
3= Weekly 
4= Daily 
-77  Don’t know  







Source: Health Canada Draft 
Survey. 
How many days a week do you usually use marijuana? 
 
1= Less than 1 day 




6=5 days  
7=6 days 
8=7 days 
-77  Don’t know  









Source: Health Canada Draft Survey 
In the past 12 months, did you use marijuana in any of the following ways? 
  No, I have 
never 
done this 
Yes, but not 
in past 12 
months 
Yes, in past 
12 months 
1= Smoked Dried herb/flower/leaf ○ ○ ○ 
2= Vaporized Dried flower/flower/leaf ○ ○ ○ 
3= Vaporized liquid form in an e-cigarette ○ ○ ○ 
4= Mixed with or rolled in tobacco (e.g., blunt) ○ ○ ○ 
5= Hashish ○ ○ ○ 
6= Hash oil ○ ○ ○ 
7= Concentrate (e.g., butane honey oil, shatter, budder, wax etc.) ○ ○ ○ 
8= Edibles (e.g. cookies) ○ ○ ○ 
9= Liquid (e.g., cola/tea) ○ ○ ○ 
10= Tinctures (e.g., concentrated amounts ingested orally or taken 
under the tongue) ○ ○ ○ 
11= Topical Ointments (e.g., lotions, salves, balms applied directly 
to the skin) ○ ○ ○ 
12= Fresh flower/leaf (e.g., for juicing) ○ ○ ○ 
13= Other  _________ (please specify without providing any 
identifiable information) ○ ○ ○ 
UNIVERSE: USE.RECENT=2,3,4 





In the past 12 months, how often did you use marijuana in the following ways? 
 
PROGRAMMER NOTE: INSERT LIST OF OPTIONS SELECTED IN THE PAST 12 MONTHS FROM USE.MODES VARIABLE; SHOW IN 
TABLE FORMAT WITH OPTIONS LISTED BELOW. 
 




-77  Don’t know  
-88  Refuse to answer 
 






PROGRAMMER NOTE: DERIVE TIME FRAME (I.E., DAY/WEEK/MONTH/PAST-12MONTHS) BASED ON RESPONSE TO 
MODE.FREQUENCY 
 
[In a usual day/In a usual week/ In a usual month/In the past 12-months], up to HOW MUCH 




1= Less than 1/8 (one eighth) gram 
2= 1/8 (one eighth) Gram  
3= ¼ (one quarter) Gram 
4= ½ (half) Gram  
5= ¾ (three quarters) Gram  
6= 1 gram 
7= 2 grams 
8= 3 grams 
9= 1/8 (one eighth) Ounce  
10= ¼ (one quarter) Ounce  
11= More than ¼ (one quarter) Ounce 
-77  Don’t know  
-88  Refuse to answer 
 





PROGRAMMER NOTE:  SHOW IMAGE: [H.DriedFlowerQtys.jpeg] ON THE RIGHT HAND SIDE OF THE SCREEN WITH ANSWER 
OPTIONS ON THE LEFT. 
 
[In a usual day/In a usual week/ In a usual month/In the past 12-months], up to HOW MUCH 
dried herb/flower/leaf did you use? (Include smoking and vaping dried herb)] 
 
Did you use...  
 
1= Half of one ounce  
2= One ounce 
3= More than one ounce 
-77  Don’t know  
-88  Refuse to answer 
 
IF [SMOKETOB.AMOUNT2=3] ASK AND ALLOW TWO DECIMAL SPACES [000.00]: 
 
[In a usual day/In a usual week/ In a usual month/In the past 12-
months], up to HOW MUCH dried herb/flower/leaf did you 
use? (Include smoking and vaping dried herb)] 
 
Please indicate the usual amount using ONE of the following: 
 
[Numeric field] Number of OUNCES OR 
 
[Numeric field] Number of POUNDS OR 
 
[Numeric field] Number of KILOGRAMS  
 
-77  Don’t know  
-88  Refuse to answer 
 
 





Source: Health Canada Draft 
Survey. 





Never Less than 1 in 10 times 
Less than 
one quarter 
of the time 
About half 





of  the time 
All the 
time 
        
Vape without 
tobacco ○ ○ ○ ○ ○ ○ ○ 
Vape with 
tobacco ○ ○ ○ ○ ○ ○ ○ 
        
Smoke without 
tobacco ○ ○ ○ ○ ○ ○ ○ 
Smoke with 




○ ○ ○ ○ ○ ○ ○ 
 
UNIVERSE: USE.MODES=1,2,4=PAST 12-MONTH USE 
 





Source: Modified Health Canada 
Survey Draft 
In the past 12 months, how did you get the DRIED HERB/FLOWER/LEAF YOU USED?  
 
Select all that apply. 
 
1=I grew my own  
2=It was grown for me  
3=It was shared around a group of friends  
4=From a family member or friend  
5=From someone else I know  
6=From a dealer (in person)  
7=From a dealer (mail delivery)  
8=medical marijuana through the mail from a licensed producer  
9=medical marijuana from a store (e.g., a dispensary or compassion club) 
10=non-medical marijuana from a store 
11=Ordered it online (from someone other than a licensed producer)  
12=Other_____ (please specify without providing any identifiable information)  
-77  Don’t know  
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-88  Refuse to answer 
 





Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF HERB.SOURCE>1 OPTION SELECTED ASK: 
 
What per cent (%) of DRIED HERB/FLOWER/LEAF did you get from each source: 
 
[INSERT Sources selected from HERB.SOURCE1 with open fields for entry of % numbers that 
sum to 100%] 
-77  Don’t know  





Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF HERB.SOURCE=6-12 go to HERB.TIMEFRAME 
 
PROGRAMMER NOTE: IF HERB.SOURCE=1 ASK: 
 
Did you buy or pay for the SEEDS for plant you grew? 
1= Yes 
2= No 
-77  Don’t know  




We would like to know how many SEEDS you bought or paid for.  
 
Which time-frame is easiest for you to report the amount of SEEDS you purchased; in a usual day, 





4=12-months (entire year) 
5=I did not buy any of the marijuana I used over the past year 
-77  Don’t know  














ENTER NUMBER OF SEEDS: _____ 
 
-77  Don’t know  
-88  Refuse to answer 
 






In total, how much money did you spend on all of the SEEDS you bought [In a typical 
[day/week/month/ or In the past 12-months]…. 
 
ENTER DOLLAR AMOUNT: ____ 
 
-77  Don’t know  
-88  Refuse to answer 
 





Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF HERB.SOURCE=2-5 ASK: 
 
Did you buy or pay for the DRIED HERB/FLOWER/LEAF you used? 
1= Yes 
2= No 
-77  Don’t know  
-88  Refuse to answer 
 






We would like to know how much DRIED FLOWER/HERB/LEAF you bought or paid for.  
 
Which time-frame is easiest for you to report the amount of DRIED FLOWER/HERB/LEAF you 





4=12-months (entire year) 
5=I did not buy any of the marijuana I used over the past year 
-77  Don’t know  








In total, how much DRIED FLOWER/HERB/LEAF did you BUY [In a typical 
[day/week/month/ or In the past 12-months]…. 
 
 
1= Less than 1/8 (one eighth) gram 
2= 1/8 (one eighth) Gram  
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3= ¼ (one quarter) Gram 
4= ½ (half) Gram  
5= ¾ (three quarters) Gram  
6= 1 gram 
7= 2 grams 
8= 3 grams 
9= 1/8 (one eighth) Ounce  
10= ¼ (one quarter) Ounce  
11= More than ¼ (one quarter) Ounce 
-77  Don’t know  
-88  Refuse to answer 
 






PROGRAMMER NOTE:  SHOW IMAGE: [H.DriedFlowerQtys.jpeg] ON THE RIGHT HAND SIDE OF THE SCREEN WITH ANSWER 
OPTIONS ON THE LEFT. 
 
In total, how much DRIED FLOWER/HERB/LEAF did you BUY [In a typical 
[day/week/month/ or In the past 12-months]…. 
 
Did you buy...  
 
1= Half of one ounce 
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2= One ounce 
3= More than one ounce  
-77  Don’t know  
-88  Refuse to answer 
 
IF [PURCH.HERB2=3] ASK AND ALLOW TWO DECIMAL SPACES [000.00]: 
 
In total, how much DRIED FLOWER/HERB/LEAF did you 
BUY [In a typical [day/week/month/ or In the past 12-
months]…. 
 
Please indicate the usual amount using ONE of the following: 
 
[Numeric field] Number of OUNCES OR 
 
[Numeric field] Number of POUNDS OR 
 
[Numeric field] Number of KILOGRAMS  
 
-77  Don’t know  
-88  Refuse to answer 
 






In total, how much money did you spend on all of the DRIED FLOWER/HERB/LEAF you 
bought [In a typical [day/week/month/ or In the past 12-months]…. 
 
ENTER DOLLAR AMOUNT:  
 
-77  Don’t know  
-88  Refuse to answer 
 









1= Less than 1/8 (one eighth) gram 
2= 1/8 (one eighth) Gram  
3= ¼ (one quarter) Gram 
4= ½ (half) Gram  
5= ¾ (three quarters) Gram  
6= 1 gram 
7= 2 grams 
8= 3 grams 
9= 1/8 (one eighth) Ounce  
10= ¼ (one quarter) Ounce  
11= More than ¼ (one quarter) Ounce 
-77  Don’t know  





THE LAST TIME you purchased DRIED FLOWER/HERB/LEAF, how much did you buy… 
 




1= Half of one ounce 
2= One ounce 
3= More than one ounce 
-77  Don’t know  
-88  Refuse to answer 
 
IF [LASTPURCH1A=3] ASK AND ALLOW TWO DECIMAL SPACES [000.00]: 
 
Thinking of the LAST TIME you purchased DRIED 
FLOWER/HERB/LEAF, please indicate the amount using one 
of the following:  
[Numeric field] Number of OUNCES OR 
 
[Numeric field] Number of POUNDS OR 
 
[Numeric field] Number of KILOGRAMS  
 
-77  Don’t know  





THE LAST TIME you purchased DRIED FLOWER/HERB/LEAD, how much did you pay for 
the amount you bought? 
 
ENTER DOLLAR AMOUNT: ______ 
-77  Don’t know  






Source: Modified Health Canada 
Survey Draft 




3= Both medical and non-medical 
-77  Don’t know  
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Source: Modified Health Canada 
Survey Draft 











Source: Modified Health Canada 
Survey Draft 
What is the usual THC level in the DRIED HERB/FLOWER/LEAF you used?  
 
Enter number: ______ dropdown menu: mg THC, %THC  
-88  Refuse to answer 
 





Source: Modified Health Canada 
Survey Draft 











Source: Modified Health Canada 
Survey Draft 
What is the usual level of CBD in the DRIED HERB/FLOWER/LEAF you used?  
 
1=  Insert CBD mg [   ] OR        Insert CBD level % [   ]  
-88  Refuse to answer 
 




PROGRAMMER NOTE: SHOW IF MODE.FREQUENCY INCLUDES USE.MODES=3=PAST 12-MONTHUSE 





[In a usual day/In a usual week/ In a usual month/In the past 12-months], HOW MUCH marijuana 
liquid did you VAPE?  
 
 
Enter number: _______  Dropdown menu: mL/Vape hits/fl oz 
-77  Don’t know  






Source: Modified Health Canada 
Survey Draft 
In the past 12 months, how did you get the MARIJUANA LIQUID you vaped? Select all that 
apply. 
 
1=I made my own  
2=It was made for me  
3=It was shared around a group of friends  
4=From a family member or friend  
5=From someone else I know  
6=From a dealer (in person)  
7=From a dealer (mail delivery)  
8=medical marijuana through the mail from a licensed producer  
9=medical marijuana from a store (e.g., a dispensary or compassion club) 
10=non-medical marijuana from a store 
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11=Ordered it online (from someone other than a licensed producer)  
12=Other_____ (please specify without providing any identifiable information)  
-77  Don’t know  
-88  Refuse to answer 
 





Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF LIQUID.SOURCE>1 OPTION SELECTED ASK: 
 
What per cent (%) of MARIJUANA LIQUID FOR VAPING did you get from each source: 
 
[INSERT Sources selected from LIQUID.SOURCE1 with open fields for entry of % numbers that 
sum to 100%] 
-77  Don’t know  






Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF LIQUID.SOURCE=6-12 go to LIQUID.TIMEFRAME 
 
PROGRAMMER NOTE: IF LIQUID.SOURCE=1 ASK: 
 
Did you buy or pay for the materials to make the MARIJUANA LIQUID you vaped? 
1= Yes 
2= No 
-77  Don’t know  
-88  Refuse to answer 
 
PROGRAMMER NOTE: IF LIQUID.SOURCE=2-5 ASK: 
 
Did you buy or pay for the MARIJUANA LIQUID you vaped? 
1= Yes 
2= No 
-77  Don’t know  
-88  Refuse to answer 
 








Which time-frame is easiest for you to report the amount of MARIJUANA LIQUID FOR 





4=12-months (entire year) 
5=I did not buy any of the marijuana I used over the past year 
-77  Don’t know  
-88  Refuse to answer 
 






In total, how much MARIJUANA LIQUID FOR VAPING did you BUY [In a typical 




Enter number: _______ mL 
 
-77  Don’t know  











In total, how much money did you spend on all of the MARIJUANA LIQUID FOR VAPING you 
bought [In a typical [day/week/month/ or In the past 12-months]…. 
 
ENTER DOLLAR AMOUNT:  
-77  Don’t know  
-88  Refuse to answer 
 
 





Source: Modified Health Canada 
Survey Draft 




3= Both medical and non-medical 
-77  Don’t know  







Source: Modified Health Canada 
Survey Draft 











Source: Modified Health Canada 
Survey Draft 
What is the usual THC level in the MARIJUANA LIQUID you vaped?  
 
Enter number: ____ Dropdown menu: mg THC, %THC  
-88  Refuse to answer 
 




















Source: Modified Health Canada 
Survey Draft 
What is the usual level of CBD in the MARIJUANA LIQUID you vaped?  
 
Enter number: ____ Dropdown menu: mg CBD, % CBD  
-88  Refuse to answer 
 




PROGRAMMER NOTE: SHOW IF MODE.FREQUENCY INCLUDES USE.MODES=5=PAST 12-MONTH USE 
PROGRAMMER NOTE: ONLY IF MODE.FREQUENCY=1-4 FOR USE.MODE=5. DERIVE TIME FRAME BASED ON RESPONSE TO 
MODE.FREQUENCY 
 
[In a usual day/In a usual week/ In a usual month/In the past 12-months], HOW MUCH hash or 
hashish did you USE?  
 
 
Enter number: _______  Dropdown menu: Gram(s)/Hits/Tokes 
 
-77  Don’t know  









Source: Modified Health Canada 
Survey Draft 
1=I made my own  
2=It was made for me  
3=It was shared around a group of friends  
4=From a family member or friend  
5=From someone else I know  
6=From a dealer (in person)  
7=From a dealer (mail delivery)  
8=medical marijuana through the mail from a licensed producer  
9=medical marijuana from a store (e.g., a dispensary or compassion club) 
10=non-medical marijuana from a store 
11=Ordered it online (from someone other than a licensed producer)  
12=Other_____ (please specify without providing any identifiable information)  
-77  Don’t know  







Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF HASH.SOURCE>1 OPTION SELECTED ASK: 
 
What per cent (%) of HASH OR HASHISH did you get from each source: 
 
[INSERT Sources selected from HASH.SOURCE1 with open fields for entry of % numbers that 
sum to 100%] 
 
-77  Don’t know  





Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF HASH.SOURCE=6-12 go to HASH.TIMEFRAME 
 
PROGRAMMER NOTE: IF HASH.SOURCE=1 ASK: 
 
Did you buy or pay for the materials to make the HASH OR HASHISH you used? 
1= Yes 
2= No 
-77  Don’t know  
-88  Refuse to answer 
 




Did you buy or pay for the HASH OR HASHISH you used? 
1= Yes 
2= No 
-77  Don’t know  
-88  Refuse to answer 
 




We would like to know how much hash or hashish you bought or paid for.  
 
Which time-frame is easiest for you to report the amount of HASH OR HASHISH you purchased; 





4= 12-months (entire year) 
5= I did not buy any of the marijuana I used over the past year 
-77  Don’t know  








In total, how much HASHISH OR HASHISH did you BUY [In a typical [day/week/month/ or 






Enter number: _______ Gram(s) 
-77  Don’t know  
-88  Refuse to answer 
 
 






In total, how much money did you spend on all of the HASH OR HASHISH you bought [In a 
typical [day/week/month/ or In the past 12-months]…. 
 
ENTER DOLLAR AMOUNT:  
-77  Don’t know  
-88  Refuse to answer 
 
 





Source: Modified Health Canada 
Survey Draft 




3= Both medical and non-medical 
-77  Don’t know  









Source: Modified Health Canada 
Survey Draft 











Source: Modified Health Canada 
Survey Draft 
What is the usual THC level in the HASH OR HASHISH you used?  
 
Enter number: ____ Dropdown menu: mg THC, %THC  
-88  Refuse to answer 
 





Source: Modified Health Canada 
Survey Draft 











Source: Modified Health Canada 
Survey Draft 
What is the usual level of CBD in the dried HASH OR HASHISH you used?  
 
Enter number: ____ Dropdown menu: mg CBD, %CBD  
-88  Refuse to answer 
 




PROGRAMMER NOTE: SHOW IF MODE.FREQUENCY INCLUDES USE.MODES=6=PAST 12-MONTH USE 
PROGRAMMER NOTE: ONLY IF MODE.FREQUENCY=1-4 FOR USE.MODE=6. DERIVE TIME FRAME BASED ON RESPONSE TO 
MODE.FREQUENCY 
 
[In a usual day/In a usual week/ In a usual month/In the past 12-months], HOW MUCH hash oil 










Source: Modified Health Canada 
Survey Draft 
In the past 12 months, how did you get the hash oil  YOU USED? Select all that apply. 
 
1=I made my own  
2=It was made for me  
3=It was shared around a group of friends  
4=From a family member or friend  
5=From someone else I know  
6=From a dealer (in person)  
7=From a dealer (mail delivery)  
8=medical marijuana through the mail from a licensed producer  
9=medical marijuana from a store (e.g., a dispensary or compassion club) 
10=non-medical marijuana from a store 
11=Ordered it online (from someone other than a licensed producer)  
12=Other_____ (please specify without providing any identifiable information) -77  Don’t know  







Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF HASHOIL.SOURCE>1 OPTION SELECTED ASK: 
 
What per cent (%) of HASH OIL did you get from each source: 
 
[INSERT Sources selected from HASHOIL.SOURCE1 with open fields for entry of % numbers 
that sum to 100%] 
 
-77  Don’t know  







Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF HASHOIL.SOURCE=6-12 go to HASH.TIMEFRAME 
 
PROGRAMMER NOTE: IF HASHOIL.SOURCE=1 ASK: 
 
Did you buy or pay for the materials to make the HASH OIL you used? 
1= Yes 
2= No 
-77  Don’t know  
-88  Refuse to answer 
 
PROGRAMMER NOTE: IF HASHOIL.SOURCE=2-5 ASK: 
 
Did you buy or pay for the HASH OIL you used? 
1= Yes 
2= No 
-77  Don’t know  
-88  Refuse to answer 
 




We would like to know how much hash oil you bought or paid for.  
 
Which time-frame is easiest for you to report the amount of HASH OIL you purchased; in a usual 





4=12-months (entire year) 
5=I did not buy any of the marijuana I used over the past year 
-77  Don’t know  











Source: New  
 
Enter number: _______ Gram(s) 
-77  Don’t know  
-88  Refuse to answer 
 
 







In total, how much money did you spend on all of the HASH OIL you bought [In a typical 
[day/week/month/ or In the past 12-months]…. 
 
ENTER DOLLAR AMOUNT:  
-77  Don’t know  
-88  Refuse to answer 
 





Source: Modified Health Canada 
Survey Draft 




3= Both medical and non-medical 
-77  Don’t know  






















Source: Modified Health Canada 
Survey Draft 
What is the usual THC level in the HASH OIL you used?  
 
Enter number: ____ Dropdown menu: mg THC, %THC  
-88  Refuse to answer 
 





Source: Modified Health Canada 
Survey Draft 











Source: Modified Health Canada 
Survey Draft 
What is the usual level of CBD in the dried HASH OIL you used?  
 
Enter number: ____ Dropdown menu: mg CBD, %CBD  
-88  Refuse to answer 
 




PROGRAMMER NOTE: SHOW IF MODE.FREQUENCY INCLUDES USE.MODES=7=PAST 12-MONTH USE 
PROGRAMMER NOTE: ONLY IF MODE.FREQUENCY=1-4 FOR USE.MODE=7. DERIVE TIME FRAME BASED ON RESPONSE TO 
MODE.FREQUENCY 
 
[In a usual day/In a usual week/ In a usual month/In the past 12-months], HOW MUCH 





Enter number: _______ Dropdown menu: Gram(s)/HITS/TOKES/DABS 
-77  Don’t know  





Source: Modified Health Canada 
Survey Draft 
In the past 12 months, how did you get the concentrate (e.g., Butane honey oil/shatter/budder/etc.)  
YOU USED? Select all that apply. 
 
1=I made my own  
2=It was made for me  
3=It was shared around a group of friends  
4=From a family member or friend  
5=From someone else I know  
6=From a dealer (in person)  
7=From a dealer (mail delivery)  
8=medical marijuana through the mail from a licensed producer  
9=medical marijuana from a store (e.g., a dispensary or compassion club) 
10=non-medical marijuana from a store 
11=Ordered it online (from someone other than a licensed producer)  
12=Other_____ (please specify without providing any identifiable information)  
-77  Don’t know  







Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF CONCEN.SOURCE>1 OPTION SELECTED ASK: 
 
What per cent (%) of CONCENTRATE (E.G., BUTANE HONEY 




[INSERT Sources selected from CONCEN.SOURCE1 with open fields for entry of % numbers that 
sum to 100%] 
-77  Don’t know  






Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF CONCEN.SOURCE=6-12 go to CONCEN.TIMEFRAME 
 
PROGRAMMER NOTE: IF CONCEN.SOURCE=1 ASK: 
 
Did you buy or pay for the materials to make the CONCENTRATE (E.G., BUTANE HONEY 
OIL/SHATTER/BUDDER/ETC.) you used? 
1= Yes 
2= No 
-77  Don’t know  
-88  Refuse to answer 
 
PROGRAMMER NOTE: IF CONCEN.SOURCE=2-5 ASK: 
 
Did you buy or pay for the CONCENTRATE (E.G., BUTANE HONEY 
OIL/SHATTER/BUDDER/ETC.) you used? 
1= Yes 
2= No 
-77  Don’t know  
-88  Refuse to answer 
 




We would like to know how much concentrate (e.g., butane honey oil/shatter/budder/etc.) you 
bought or paid for.  
 
Which time-frame is easiest for you to report the amount of CONCENTRATE (E.G., BUTANE 
HONEY OIL/SHATTER/BUDDER/ETC.) you purchased; in a usual day, a usual week, a usual 







4=12-months (entire year) 
5=I did not buy any of the marijuana I used over the past year 
-77  Don’t know  
-88  Refuse to answer 
 






In total, how much CONCENTRATE (E.G., BUTANE HONEY 




Enter number: _______ Gram(s) 
-77  Don’t know  
-88  Refuse to answer 
 
 






In total, how much money did you spend on all of the CONCENTRATE (E.G., BUTANE 
HONEY OIL/SHATTER/BUDDER/ETC.) you bought [In a typical [day/week/month/ or In 
the past 12-months]…. 
 
ENTER DOLLAR AMOUNT:  
-77  Don’t know  
-88  Refuse to answer 
 







Source: Modified Health Canada 
Survey Draft 
Do you use the CONCENTRATE (E.G., BUTANE HONEY OIL/SHATTER/BUDDER/ETC.) 




3= Both medical and non-medical 
-77  Don’t know  







Source: Modified Health Canada 
Survey Draft 
Do you know the THC level in the CONCENTRATE (E.G., BUTANE HONEY 











Source: Modified Health Canada 
Survey Draft 
What is the usual THC level in the CONCENTRATE (E.G., BUTANE HONEY 
OIL/SHATTER/BUDDER/ETC.) you used?  
 
Enter number: ____ Dropdown menu: mg THC, %THC  
-88  Refuse to answer 
 





Source: Modified Health Canada 
Survey Draft 
Do you know the CBD level in the CONCENTRATE (E.G., BUTANE HONEY 













Source: Modified Health Canada 
Survey Draft 
What is the usual level of CBD in the dried CONCENTRATE (E.G., BUTANE HONEY 
OIL/SHATTER/BUDDER/ETC.) you used?  
 
Enter number: ____ Dropdown menu: mg CBD, %CBD  
-88  Refuse to answer 
 




PROGRAMMER NOTE: SHOW IF MODE.FREQUENCY INCLUDES USE.MODES=10=PAST 12-MONTH USE 
PROGRAMMER NOTE: ONLY IF MODE.FREQUENCY=1-4 FOR USE.MODE=10. DERIVE TIME FRAME BASED ON RESPONSE TO 
MODE.FREQUENCY 
 
[In a usual day/In a usual week/ In a usual month/In the past 12-months], HOW MUCH liquid 
concentrate in the form of Tinctures (e.g., concentrated amounts ingested orally or taken under the 
tongue), did you USE?  
 
 
Enter number: _______ Dropdown menu: mL/fl oz/Drops/Capsules/Ounces/Grams 
-77  Don’t know  





Source: Modified Health Canada 
Survey Draft 
In the past 12 months, how did you get the liquid concentrate in the form of Tinctures (e.g., 
concentrated amounts ingested orally or taken under the tongue) YOU USED? Select all that apply. 
 
1=I made my own  
2=It was made for me  
 
 264 
3=It was shared around a group of friends  
4=From a family member or friend  
5=From someone else I know  
6=From a dealer (in person)  
7=From a dealer (mail delivery)  
8=medical marijuana through the mail from a licensed producer  
9=medical marijuana from a store (e.g., a dispensary or compassion club) 
10=non-medical marijuana from a store 
11=Ordered it online (from someone other than a licensed producer)  
12=Other_____ (please specify without providing any identifiable information)  
-77  Don’t know  







Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF TINCT.SOURCE>1 OPTION SELECTED ASK: 
 
What per cent (%) of liquid concentrate in the form of TINCTURES (e.g., concentrated 
amounts ingested orally or taken under the tongue) did you get from each source: 
 
[INSERT Sources selected from TINCT.SOURCE1 with open fields for entry of % numbers that 
sum to 100%] 
-77  Don’t know  





Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF TINCT.SOURCE=6-12 go to TINCT.TIMEFRAME 
 
PROGRAMMER NOTE: IF TINCT.SOURCE=1 ASK: 
 
Did you buy or pay for the materials to make the liquid concentrate in the form of TINCTURES 
(e.g., concentrated amounts ingested orally or taken under the tongue) you used? 
1= Yes 
2= No 
-77  Don’t know  
-88  Refuse to answer 
 




Did you buy or pay for the liquid concentrate in the form of TINCTURES (e.g., concentrated 
amounts ingested orally or taken under the tongue) you used? 
1= Yes 
2= No 
-77  Don’t know  
-88  Refuse to answer 
 




We would like to know how much liquid concentrate in the form of TINCTURES (e.g., 
concentrated amounts ingested orally or taken under the tongue) you bought or paid for.  
 
Which time-frame is easiest for you to report the amount of liquid concentrate in the form of 
TINCTURES (e.g., concentrated amounts ingested orally or taken under the tongue) you 





4=12-months (entire year) 
5=I did not buy any of the marijuana I used over the past year 
-77  Don’t know  
-88  Refuse to answer 
 






In total, how much liquid concentrate in the form of TINCTURES (e.g., concentrated amounts 
ingested orally or taken under the tongue) did you BUY [In a typical [day/week/month/ or In 





Enter number: _______ mL/fl oz/Drops/Capsules/Ounces/Grams  
-77  Don’t know  
-88  Refuse to answer 
 






In total, how much money did you spend on all of the liquid concentrate in the form of 
TINCTURES (e.g., concentrated amounts ingested orally or taken under the tongue) you 
bought [In a typical [day/week/month/ or In the past 12-months]…. 
 
ENTER DOLLAR AMOUNT:  
-77  Don’t know  
-88  Refuse to answer 
 





Source: Modified Health Canada 
Survey Draft 
Do you use the liquid concentrate in the form of TINCTURES (e.g., concentrated amounts 




3= Both medical and non-medical 
-77  Don’t know  









Source: Modified Health Canada 
Survey Draft 
Do you know the THC level in the liquid concentrate in the form of TINCTURES (e.g., 











Source: Modified Health Canada 
Survey Draft 
What is the usual THC level in the liquid concentrate in the form of TINCTURES (e.g., 
concentrated amounts ingested orally or taken under the tongue) you used?  
 
Enter number: ____ Dropdown menu: mg THC, %THC  
-88  Refuse to answer 
 





Source: Modified Health Canada 
Survey Draft 
Do you know the CBD level in the liquid concentrate in the form of TINCTURES (e.g., 











Source: Modified Health Canada 
Survey Draft 
What is the usual level of CBD in the dried liquid concentrate in the form of TINCTURES (e.g., 
concentrated amounts ingested orally or taken under the tongue) you used?  
 
Enter number: ____ Dropdown menu: mg CBD, %CBD  
-88  Refuse to answer 
 




PROGRAMMER NOTE: SHOW IF MODE.FREQUENCY INCLUDES USE.MODES=8 





[In a usual day/In a usual week/ In a usual month/In the past 12-months], HOW MANY edible 
marijuana products did you eat?  
 
ENTER NUMBER OF EDIBLE PRODUCTS: 
-77  Don’t know  





Source: Modified Health Canada 
Survey Draft 
In the past 12 months, how did you get the edible marijuana products YOU ATE? Select all that 
apply. 
 
1=I made my own  
2=It was made for me  
3=It was shared around a group of friends  
4=From a family member or friend  
5=From someone else I know  
6=From a dealer (in person)  
7=From a dealer (mail delivery)  
8=medical marijuana through the mail from a licensed producer  
9=medical marijuana from a store (e.g., a dispensary or compassion club) 
10=non-medical marijuana from a store 
11=Ordered it online (from someone other than a licensed producer)  
12=Other_____ (please specify without providing any identifiable information)  
-77  Don’t know  







Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF EDIBLE.SOURCE>1 OPTION SELECTED ASK: 
 
What per cent (%) of EDIBLE MARIJUANA PRODUCTS did you get from each source: 
 
[INSERT Sources selected from EDIBLE.SOURCE1 with open fields for entry of % numbers that 
sum to 100%] 
-77  Don’t know  








Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF EDIBLE.SOURCE=6-12 go to EDIBLE.TIMEFRAME 
 
PROGRAMMER NOTE: IF EDIBLE.SOURCE=1 ASK: 
 
Did you buy or pay for the materials to make the EDIBLE MARIJUANA PRODUCTS you ate? 
1= Yes 
2= No 
-77  Don’t know  
-88  Refuse to answer 
 
PROGRAMMER NOTE: IF EDIBLE.SOURCE=2-5 ASK: 
 
Did you buy or pay for the EDIBLE MARIJUANA PRODUCTS you ate? 
1= Yes 
2= No 
-77  Don’t know  
-88  Refuse to answer 
 




We would like to know how many edible marijuana products you bought or paid for.  
 
Which time-frame is easiest for you to report the amount of EDIBLE MARIJUANA PRODUCTS 





4=12-months (entire year) 
5=I did not buy any of the marijuana I used over the past year 
-77  Don’t know  








In total, how many EDIBLE MARIJUANA PRODUCTS did you BUY [In a typical 





ENTER NUMBER: ____ UNITS (e.g., muffins, cookies, brownies,…etc) 
-77  Don’t know  
-88  Refuse to answer 
 






In total, how much money did you spend on all of the EDIBLE MARIJUANA PRODUCTS you 
bought [In a typical [day/week/month/ or In the past 12-months]…. 
 
ENTER DOLLAR AMOUNT:  
-77  Don’t know  
-88  Refuse to answer 
 





Source: Modified Health Canada 
Survey Draft 




3= Both medical and non-medical 
-77  Don’t know  







Source: Modified Health Canada 
Survey Draft 











Source: Modified Health Canada 
Survey Draft 
What is the usual THC level in the EDIBLE MARIJUANA PRODUCTS you used?  
 
Enter number: ____ Dropdown menu: mg THC, %THC  









Source: Modified Health Canada 
Survey Draft 











Source: Modified Health Canada 
Survey Draft 
What is the usual level of CBD in the dried EDIBLE MARIJUANA PRODUCTS you used?  
 
Enter number: ____ Dropdown menu: mg CBD, %CBD  
-88  Refuse to answer 
 




PROGRAMMER NOTE: SHOW IF MODE.FREQUENCY INCLUDES USE.MODES=9=PAST 12-MONTH USE 
PROGRAMMER NOTE: ONLY IF MODE.FREQUENCY=1-4 FOR USE.MODE=9. DERIVE TIME FRAME BASED ON RESPONSE TO 
MODE.FREQUENCY 
 
[In a usual day/In a usual week/ In a usual month/In the past 12-months], HOW MANY beverages 
containing marijuana extracts did you DRINK?  
 
Enter number of beverages: 
-77  Don’t know  





Source: Modified Health Canada 
Survey Draft 
In the past 12 months, how did you get the marijuana liquid (e.g. cola/tea) products YOU 
DRANK? Select all that apply. 
 
1=I made my own  
2=It was made for me  
3=It was shared around a group of friends  
4=From a family member or friend  
5=From someone else I know  
6=From a dealer (in person)  
7=From a dealer (mail delivery)  
8=medical marijuana through the mail from a licensed producer  
 
 272 
9=medical marijuana from a store (e.g., a dispensary or compassion club) 
10=non-medical marijuana from a store 
11=Ordered it online (from someone other than a licensed producer)  
12=Other_____ (please specify without providing any identifiable information)  
-77  Don’t know  
-88  Refuse to answer 
 





Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF DRINKS.SOURCE>1 OPTION SELECTED ASK: 
 
What per cent (%) of MARIJUANA LIQUID (E.G. COLA/TEA) PRODUCTS did you get from 
each source: 
 
[INSERT Sources selected from DRINKS.SOURCE1 with open fields for entry of % numbers that 
sum to 100%] 
-77  Don’t know  






Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF DRINKS.SOURCE=6-12 go to DRINKS.TIMEFRAME 
 
PROGRAMMER NOTE: IF DRINKS.SOURCE=1 ASK: 
 
Did you buy or pay for the materials to make the MARIJUANA LIQUID (E.G. COLA/TEA) 




-77  Don’t know  
-88  Refuse to answer 
 
PROGRAMMER NOTE: IF DRINKS.SOURCE=2-5 ASK: 
 
Did you buy or pay for the MARIJUANA LIQUID (E.G. COLA/TEA) PRODUCTS you drank? 
1= Yes 
2= No 
-77  Don’t know  








We would like to know how many marijuana liquid (e.g., cola/tea) products you bought or paid for.  
 
Which time-frame is easiest for you to report the amount of MARIJUANA LIQUID (E.G. 





4=12-months (entire year) 
5=I did not buy any of the marijuana I used over the past year 
-77  Don’t know  








In total, how many MARIJUANA LIQUID (E.G. COLA/TEA) PRODUCTS did you BUY [In a 
typical [day/week/month/ or In the past 12-months]…. 
 
 
Enter number of products (e.g., cola/tea) : _________ 
-77  Don’t know  
-88  Refuse to answer 
 






In total, how much money did you spend on all of the MARIJUANA LIQUID (E.G. COLA/TEA) 
PRODUCTS you bought [In a typical [day/week/month/ or In the past 12-months]…. 
 
ENTER DOLLAR AMOUNT:  
-77  Don’t know  
-88  Refuse to answer 
 







Source: Modified Health Canada 
Survey Draft 
Do you use the MARIJUANA LIQUID (E.G. COLA/TEA) PRODUCTS for medical or non-




3= Both medical and non-medical 
-77  Don’t know  







Source: Modified Health Canada 
Survey Draft 
Do you know the THC level in the MARIJUANA LIQUID (E.G. COLA/TEA) PRODUCTS 











Source: Modified Health Canada 
Survey Draft 
What is the usual THC level in the MARIJUANA LIQUID (E.G. COLA/TEA) PRODUCTS 
you used?  
 
Enter number: ____ Dropdown menu: mg THC, %THC  
-88  Refuse to answer 
 





Source: Modified Health Canada 
Survey Draft 
Do you know the CBD level in the MARIJUANA LIQUID (E.G. COLA/TEA) PRODUCTS you 













Source: Modified Health Canada 
Survey Draft 
What is the usual level of CBD in the dried MARIJUANA LIQUID (E.G. COLA/TEA) 
PRODUCTS you used?  
 
Enter number: ____ Dropdown menu: mg CBD, %CBD  
-88  Refuse to answer 
 




PROGRAMMER NOTE: SHOW IF MODE.FREQUENCY INCLUDES USE.MODES=11 




[In a usual day/In a usual week/ In a usual month/In the past 12-months], HOW MUCH of the 
topical products (e.g., creams, lotions, balms, salves, etc.), did you USE?  
 
Enter number: ______ Dropdown menu: Ounces, grams, palmfuls 
-77  Don’t know  





Source: Modified Health Canada 
Survey Draft 
In the past 12 months, how did you get the marijuana topical products (e.g., creams, lotions, balms, 
salves, etc.) YOU USED? Select all that apply. 
 
1=I made my own  
2=It was made for me  
3=It was shared around a group of friends  
4=From a family member or friend  
5=From someone else I know  
6=From a dealer (in person)  
7=From a dealer (mail delivery)  
8=medical marijuana through the mail from a licensed producer  
9=medical marijuana from a store (e.g., a dispensary or compassion club) 
10=non-medical marijuana from a store 
11=Ordered it online (from someone other than a licensed producer)  
12=Other_____ (please specify without providing any identifiable information) 
-77  Don’t know  









Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF TOPICAL.SOURCE>1 OPTION SELECTED ASK: 
 
What per cent (%) of MARIJUANA TOPICAL PRODUCTS (E.G., CREAMS, LOTIONS, 
BALMS, SALVES, ETC.) did you get from each source: 
 
[INSERT Sources selected from TOPICAL.SOURCE1 with open fields for entry of % numbers that 
sum to 100%] 
 
-77  Don’t know  





Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF TOPICAL.SOURCE=6-12 go to TOPICAL.TIMEFRAME 
 
PROGRAMMER NOTE: IF TOPICAL.SOURCE=1 ASK: 
 
Did you buy or pay for the materials to make the MARIJUANA TOPICAL PRODUCTS (E.G., 




-77  Don’t know  
-88  Refuse to answer 
 
PROGRAMMER NOTE: IF TOPICAL.SOURCE=2-5 ASK: 
 
Did you buy or pay for the MARIJUANA TOPICAL PRODUCTS (E.G., CREAMS, 
LOTIONS, BALMS, SALVES, ETC.) you used? 
1= Yes 
2= No 
-77  Don’t know  
-88  Refuse to answer 
 






We would like to know how many marijuana topical products (e.g., creams, lotions, balms, salves, 
etc.) products you bought or paid for.  
 
Which time-frame is easiest for you to report the amount of MARIJUANA TOPICAL 
PRODUCTS (E.G., CREAMS, LOTIONS, BALMS, SALVES, ETC.) you purchased; in a usual 





4=12-months (entire year) 
5=I did not buy any of the marijuana I used over the past year 
-77  Don’t know  








In total, how many MARIJUANA TOPICAL PRODUCTS (E.G., CREAMS, LOTIONS, 




ENTER NUMBER: ____ Dropdown menu: OUNCES/GRAMS/PALMFULS 
-77  Don’t know  
-88  Refuse to answer 
 
 







In total, how much money did you spend on all of the MARIJUANA TOPICAL PRODUCTS 
(E.G., CREAMS, LOTIONS, BALMS, SALVES, ETC.) you bought [In a typical 
[day/week/month/ or In the past 12-months]…. 
 
ENTER DOLLAR AMOUNT:  
-77  Don’t know  









Source: Modified Health Canada 
Survey Draft 
Do you use the MARIJUANA TOPICAL PRODUCTS (E.G., CREAMS, LOTIONS, BALMS, 




3= Both medical and non-medical 
-77  Don’t know  







Source: Modified Health Canada 
Survey Draft 
Do you know the THC level in the MARIJUANA TOPICAL PRODUCTS (E.G., CREAMS, 











Source: Modified Health Canada 
Survey Draft 
What is the usual THC level in the MARIJUANA TOPICAL PRODUCTS (E.G., CREAMS, 
LOTIONS, BALMS, SALVES, ETC.) you used?  
 
Enter number: ____ Dropdown menu: mg THC, %THC  
-88  Refuse to answer 
 





Source: Modified Health Canada 
Survey Draft 
Do you know the CBD level in the MARIJUANA TOPICAL PRODUCTS (E.G., CREAMS, 













Source: Modified Health Canada 
Survey Draft 
What is the usual level of CBD in the dried MARIJUANA TOPICAL PRODUCTS (E.G., 
CREAMS, LOTIONS, BALMS, SALVES, ETC.) you used?  
 
Enter number: ____ Dropdown menu: mg CBD, %CBD  
-88  Refuse to answer 
 




PROGRAMMER NOTE: SHOW IF MODE.FREQUENCY INCLUDES USE.MODES=12 
PROGRAMMER NOTE: ONLY IF MODE.FREQUENCY=1-4 FOR USE.MODE=12. DERIVE TIME FRAME BASED ON RESPONSE TO 
MODE.FREQUENCY 
 
[In a usual day/In a usual week/ In a usual month/In the past 12-months], HOW MUCH fresh 
flower/leaf did you USE?  
 
Enter number: ______ Dropdown menu: ounces, grams, leaves 
-77  Don’t know  






Source: Modified Health Canada 
Survey Draft 
In the past 12 months, how did you get the marijuana fresh flowers/leaves (e.g., for juicing) YOU 
USED? Select all that apply. 
 
1=I grew my own  
2=It was grown for me  
3=It was shared around a group of friends  
4=From a family member or friend  
5=From someone else I know  
6=From a dealer (in person)  
7=From a dealer (mail delivery)  
8=medical marijuana through the mail from a licensed producer  
9=medical marijuana from a store (e.g., a dispensary or compassion club) 
10=non-medical marijuana from a store 
11=Ordered it online (from someone other than a licensed producer)  
12=Other_____ (please specify without providing any identifiable information)  
-77  Don’t know  
 
 280 







Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF FRESHFLOWER.SOURCE >1 OPTION SELECTED ASK: 
 
What per cent (%) of FRESH FLOWERS/LEAVES (E.G., FOR JUICING) did you get from 
each source: 
 
[INSERT Sources selected from FRESHFLOWER.SOURCE1 with open fields for entry of % 
numbers that sum to 100%] 
 
-77  Don’t know  





Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF FRESHFLOWER.SOURCE=6-12 go to FRESHFLOWER.TIMEFRAME 
 
PROGRAMMER NOTE: IF FRESHFLOWER.SOURCE=1 ASK: 
 
Did you buy or pay for the SEEDS for plant you grew? 
1= Yes 
2= No 
-77  Don’t know  




We would like to know how many SEEDS you bought or paid for.  
 
Which time-frame is easiest for you to report the amount of SEEDS you purchased; in a usual day, 





4=12-months (entire year) 
5=I did not buy any of the marijuana I used over the past year 
-77  Don’t know  














[NUMBER OF SEEDS] 
-77  Don’t know  
-88  Refuse to answer 
 






In total, how much money did you spend on all of the SEEDS you bought [In a typical 
[day/week/month/ or In the past 12-months]…. 
 
ENTER DOLLAR AMOUNT:  
-77  Don’t know  
-88  Refuse to answer 
 
 




We would like to know how many FRESH FLOWERS/LEAVES (E.G., FOR JUICING) you 
bought or paid for.  
 
Which time-frame is easiest for you to report the amount of FRESH FLOWERS/LEAVES (E.G., 








4=12-months (entire year) 
5=I did not buy any of the marijuana I used over the past year 
-77  Don’t know  
-88  Refuse to answer 
 





Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF FRESHFLOWER.SOURCE=2-5 ASK: 
 
Did you buy or pay for the FRESH FLOWERS/LEAVES (E.G., FOR JUICING) you used? 
1= Yes 
2= No 
-77  Don’t know  
-88  Refuse to answer 
 




We would like to know how much fresh flowers/leaves (e.g., for juicing) you bought or paid for.  
 
Which time-frame is easiest for you to report the amount of FRESH FLOWERS/LEAVES (E.G., 






3=12-months (entire year) 
4=I did not buy any of the marijuana I used over the past year 
-77  Don’t know  
-88  Refuse to answer 
 








In total, how many FRESH FLOWERS/LEAVES (E.G., FOR JUICING) did you BUY [In a 
typical [day/week/month/ or In the past 12-months]…. 
 
 
Enter number: ______ Dropdown menu: OUNCES/GRAMS/LEAVES 
-77  Don’t know  
-88  Refuse to answer 
 
 







In total, how much money did you spend on all of the FRESH FLOWERS/LEAVES (E.G., FOR 
JUICING) you bought [In a typical [day/week/month/ or In the past 12-months]…. 
 
ENTER DOLLAR AMOUNT:  
-77  Don’t know  
-88  Refuse to answer 
 





Source: Modified Health Canada 
Survey Draft 
Do you use the FRESH FLOWERS/LEAVES (E.G., FOR JUICING) for medical or non-




3= Both medical and non-medical 
-77  Don’t know  







Source: Modified Health Canada 
Survey Draft 
Do you know the THC level in the FRESH FLOWERS/LEAVES (E.G., FOR JUICING) you 













Source: Modified Health Canada 
Survey Draft 
What is the usual THC level in the FRESH FLOWERS/LEAVES (E.G., FOR JUICING) you 
used?  
 
Enter number: ____ Dropdown menu: mg THC, %THC  
-88  Refuse to answer 
 





Source: Modified Health Canada 
Survey Draft 
Do you know the CBD level in the FRESH FLOWERS/LEAVES (E.G., FOR JUICING) you 











Source: Modified Health Canada 
Survey Draft 
What is the usual level of CBD in the dried FRESH FLOWERS/LEAVES (E.G., FOR 
JUICING) you used?  
 
Enter number: ____ Dropdown menu: mg CBD, %CBD  
-88  Refuse to answer 
 




PROGRAMMER NOTE: SHOW IF MODE.FREQUENCY INCLUDES USE.MODES=13 
PROGRAMMER NOTE: ONLY IF MODE.FREQUENCY=1-4 FOR USE.MODE=13. DERIVE TIME FRAME BASED ON RESPONSE TO 
MODE.FREQUENCY 
 
[In a usual day/In a usual week/ In a usual month/In the past 12-months], HOW MUCH of the 
other forms of marijuana not mentioned in this survey did you USE?  
 
 _______ GRAMS 
-77  Don’t know  








Source: Modified Health Canada 
Survey Draft 
In the past 12 months, how did you get the other forms of marijuana not mentioned in this survey 
YOU USED? Select all that apply. 
 
1=I made/grew my own  
2=It was made/grown for me  
3=It was shared around a group of friends  
4=From a family member or friend  
5=From someone else I know  
6=From a dealer (in person)  
7=From a dealer (mail delivery)  
8=medical marijuana through the mail from a licensed producer  
9=medical marijuana from a store (e.g., a dispensary or compassion club) 
10=non-medical marijuana from a store 
11=Ordered it online (from someone other than a licensed producer)  
12=Other_____ (please specify without providing any identifiable information)  
-77  Don’t know  







Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF OTHER.SOURCE>1 OPTION SELECTED ASK: 
 
What per cent (%) of OTHER FORMS OF MARIJUANA NOT MENTIONED IN THIS 
SURVEY did you get from each source: 
 
[INSERT Sources selected from OTHER.SOURCE1 with open fields for entry of % numbers that 
sum to 100%] 
 
-77  Don’t know  





Source: Modified Health Canada 
Survey Draft 
PROGRAMMER NOTE: IF OTHER.SOURCE=6-12 go to OTHER.TIMEFRAME 
 
PROGRAMMER NOTE: IF OTHER.SOURCE=1 ASK: 
 
Did you buy or pay for the materials to make the OTHER FORMS OF MARIJUANA NOT 






-77  Don’t know  
-88  Refuse to answer 
 
PROGRAMMER NOTE: IF OTHER.SOURCE=2-5 ASK: 
 
Did you buy or pay for the OTHER FORMS OF MARIJUANA NOT MENTIONED IN THIS 
SURVEY you used? 
1= Yes 
2= No 
-77  Don’t know  
-88  Refuse to answer 
 




We would like to know how many OTHER FORMS OF MARIJUANA NOT MENTIONED IN 
THIS SURVEY you bought or paid for.  
 
Which time-frame is easiest for you to report the amount of OTHER FORMS OF MARIJUANA 






4=12-months (entire year) 
5=I did not buy any of the marijuana I used over the past year 
-77  Don’t know  
-88  Refuse to answer 
 






In total, how many OTHER FORMS OF MARIJUANA NOT MENTIONED IN THIS 





Enter number: ____ Dropdown menu:OUNCES/GRAMS 
-77  Don’t know  
-88  Refuse to answer 
 






In total, how much money did you spend on all of the OTHER FORMS OF MARIJUANA NOT 
MENTIONED IN THIS SURVEY you bought [In a typical [day/week/month/ or In the past 
12-months]…. 
 
ENTER DOLLAR AMOUNT:  
-77  Don’t know  
-88  Refuse to answer 
 
 





Source: Modified Health Canada 
Survey Draft 
Do you use the OTHER FORMS OF MARIJUANA NOT MENTIONED IN THIS SURVEY 




3= Both medical and non-medical 
-77  Don’t know  







Source: Modified Health Canada 
Survey Draft 
Do you know the THC level in the OTHER FORMS OF MARIJUANA NOT MENTIONED IN 











What is the usual THC level in the OTHER FORMS OF MARIJUANA NOT MENTIONED IN 
THIS SURVEY you used?  
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Source: Modified Health Canada 
Survey Draft 
 
Enter number: ____ Dropdown menu: mg THC, %THC  
-88  Refuse to answer 
 





Source: Modified Health Canada 
Survey Draft 
Do you know the CBD level in the OTHER FORMS OF MARIJUANA NOT MENTIONED IN 




-77  Don’t know  







Source: Modified Health Canada 
Survey Draft 
What is the usual level of CBD in the dried OTHER FORMS OF MARIJUANA NOT 
MENTIONED IN THIS SURVEY you used?  
 
Enter number: ____ Dropdown menu: mg CBD, %CBD  
-88  Refuse to answer 
 








Source: Modified from CSTADS 
2014/15 
PROGRAMMER NOTE 
IF EVER.TRIED=2 OR IF USE.RECENT=1,2 
  
Overall, how easy or difficult would it be for you to get marijuana? 
 
IF USE.RECENT=3,4 









-77  Don’t know  












3=Neither easy nor difficult 
4=Fairly difficult 
5=Very difficult 
-77  Don’t know  








How easy or difficult would it be for you to buy marijuana from a store in the town or city where 




3=Neither easy nor difficult 
4=Fairly difficult 
5=Very difficult 
-77  Don’t know  








How close do you live to a store that sells marijuana? 
 
1=Within walking distance 
2=Within a short drive 
3=Within a long drive 
4=I don’t know of any stores that sell marijuana where I live 
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-77  Don’t know  












3=3 More than once 
-77  Don’t know  







Source: Health Canada Survey 
Draft 




-77  Don’t know  






Have you ever heard of people using butane or CO2 for making marijuana extracts or concentrates such as 




-77  Don’t know  
-88  Refuse to answer 
 




Have you ever tried to make marijuana extracts or concentrates yourself? 
 
1=No 
2=Yes – using butane 
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3=Yes – using CO2 
4=Yes – some other way [_____] ßOpen text field 
-77 Don’t know 
-88 Refuse to answer 
 








3=Neither safe nor dangerous 
4=Dangerous 
5=Very dangerous 
-77 Don’t know 
-88 Refuse to answer 
 








3=Neither safe nor dangerous 
4=Dangerous 
5= Very dangerous 
-77 Don’t know 









IF participant selected, “Yes – some other way [______]” in EXTRACTTRY take them to a new variable var OTHERSAFE and populate what they 
put into the open field in the blank after the  colon. 
 









5= Very dangerous 
-77 Don’t know 
-88 Refuse to answer 
 
 
Cannabis Use for Medical Purposes 
 
MED CANNABIS USE 
[EVER.MED] 
 
Source: Health Canada Survey 
Draft 





-77  Don’t know  




MED CANNABIS USE 
[DOC.AUTH.EVER] 
 
Source: Health Canada Draft 
Survey 
 




-77  Don’t know  




MED CANNABIS USE 
[PAST12MOS.MED] 
 
Source: Health Canada Survey 
Draft 




-77  Don’t know  






MED CANNABIS USE 
[DOC.AUTH.12MON] 
 
Source: Health Canada Draft 
Survey 
 





-77  Don’t know  




MED CANNABIS USE 
[MED.COND] 
 
Source: Health Canada Draft 
Survey.Modified 
 
For what general condition(s) did your physician authorize the use of marijuana? 
 
□ Acute pain 
□ Chronic pain 
□ Nausea/vomiting 
□ Lack of appetite 
□ Seizures 
□ Headaches/migraines 
□ Muscle spasms 
□ Anxiety 









Source: ADAPATED FROM Health 
Canada Draft Survey 
Have you ever experienced any of the following unintended adverse effects/reactions from using 





4=Dry or red eyes 
5=Heart and blood pressure problems 










14=I have never experience any unintended adverse effects/reactions from using marijuana. 
-77  Don’t know  












-77  Don’t know  












-77  Don’t know  








When you experienced side effects from marijuana, were you also… (Select all that apply)  
 
1=Drinking alcohol  
2=Taking recreational drugs other than marijuana 




5=None of these [PROGRAMMER: ONLY ALLOW IF NEITHER OPTION CHOSEN ABOVE]  
-77  Don’t know  








When you experienced side effects from marijuana, what type or form were you using? (Select all 
that apply)  
 
1=Smoked Dried flower/leaf  
2=Vaporized Dried flower/leaf 
3=Vaporized liquid form in an e-cigarette 
4=Mixed with tobacco (blunt) 
5=Hashish 
6=Hash oil 
7=Concentrate (e.g., Butane honey oil/shatter/budder/etc.) 
8=Edibles (e.g. cookies) 
9=Liquid (e.g., cola/tea) 
10=Tinctures (e.g., concentrated amounts ingested orally or taken under the tongue) 
11=Topical Ointments (e.g., lotions, salves, balms applied directly to the skin) 
12=Fresh flower/leaf (e.g., for juicing) 
13=Other  _________ (please specify without providing any identifiable information) 
-77  Don’t know  





Initiation & Susceptibility 
 
AGE OF INITIATION 
[AOI] 
 
Source: Draft Survey 
How old were you when you tried or started using marijuana?  
 






CANNABIS USE INTENTIONS 
OF NEVER USERS 
[FUTURE.TRY1] 
 
Source: CSTADS 2016/2017 Edited 
from “smoking cigarettes” to 
“using marijuana or cannabis (a 
joint, pot, weed, hash, or hash oil)”. 
PROGRAMMER NOTE 
If EVER.TRIED=2:  
Do you think in the future you might try using marijuana? 
 
If USE.RECENT: =1-3 






-77  Don’t know  




CANNABIS USE INTENTIONS 
OF NEVER USERS 
[FUTURE.TRY2] 
 
Source: CSTADS 2016/2017 Edited 
from “smoking cigarettes” to 
“using marijuana or cannabis (a 
joint, pot, weed, hash, or hash oil)”. 






-77  Don’t know  
-88  Refuse to answer  
 
UNIVERSE: EVER.TRIED=2 OR USE.RECENT=1-3 
 
CANNABIS USE INTENTIONS 
OF NEVER USERS 
[FUTURE.TRY3] 
 
Source: CSTADS 2016/2017 Edited 
from “smoking cigarettes” to 
“using marijuana or cannabis (a 
joint, pot, weed, hash, or hash oil)”. 






-77  Don’t know  
-88  Refuse to answer  
 







Source: Modified Health Canada 
Draft Survey 
If marijuana were LEGAL to use, how would it affect whether you would use marijuana? 
 
1=Definitely more likely to use 
2=Probably more likely to use 
3=No effect 
4=Probably less likely to use 
5=Definitely less likely to use 
-77  Don’t know  





Perceptions of Risk and Harm 




Source: Focus Group Work 
PROGRAMMER NOTE: PLEASE INCLUDE 5 SEPARATE OPEN-ENDED ENTRY FIELDS. If they click next before writing in each one, prompt 
with question:  
“Are there any others?” 
 
In your opinion, what are the MOST IMPORTANT NEGATIVE HEALTH EFFECTS from 








Source: Focus Group Work 
How likely is someone to become addicted to smoking marijuana? 
 
1 Very unlikely 
2 Somewhat unlikely 
3 Neither likely nor unlikely 
4 Somewhat likely 
5 Very likely 
-77 Don’t know 




MARIJUANA ADDICTIVE  
[SELF.ADDICTED] 
 
Source: ITC Adapted 
 
Do you consider yourself addicted to marijuana? 
 
1= Not at all 
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 2= Yes, a little addicted 
3= Yes, very addicted 
-77 Don’t know 
-88 Refused    
 
UNIVERSE: RESPONDENTS WHO USED MARIJUANA IN PAST 30 DAYS (USE.RECENT=3,4) 
 




Source: ITC Adapted 
 
Are you worried that using marijuana will damage your health in the future? 
 
1= Not at all worried 
2= A little worried 
3= Moderately worried 
4= Very worried 
-77  Don’t know  






























Modified from Health Canada 
Survey Draft 
PROGRAMMER NOTE 
DISPLAY IN TABLE FORMAT WITH RESPONSE OPTIONS FOR EACH LINE 
 
During the past 12 months, how did your marijuana use affect the following areas of life: 
 
1= friendships or social life? 
2= physical health?  
3= mental health? 
4= home or family life? 
5= work, studies or employment opportunities? 
6= financial position? 
 
RESPONSE OPTIONS: 
1 Positive effect 
2 Negative effect 
3 No effect 
4 I don’t know 






Modified from Health Canada 
Survey Draft 
Overall, during the past 12 months, how has your marijuana affected your QUALITY OF LIFE? 
 
1= Improved my quality of life 
2= Worsened my quality of life 
3= No effect on my quality of life 
-77  Don’t know  















Have you ever used marijuana BEFORE OR DURING WORK?  
 
1= Never 
2= Once  
3= 2 to 5 times 
4= 6 to 10 times 
5= More than 10 times 
-77  Don’t know  








Have you used marijuana before or during work in the past 12 months? 
 
1= Never 
2= Once  
3= 2 to 5 times 
4= 6 to 10 times 
5= More than 10 times 
-77  Don’t know  
-88  Refuse to answer 
 





Source: Health Canada Draft 
Survey.Modified 
In the past 12 months, have you noticed someone using marijuana near you in a public space (e.g., 
street, park, alley, mall, etc.)? 
 
1=Not in the past 12 months 
2=Less than monthly 
3=Weekly 
4=Every day 
5=More than once a day 
-77  Don’t know  






Problematic Use (ASSIST Instrument) 





Source: ASSIST Tool 
During the past 3 months, how often have you had a strong desire or urge to use marijuana? 
1=Never 
2=Once or twice 
3=Monthly 
4=Weekly 
5=Daily or almost daily 
-77  Don’t know  







Source: ASSIST Tool 




2=Once or twice 
3=Monthly 
4=Weekly 
5=Daily or almost daily 
-77  Don’t know  







Source: ASSIST Tool 
During the past 3 months, how often have you failed to do what was normally expected of you 
because of your use of marijuana? 
 
1=Never 
2=Once or twice 
3=Monthly 
4=Weekly 
5=Daily or almost daily 
-77  Don’t know  
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Source: ASSIST Tool 
Has a friend or relative or anyone else expressed concern about your use of marijuana? 
 
1=No, never 
2=Yes, in the past 3 months 
3=Yes, but not in the past 3 months 
-77  Don’t know  







Source: ASSIST Tool 
Have you ever tried and failed to control, cut down or stop using marijuana? 
 
1=No, never 
2=Yes, in the past 3 months 
3=Yes, but not in the past 3 months 
-77  Don’t know  










Source: Global Drug Survey 




-77  Don’t know  






In the last 12 months, have you ever thought about getting help to manage problems with your 
marijuana use?  
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Source: Global Drug Survey  
1=Yes 
2=No 
-77  Don’t know  










Source: Modified ESPAD 2015 
How much do you think PEOPLE RISK harming themselves (physically or in other ways), if they … 
 No risk Slight Moderate Great Don’t 
  risk risk risk know 
 
 a) smoke cigarettes occasionally ......................................................................  .............  .............  .............  .............  
 b) smoke cigarettes every day ...........................................................................  .............  .............  .............  .............   
 d) drink alcohol (3 – 4 drinks) occasionally .....................................................  .............  .............  .............  .............  
 e) drink alcohol (3- 4 drinks) daily ...................................................................  .............  .............  .............  .............  
 
UNIVERSE: ALL 
Note: live version also included a Refuse to answer column. 




Source: Modified ESPAD 2015 
PROGRAMMER NOTE: PLEASE LEAVE A SMALL SPACE BETWEEN EACH SUBSTANCE 
 
How much do you think PEOPLE RISK harming themselves (physically or in other ways), if they … 
 Mark one box for each line. 
 No risk Slight Moderate Great Don’t 
  risk risk risk know 
 
 
 a) smoke marijuana occasionally ......................................................................  .............  .............  .............  .............  
 b) smoke marijuana daily ..................................................................................  .............  .............  .............  .............  
 
 i) vape marijuana occasionally .........................................................................  .............  .............  .............  .............  
 i) vape marijuana daily .....................................................................................  .............  .............  .............  .............  
 
 j) eat or drink marijuana edibles occasionally ..................................................  .............  .............  .............  .............  
 j) eat or drink  marijuana edibles daily .............................................................  .............  .............  .............  .............  
 
 k) use synthetic marijuana occasionally ...........................................................  .............  .............  .............  .............  
 l) use synthetic marijuana daily ........................................................................  .............  .............  .............  .............  
 
 l) use high potency marijuana extracts occasionally ........................................  .............  .............  .............  .............  
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 l) use high potency marijuana extracts daily ....................................................  .............  .............  .............  .............  
 1 2 3 4 5 
UNIVERSE: ALL 





Source: CCHS modified 
Do you have a family history of significant emotional or mental health problems related to any of the 
following? (Select all that apply.) 
 
1=Anxiety (including phobia, obsessive-compulsive disorder or a panic disorder) 
2=Depression (including bipolar disorder, mania or dysthymia) 
3=PTSD or traumatic event (post-traumatic stress disorder) 
4=Psychosis (including schizophrenia) 
5=Drug or alcohol use 
6 =Other significant emotional or mental health problem 







Source: CCHS modified 
Have you ever experienced significant emotional or mental health problems related to any of the 
following? (Select all that apply.) 
 
1=Anxiety (including phobia, obsessive-compulsive disorder or a panic disorder) 
2=Depression (including bipolar disorder, mania or dysthymia) 
3=PTSD or traumatic event (post-traumatic stress disorder) 
4=Psychosis (including schizophrenia) 
5= Drug or alcohol use 
6 =Other significant emotional or mental health problem 







Source: CCHS modified 
PROGRAMMER NOTE: ONLY SHOW RESPONSES SELECTED IN MENTAL.SELF 
 
Have you ever, seen or talked to a health professional about your emotional or mental health for any 
of the following? (Select all that apply.) 
 
1=Anxiety (including phobia, obsessive-compulsive disorder or a panic disorder) 
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2=Depression (including bipolar disorder, mania or dysthymia) 
3=PTSD or traumatic event (post-traumatic stress disorder) 
4=Psychosis (including schizophrenia) 
5=Substance dependence disorder 
6=Other [Specify] 
7=I have never experienced significant emotional or mental health problems. 
 





PROGRAMMER NOTE: ONLY SHOW RESPONSES SELECTED IN MENTAL.SELF 
 
How you experienced significant emotional or mental health problems in the last 12 months? (Select 
all that apply.) 
 
1=Anxiety (including phobia, obsessive-compulsive disorder or a panic disorder) 
2=Depression (including bipolar disorder, mania or dysthymia) 
3=PTSD or traumatic event (post-traumatic stress disorder) 
4=Psychosis (including schizophrenia) 
5=Substance dependence disorder 
6=Other [Specify] 
7=None of the above 
 





Have you ever used marijuana to manage or improve emotional or mental health problems? 




-77  Don’t know  
-88  Refuse to answer 
 









1= Improved my mental health 
2= Worsened my mental health 
3= No effect on my mental health 
-77  Don’t know  








SOCIAL NORMS  
[NORMS.FRIENDS] 
 
Source: Health Canada Draft 
Survey 








-77   Don't know 








Source: P01 MEASURE 
Do people your age approve or disapprove of using marijuana? 
 
1= Strongly approve 
2= Somewhat approve 
3= Neither approve nor disapprove 
4= Somewhat disapprove 
5= Strongly disapprove 
-77   Don't know 









Source: P01 MEASURE 
Do people your age think it’s cool to use marijuana? 
 
1= Not at all cool 
2= A little  
3= Somewhat 
4= Very cool 
-77   Don't know 












Source: Adapted from 
tobacco/ecig 
In the last 30 days, have you noticed marijuana products being advertised or promoted in any of the 
following places? 
 
1= In regular postal mail? 
2= On websites or social media, like Facebook, Twitter, YouTube, Instagram or Snapchat? 
3= In email or text messages? 
4= In bars or pubs? 
5= In shops/stores that sell marijuana? 
6= Outside shops/stores that sell marijuana? 
7= At a pharmacy? 
8= At events like fairs, markets, festivals, sporting events, or music concerts? 
9= At kiosks or temporary sales locations (in shopping centres, parked in the street, other places, but 
not at specific events)? 
10= On television or radio? 
11= On billboards or posters? 
12= In print newspapers or magazines? 
13= At the movies? 
14= Taxis or buses/public transit? 
15= In flyers? 
-77 Don’t know 











Have you seen any education campaigns or public health messages warning about the risks of 




-77  Don’t know  













3=On websites or social media, like Facebook, Twitter, YouTube, Instagram or Snapchat? 
4=In email or text messages? 
5=In bars or pubs? 
6=In shops/stores that sell marijuana? 
7=Outside shops/stores that sell marijuana? 
8=At a pharmacy? 
9=At events like fairs, markets, festivals, sporting events, or music concerts? 
10=At kiosks or temporary sales locations (in shopping centres, parked in the street, other places, but 
not at specific events)? 
11=On television or radio? 
12=On billboards or posters? 
13=In print newspapers or magazines? 
14=At the movies? 
15=Taxis or buses/public transit? 
16=In flyers? 
-77 Don’t know 














-77 Don’t know 









Source: CSTADS 2014, 
modified 
Have you driven a vehicle (e.g., car, snowmobile, motor boat, or an off-road vehicle (ATV) within 2 
hours of using marijuana? 
 
1=No, never 
2=Yes, in the last 30 days 
3=Yes, in the last 12 months 
4=Yes, more than 12 months ago 
-77 Don’t know 







Source: CSTADS 2014 
Have you ever been a passenger in a vehicle (e.g., car, snowmobile, motor boat, or an off-road vehicle 
(ATV) driven by someone who had been using marijuana in the last 2 hours? 
 
1=No, never 
2=Yes, in the last 30 days 
3=Yes, in the last 12 months 
4=Yes, more than 12 months ago 
-77 Don’t know 










Source: Modified BC Roadside 
Survey 
How likely do you think it is, that if a person drives after drinking too much alcohol, they will be 
stopped by the police? 
 
1= Extremely unlikely 
2= Unlikely 
3= In the middle 
4= Likely  
5= Extremely likely 
-77 Don’t know 








Source: Modified BC Roadside 
Survey 
How likely do you think it is, that if a person drives after using marijuana, they will be stopped by 
the police? 
 
1= Extremely unlikely 
2= Unlikely 
3= In the middle 
4= Likely  
5= Extremely likely 
-77 Don’t know 








Source: Modified BC Roadside 
Survey 
If a person is stopped by the police after drinking too much alcohol, how likely are they to be 
charged? 
 
1= Extremely unlikely 
2= Unlikely 
3= In the middle 
4= Likely  
5= Extremely likely 
-77 Don’t know 
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Source: Modified BC Roadside 
Survey 
If a person is stopped by the police after using marijuana, how likely are they to be charged? 
 
1= Extremely unlikely 
2= Unlikely 
3= In the middle 
4= Likely  
5= Extremely likely 
-77 Don’t know 









If a friend had used marijuana and was going to drive, would you try to stop them? 
 
1= I wouldn’t do anything 
2= I would tell them not to drive, but I wouldn’t try to stop them 
3= I would try  a little bit to stop them from driving 
4= I would try very hard to stop them from driving 
-77 Don’t know 










If a friend had drank too much alcohol and was going to drive, would you try to stop them? 
 
1= I wouldn’t do anything 
2= I would tell them not to drive, but I wouldn’t try to stop them 
3= I would try a little bit to stop them from driving 
4= I would try very hard to stop them from driving 
-77 Don’t know 






DRIVING SOCIAL NORMS 
[DRIVING.SOC6] 




3=In the middle 
4=Difficult 
5=Very difficult 
-77 Don’t know 









Do you think driving after using marijuana increases the risk of getting into an accident? 
 




-77 Don’t know 









Is driving after using marijuana more or less dangerous than driving after drinking too much alcohol?  
 
1=Marijuana a lot more dangerous 
2=Marijuana a little more dangerous 
3=The same 
4=Alcohol a little more dangerous 
5=Alcohol a lot more dangerous 
-77 Don’t know 






DRIVING SOCIAL NORMS 
[DRIVING.SOC6] 




3=In the middle 
4=Difficult 
5=Very difficult 
-77 Don’t know 











Have you ever used or tried any of the following drugs. (Select all that apply.) 
 
1=Smoked cigarettes 
2=E-cigarettes / vaping nicotine 
3=Amphetamines (speed, crystal meth or ice, meth,…) 
4=MDMA (ecstasy, E, X,…) 
5=Hallucinogens (LSD, acid, PCP, magic mushrooms or ‘shrooms’,mesc..) 
6=Heroin (smack, junk, crank,…) 
7=Cocaine (crack, blow, snow,…) 
8=Synthetic marijuana (spice, synthetic marijuana, K2, K3, scene, herbal mixtures, herbal incence) 
9=Prescribed pain relievers used TO GET HIGH (E.G. Oxycodone,Fentanyl, Other prescribed pain 
relievers) 








POPULATE A TABLE WITH THE SELECTED SUBSTANCES IN [DRUGS.TRY] IN THE LEFT_HAND COLUMN WITH THE RESPONSE 
CATEGORIES LISTED BELOW. IF [DRUGS.TRY]=11, SKIP TO [BINGE.DRINKING] 
 




1= More than 12 months ago  
2= Between 3 to 12 months ago 
3= Between 1 to 3 months 
4= Within the last month 
-77  Don’t know  








POPULATE A TABLE WITH THE SELECTED SUBSTANCES IN [DRUGS.TRY] WITH THE RESPONSE CATEGORIES LISTED BELOW. 
 
Do you currently use [INSERT DRUG CATEGORY FROM DRUGS.TRY]… 
 
1= Less than once per month  
2= Monthly  
3= Weekly 
4= Daily 
-77  Don’t know  








(revised to add “(4 drinks for 
females)” as per Erin’s request) 
In the past 12 months, how often did you have [“5” if male / “4” if female] drinks of alcohol or more 
on one occasion? 
 
A DRINK means: 1 regular sized bottle, can, or draft of beer; 1 glass of wine; 1 bottle or can of 
cooler; 1 shot of liquor (rum, whiskey, etc.); or 1 mixed drink (1 shot of liquor with pop, juice, energy 
drink, etc.). 
 
1= I have never done this 
2= I did not have [5/4] or more drinks on one occasion in the last 12 months 
3= Less than once a month 
4= Once a month 
5= 2 to 3 times a month 
6= Once a week 
 
 315 
7= 2 to 5 times a week 
8= Daily or almost daily 
9= I do not know [valid answer] 






POPULATE A TABLE WITH THE SELECTED SUBSTANCES IN [DRUGS.TRY] IN THE LEFT_HAND COLUMN WITH THE RESPONSE 
CATEGORIES LISTED BELOW. INCLUDE [BINGE.DRINKING] IF >2 and <8 as “Alcohol”. 
 

















6=Time to onset and duration 
7=Nothing 
-77 Don’t know 








SECTION 2: Perceptions of Health Warnings 
Text vs. Pictures 
 
  
PROGRAMMER NOTE: RANDOMIZE PARTICIPANTS TO VIEW 4 TEXT AND 4 PICTURE WARNINGS FOR THE FOLLOWING 8 QUESTIONS 
 
 




PROGRAMMER NOTE: FIND PICTURES IN FOLDER TITLED 'SURVEY PICTURES'. COND1=DRIVINGPIC.jpeg, COND2=DRIVINGTEXT.jpeg 
   
DRIVING HIGH IS DANGEROUS  
DRIVING AFTER USING MARIJUANA SLOWS DOWN YOUR REACTION TIME SIMILAR TO 
ALCOHOL. DRIVING AFTER USING MARIJUANA CAN DOUBLE YOUR RISK OF A CAR 
CRASH. 
 
a. Overall, how EFFECTIVE is this health warning?  
[INSERT SCALE 1-10, 1= NOT AT ALL EFFECTIVE, 10=EXTREMELY EFFECTIVE] 
 
b. How BELIEVABLE is this health warning?  







PROGRAMMER NOTE: FIND PICTURES IN FOLDER TITLED 'SURVEY PICTURES'. COND1=PREGPIC.jpeg, COND2=PREGTEXT.jpeg 
   
SMOKING MARIJUANA DURING PREGNANCY HURTS YOU AND YOUR BABY  
MARIJUANA USE DURING YOUR PREGNANCY CAN HURT YOUR BABY’S GROWTH AND 
LEARNING ABILITIES 
 
a. Overall, how EFFECTIVE is this health warning?  
[INSERT SCALE 1-10, 1= NOT AT ALL EFFECTIVE, 10=EXTREMELY EFFECTIVE] 
 
b. How BELIEVABLE is this health warning?  











































PROGRAMMER NOTE: FIND PICTURES IN FOLDER TITLED 'SURVEY PICTURES'. COND1=MHPIC.jpeg, COND2=MHTEXT.jpeg 
   
MARIJUANA USE CAN HARM YOUR MENTAL HEALTH  
USING MARIJUANA CAN LEAD TO MENTAL HEALTH PROBLEMS OR MAKE THEM WORSE – 
AVOID IF YOU HAVE A PERSONAL OR FAMILY HISTORY OF MENTAL HEALTH ISSUES 
 
a. Overall, how EFFECTIVE is this health warning?  
[INSERT SCALE 1-10, 1= NOT AT ALL EFFECTIVE, 10=EXTREMELY EFFECTIVE] 
 
b. How BELIEVABLE is this health warning?  










































DRUGS & ALCOHOL 
[DURGSALC.SET] 
PROGRAMMER NOTE: FIND PICTURES IN FOLDER TITLED 'SURVEY PICTURES'. COND1=MIXPIC.jpeg, COND2=MIXTEXT.jpeg 
   
MIXING MARIJUANA WITH ALCOHOL OR OTHER DRUGS IS DANGEROUS 
MIXING DRUGS PUTS YOU AT A GREATER RISK OF ACCIDENTS LEADING TO SERIOUS 
INJURY OR DEATH  
 
a. Overall, how EFFECTIVE is this health warning?  
[INSERT SCALE 1-10, 1= NOT AT ALL EFFECTIVE, 10=EXTREMELY EFFECTIVE] 
 
b. How BELIEVABLE is this health warning?  











































PROGRAMMER NOTE: FIND PICTURES IN FOLDER TITLED 'SURVEY PICTURES'. COND1=YOUTHPIC.jpeg, COND2=YOUTHTEXT.jpeg 
   
LIVE ONCE THINK TWICE  
HEAVY MARIJUANA USE IN YOUR TEENS CAN SERIOUSLY AFFECT YOUR DEVELOPING 
BRAIN MAKING THINGS HARD TO REMEMBER OR UNDERSTAND 
 
a. Overall, how EFFECTIVE is this health warning?  
[INSERT SCALE 1-10, 1= NOT AT ALL EFFECTIVE, 10=EXTREMELY EFFECTIVE] 
 
b. How BELIEVABLE is this health warning?  










































PROGRAMMER NOTE: FIND PICTURES IN FOLDER TITLED 'SURVEY PICTURES'. COND1=ADDPIC.jpeg, COND2=ADDTEXT.jpeg 
   
MARIJUANA IS ADDICTIVE  
MARIJUANA USE CAN BECOME HARD TO STOP AND TAKE PRIORITY OVER OTHER PARTS 
OF YOUR LIFE INCLUDING FAMILY, FRIENDS, AND WORK. 
 
a. Overall, how EFFECTIVE is this health warning?  
[INSERT SCALE 1-10, 1= NOT AT ALL EFFECTIVE, 10=EXTREMELY EFFECTIVE] 
 
b. How BELIEVABLE is this health warning?  











































PROGRAMMER NOTE: FIND PICTURES IN FOLDER TITLED 'SURVEY PICTURES'. COND1=ODPIC.jpeg, COND2=ODTEXT.jpeg 
   
KNOW THE DOSE AVOID OVERDOSE 
PRODUCTS HAVE DIFFERENT THC LEVELS AND EFFECTS. SEEK IMMEDIATE MEDICAL 
ATTENTION IF YOU EXPERIENCE CHEST PAIN, PANIC ATTACKS, LOSS OF CONTACT WITH 
REALITY, OR SEIZURES AS A RESULT OF YOUR MARIJUANA USE.  
 
a. Overall, how EFFECTIVE is this health warning?  
[INSERT SCALE 1-10, 1= NOT AT ALL EFFECTIVE, 10=EXTREMELY EFFECTIVE] 
 
b. How BELIEVABLE is this health warning?  









































PROGRAMMER NOTE: FIND PICTURES IN FOLDER TITLED 'SURVEY PICTURES'. COND1=SMOKEPIC.jpeg, COND2=SMOKETEXT.jpeg 
   
MARIJUANA SMOKE IS TOXIC  
MARIJUANA SMOKE CONTAINS MANY OF THE SAME CANCER-CAUSING CHEMICALS AS 
TOBACCO SMOKE SUCH AS AMMONIA AND HYDROGEN CYANIDE. 
 
a. Overall, how EFFECTIVE is this health warning?  
[INSERT SCALE 1-10, 1= NOT AT ALL EFFECTIVE, 10=EXTREMELY EFFECTIVE] 
 
b. How BELIEVABLE is this health warning?  





















3= Don’t know 
 
UNIVERSE: if WARNING.SUPPORT = 1 OR 3 
 
HELPLINE.C1 PROGRAMMER NOTE: FIND PICTURES IN FOLDER TITLED 'SURVEY PICTURES' CALLTOACTION.jpeg 
 
Do you think this information (in red rectangle) should be included on marijuana packages? 
1=Yes 
2=No 





SECTION 3: Perceptions of Constituent Labelling 
 Labelling Dose 
DOSE 
DOSE.AMOUNT 
PROGRAMMER NOTE: RANDOMLY ASSIGN TO 1 OF 3 IMAGES. FIND PICTURES IN FOLDER TITLED 'SURVEY PICTURES' 
CONTROLCOOKIE.jpeg, COOKIE_THC_MG.jpeg, COOKIE_THC_SERVINGSIZE.jpeg 
     
Based on the information provided, how much of the cookie should someone eat on one occasion if they 
wanted a recommended serving? 
 
1= ¼ of a cookie 
2= ½ of a cookie 
3= ¾ of a cookie 
4= 1 cookie 
5= 2 cookies 
6= 3 cookies 
7=More than 3 cookies 
-77 Don’t know 















6=More than 5 
-77 Don’t know 





THC ‘Amount’ Label 
 
THC.AMOUNTLOW PROGRAMMER NOTE: RANDOMLY ASSIGN TO 1 OF 4 IMAGES. FIND PICTURES IN FOLDER TITLED 'SURVEY PICTURES' LOWTHC 
_TRADENAME.jpeg, LOWTHC_PERCENT.jpeg, LOWTHC_MG.jpeg,, LOWTHC_TRAFFCLIGHT.jpeg 
       











THC.AMOUNTHIGH PROGRAMMER NOTE: RANDOMLY ASSIGN TO 1 OF 4 IMAGES. FIND PICTURES IN FOLDER TITLED 'SURVEY PICTURES' HIGHTHC 
_TRADENAME.jpeg,HIGHTHC_PERCENT.jpeg, HIGHTHC_MG.jpeg,, HIGHTHC_TRAFFCLIGHT.jpeg 
       












Time to Onset & Product Type 
 
TIME.Q1 PROGRAMMER NOTE: RANDOMLY ASSIGN TO 1 OF 3 IMAGES. FIND PICTURES IN FOLDER TITLED 'SURVEY PICTURES’ 
TIME_JOINT.jpeg, TIME_COOKIE.jpeg, TIME_BEV.png, 
     
How soon would you feel the effects from using this marijuana product? 
 
1=Less than 5 minutes 
2=Within 30 minutes 
3=Within 60 minutes (1hr) 
4=1 to 2 hours 









Recognition of THC Symbol 
SYMBOLS.Q1 PROGRAMMER NOTE: SHOW ALL 4 WARNINGS ON THE SCREEN. FIND PICTURES IN FOLDER TITLED 'SURVEY PICTURES’ 
SYMBOL_CO.png, SYMBOL_BPA.jpeg, SYMBOL_KIDS.png,, SYMBOL_OR.jpeg 
 
 










Driving & product type 
DRIVINGSET.Q1 PROGRAMMER NOTE: RANDOMLY ASSIGN TO 1 OF 3 IMAGES. FIND PICTURES IN FOLDER TITLED 'SURVEY PICTURES’ 
SAFE_JOINT.jpeg, SAFE_COOKIE.png 
PROGRAMMER NOTE: FOR ALCOHOL IMAGE, FEMALE= SAFE_ALC_WOMEN_jpeg, MALE=SAFE_ALC_MEN 
 




1= Less than 1 hour 
2= 1 hour 
3= 2 hours 
4= 3 hours 
5= 4 hours 
6= More than 4 hours 






SECTION 4: Perceptions of Brand Imagery on Packaging 
Branding 
Standard pack, branded pack, health warning label 
PACK.GENDER.APPEAL PROGRAMMER NOTE: RANDOMLY ASSIGN TO 1 OF 4 IMAGES: Gender 1.jpeg, Gender 2.jpeg, Gender 3.jpeg, or Gender 4.jpeg 
 
How APPEALING would this marijuana product be to try?  
 
0            1           2            3            4            5            6             7            8            9            10    
Not at all                                                                                                                 Very appealing 
appealing                                  
 







PACK.GENDER.AGE In your opinion, someone who chooses to use this product is more likely to be… 
 
1= Younger than me 
2= My age 
3= Older than me 








3= No difference 




















Flavoured pack vs pack without flavour description 
PACK.FLAV.APPEAL PROGRAMMER NOTE: RANDOMLY ASSIGN TO 1 OF 2 IMAGES: Flabour1.jpeg or Flavour2.jpeg 
 
How APPEALING would this marijuana product be to try?  
 
0            1           2            3            4            5            6             7            8            9            10    
Not at all                                                                                                               Very appealing 
appealing                                  
 






















PACK.FLAV.AGE In your opinion, someone who chooses to use this product is more likely to be… 
 
1= Younger than me 
2= My age 
3= Older than me 









3= No difference 





















Pack displaying energy boost claims vs pack without energy claims 
PACK.ENERGY.APPEAL PROGRAMMER NOTE: RANDOMLY ASSIGN TO 1 OF 2 IMAGES: Energy1.jpeg or Energy 2.jpeg 
 
How APPEALING would this marijuana product be to try? 
  
0            1           2            3            4            5            6             7            8            9            10    
Not at all                                                                                                               Very appealing 
appealing                                  
 






















PACK.ENERGY.AGE In your opinion, someone who chooses to use this product is more likely to be… 
 
1= Younger than me 
2= My age 
3= Older than me 





PACK.ENERGY.PARTY In your opinion, someone who chooses to use this product is more likely to… 
 
1= Go out and party 
2= Stay home 
3= No difference 





















Pack displaying celebrity sponsor vs unsponsored pack 
PACK.SPON.APPEAL PROGRAMMER NOTE: RANDOMLY ASSIGN TO 1 OF 2 IMAGES: Sponsored1.jpeg or Sponsored2.jpeg 
 
How APPEALING would this marijuana product be to try?  
 
0            1           2            3            4            5            6             7            8            9            10    
Not at all                                                                                                               Very appealing 
appealing                                  
 




















PACK.SPON.AGE In your opinion, someone who chooses to use this product is more likely to be… 
 
1= Younger than me 
2= My age 
3= Older than me 





PACK.SPON.PARTY In your opinion, someone who chooses to use this product is more likely to… 
 
1= Go out and party 
2= Stay home 
3= No difference 





















Pack displaying organic/natural descriptors vs pack without such descriptors 
PACK.NATURAL.APPEAL PROGRAMMER NOTE: RANDOMLY ASSIGN TO 1 OF 2 IMAGES: Organix1.jpeg or Organic2.jpeg 
 
How APPEALING would this marijuana product be to try?  
 
0            1           2            3            4            5            6             7            8            9            10    
Not at all                                                                                                               Very appealing 
appealing                                  
 




















PACK.NATURAL.AGE In your opinion, someone who chooses to use this product is more likely to be… 
 
1= Younger than me 
2= My age 
3= Older than me 





PACK.NATURAL.HEALTH In your opinion, someone who chooses to use this product is more likely to be… 
 
1= Someone who takes more care of their health 
2= Someone who takes less care of their health 
3= No difference 





















Pack with music references vs pack without such references 
PACK.MUSIC.APPEAL PROGRAMMER NOTE: RANDOMLY ASSIGN TO 1 OF 2 IMAGES: Music1.jpeg or Music2.jpeg 
 
How APPEALING would this marijuana product be to try?  
 
0            1           2            3            4            5            6             7            8            9            10    
Not at all                                                                                                             Very appealing 
appealing                                  
 















PACK.MUSIC.AGE In your opinion, someone who chooses to use this product is more likely to be… 
 
1= Younger than me 
2= My age 
3= Older than me 





PACK.MUSIC.PARTY In your opinion, someone who chooses to use this product is more likely to… 
 
1= Go out and party 
2= Stay home 
3= No difference 






















Pack with fashion references vs pack without such references 
PACK.FASH.APPEAL PROGRAMMER NOTE: RANDOMLY ASSIGN TO 1 OF 2 IMAGES: Fashion1.jpeg or Fashion2.jpeg 
 
How APPEALING would this marijuana product be to try?  
 
0            1           2            3            4            5            6             7            8            9            10    
Not at all                                                                                                               Very appealing 
appealing                                  
 























3= No difference 





PACK.FASH.FASHION In your opinion, someone who chooses to use this product is more likely to be…. 
 
1= More fashionable  
2= Less fashionable 
3= No difference 





















Pack with party references vs pack without such references 
PACK.FESTIVAL.APPEAL PROGRAMMER NOTE: RANDOMLY ASSIGN TO 1 OF 2 IMAGES : Party1.jpeg or Party2.jpeg 
 
How APPEALING would this marijuana product be to try?  
 
0            1           2            3            4            5            6             7            8            9            10    
Not at all                                                                                                          Very appealing 
appealing                                  
 























PACK.FESTIVAL.AGE In your opinion, someone who chooses to use this product is more likely to be… 
 
1= Younger than me 
2= My age 
3= Older than me 





PACK.FESTIVAL.PARTY In your opinion, someone who chooses to use this product is more likely to… 
 
1= Go out and party 
2= Stay home 
3= No difference 










WARNING.RECALL PROGRAMMER NOTE: Please display 5 separate ‘fill in the blank’ fields 
 
Earlier, we showed you 4 different health warnings. We’d like you to try to list as many of the 4 





Additional Sociodemographic Questions 
 
INFO SCREEN We would like to ask you a few final questions about yourself before we finish. 




What is the current month? 
 












-77 Don’t know 

















Are you in… 
 
1=High School – Grades 7-9 
2=High School – Grades 10-12 
3=CEGEP, college, or trade school 
4=University 
5=Post-graduate/Professional 
6=I am not a student 
-77 Don’t know 







Source: ITC 2016 
What is the highest level of formal education that you have completed? 
 
1= Grade school/ some high school 
2= Completed high school 
3= Technical/ trade school or community college 
4= Some university, no degree 
5= Completed university degree 
6= Post-graduate degree 
-77 Don’t know 







Source: Saewyc et al. 2004, 
Evaluation of Adolescent 
Health Surveys 
How would you describe your sexual orientation? 
 




3=Bisexual (attracted to both men and women) 
4=Gay or lesbian (attracted to the same sex) 
5=Other: __________ 
6=I am not sure yet 
7=I don’t understand this question 
-77 Don’t know 







Source: ITC 2016 
Which of the following categories best describes your ANNUAL household income, that is the total 
income before taxes, or gross income, of all persons in your household combined, for one year? 
 







8= $150,000 and over 
-77 Don’t know 






What are the first 3 characters of your postal code 
 
Fields:[Letter] [Number (0-9] [Letter] 
-77 Don’t know 











To help us learn more about environmental factors in your area, we’d like to know what the nearest 
intersection to your home is. This information will never be released or analyzed individually and will be 
used to group your responses with others from your neighborhood. Please name the 2 cross-streets of this 
intersection. 
 
Record first street ___________________________ 
 
Record second street _________________________ 
 
-77 Don’t know 





UNIVERSE: POSTAL.CODE=77, 88 
HONESTY 
[HONESTY] 




2= Some questions, but not all 













Your feedback is extremely valuable. 
 
This study has been reviewed and received ethics clearance through a University of 
Waterloo Research Ethics Committee (ORE#22392). If you have questions for the 
 
 351 
Committee contact the Chief Ethics Officer, Office of Research Ethics, at 1-519-888-4567 
ext. 36005 or ore-ceo@uwaterloo.ca.  
 
For all other questions or if you have general comments or questions related to this study, or 
if you would are interested in receiving a copy of the results please contact the principal 







Appendix 2 – List of Experts 
(Members for Expert Advisory Committee on Information for Physicians on Marihuana for 
Medical Purposes EAC-IPMM) 
1. Harold Kalant, MD, PhD 
Biological and Behavioural Researcher 
Prof of Pharmacology and Toxicology 
University of Toronto 
Research Director, CAMH 
harold.kalant@utoronto.ca 
(Link to PubMed hits) 
 
2. Paul Daeninck, MD, MSc 
Medical Oncologist, Palliative Care Consultant 
Department of Hematology/Medical Oncology 
St. Boniface Hospital 
University of Manitoba 
paul.daeninck@cancercare.mb.ca 
(Link to PubMed hits) 
 
3. Boris Gorzalka, PhD 
Behavioural Neuroscience and Clinical Psych 
Prof of Psychology 
University of British Columbia 
bgorzalka@psych.ubc.ca 
(Link to PubMed hits) 
 
4. Jason J. McDougall, PhD 
Physiologist 
Prof Dept of Pharmacology and Anaesthesia 
Dalhousie University 
jason.mcdougall@dal.ca 
(Link to PubMed hits) 
 
5. Keith Sharkey, PhD 
Biological Researcher 
Prof Dept Physiology and Pharmacology 
Director of the Hotchkiss Brain Institute 
University of Calgary 
ksharkey@ucalgary.ca 
(Link to PubMed hits) 
 
6. Tony George, MD 
Addictions Researcher – Schizophrenia 
Addiction of Psychiatry 
University of Toronto 
 
 353 
Clinical Director of Schizophrenia – CAMH 
tony.george@camh.ca 
(Link to PubMed hits) 
 
 
7. Mark Ware, MBBS, MRCP, MSc ///Vice Chair on the Taskforce on Marijuana 
Legalization and Regulation 
Biological Researcher – Safety and Efficacy of Cannabinoids 
Prof Family Medicine and Anaesthesia 
McGill University 
mark.ware@muhc.mcgill.ca 
(Link to PubMed hits) 
 
8. Mary Lynch, MD, LMCC 
Biological Researcher – Pain Management 
Prof Anaesthesia, Pain Management, Perioperative Medicine 
Dalhousie University 
mary.lynch@dal.ca 
(Link to PubMed hits) 
 
9. Pierre Beaulieu, MD, PhD 
Biological Researcher – Cannabinoids and Pain 
Prof Pharmacology and Anaesthesiology  
University of Montreal 
pierre.beaulieu@umontreal.ca 
(Link to PubMed hits) 
 
 
Most of the people recruited by Health Canada are also part of the Canadian Consortium for 
the Investigation of Cannabinoids.  
 
(Board of Directors of Consortium for Investigation of Cannabinoids – excluding those listed 
above) 
10. Alexander (John) Clark, MD 
Biological Researcher – opioids and cannabinoids 
Prof Anaesthesia, Pain Management, Perioperative Medicine 
Dalhousie University 
ajclark@dal.ca 
(Link to PubMed hits) 
 
11. Matthew Hill, PhD 
Biological Researcher – endocannabinoid system and stress response 
Prof Hotchkiss Brain Institute 
University of Calgary 
mnhill@ucalgary.ca 
(Link to PubMed hits) 
 
12. Linda Parker, PhD 
Behavioural Neuroscience, Psychopharmacology 
Prof Neuroscience & Applied Cognitive Science 
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University of Guelph 
parkerl@uoguelph.ca 
(Link to PubMed hits) 
 
13. Jonathan Page, PhD 
Botanist, Biochemistry and Genomics 
Prof Botany – Cannabinoid Biosynthesis 
University of British Columbia 
jon.page@botany.ubc.ca 
(Link to PubMed hits) 
 
14. Melanie Kelly, PhD 
Biological Researcher – molecular and functional pharmacology 
Optic Nerve Research Laboratory – Faculty of Medicine 
Dalhousie University 
melanie.kelly@dal.ca 
(Link to PubMed hits) 
 
15. Colleen O’Connell, MD – Could not find more about her beyond general contact info. 
 
 
(38th WHO Expert Committee on Drug Dependence – November 2016th) 
16. Prof Bruna Brands, PhD 
Biobehavioural Scientist – Clinical Pharmacology, Addiction, Neuropharmacology 
Prof Dept of Pharmacology and Toxicology 
University of Toronto 
bruna.brands@camh.ca 
(Link to Pub Med hits) 
 
(Canadian Centre on Substance Abuse - Scientific Advisory Council) 
17. Franco Vaccarino, PhD, 2nd Link 
Bioscience – Neuropsychopharmacology 
President – University of Guelph 
Collaborative Program in Neuroscience-University of Toronto 
president@uoguelph.ca 
vaccar@psych.utoronto.ca 
(Link to PubMed hits) 
 
18. Rita Notarandrea, MHSc, CHE 
CEO Canadian Centre on Substance Abuse 
613-235-4048 ext 227 
 
19. Michael Krausz, PhD 
Scientist – Addictions 
Centre for Health Evaluations and Outcome Sciences 
University of British Columbia 
m.krausz@mac.com, michael.krausz@ubc.ca 




(Not part of Advisory Council but involved in the CCSA Cannabis Portfolio) 
 
20. Dr. Amy Porath-Waller 
Director, Research and Policy for Canadian Centre on Substance Abuse 
aporath-waller@ccsa.ca 
21. Jurgen Rehm 
Health Economist 
Director, Institute for Mental Health Policy Research 




22. Prof. Louisa Degenhardt, PhD* 
Epidemiology - Substance Use 
University of New South Wales - Sydney 
l.degenhardt@unsw.edu.au 
(Link to PubMed hits) 
 
23. Prof. Wayne Hall, PhD* 
Epidemiologist 
University of Queensland Centre for Clinical Research 
National Health and Medical Research Council 
w.hall@uq.edu.au 
(Link to PubMed hits) 
 
24. Wendy Swift, PhD 
Epidemiologist 
National Drug and Alcohol Research Centre 
University of New South Wales 
w.swift@unsw.edu.au 
(Link to PubMed hits) 
 
25. Courtney L. Bagge, PhD 
Epidemiology - Suicide 
University of Mississippi Medical Centre 
cbagge@umc.edu 
(Link to PubMed hits) 
 
26. Ruben Baler, PhD 
Bioscience – neurobiology of drug abuse 
National Institute on Drug Abuse 
baler@nida.nih.gov 
(Link to PubMed hits) 
 
27. Prof. Donald P. Tashkin 
Biosciences – Effects of Cannabis on Pulmonary Tissue 
UCLA – Dept. of Medicine – Division of Pulmonary and Critical Care 




(Link to PubMed hits) 
 
28. Nora Volkow, MD 
Director, National Institute on Drug Abuse – NIH 
nvolkow@nida.nih.gov 
(Link to PubMed hits) 
 
29. David M. Fergusson, PhD 
Epidemiologist – founder of the 35yr study of birth cohort born in mid-1977 
University of Otago – Christchurch 
dm.fergusson@otago.ac.nz 
(Link to PubMed hits) 
 
30. Arpana Agrawal, PhD 
Bioscientist – genetic and environmental underpinnings of substance use behaviours, 
cannabis 
Prof Psychiatry 
Washington University in St Louis 
arpana@wistl.edu 
(Link to PubMed hits) 
 
31. Michael T Lynskey, PhD 
Epidemiology and etiology of cannabis use and cannabis use disorders 
King’s College London 
michael.lynskey@kcl.ac.uk 
(Link to PubMed hits) 
 
32. Benedikt Fischer, PhD 
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